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Abstract
This thesis concerns erythropoietic protoporphyria (EPP, MIM 177000), a rare
photodermatosis with systemic complications which results from an inherited partial
deficiency of ferrochelatase (FECH), the terminal enzyme of haem biosynthesis.
Excessive formation of the substrate, protoporphyrin IX, results in
protoporphyrinaemia and accumulation in erythrocytes, plasma, skin and liver, prior
to excretion in the bile. Protoporphyrin can absorb light, damaging surrounding
tissues through the generation of free radicals, and clinically manifesting as painful
photosensitivity within minutes of skin exposure to sunlight. Microcytic anaemia
occurs in 20 - 60% of patients. Liver dysfunction and liver failure occurs in up to
35% and 4% of patients respectively. Management of EPP is based mainly on
minimising the effects of sunlight by use of visible light sunscreens, clothing and
behavioural measures to avoid direct sunlight. Despite advances in the biochemistry
and genetic inheritance, there remains a lack of prospective clinical data for EPP.
Previous studies have been retrospective analyses, often from tertiary centres
specialising in the treatment of liver disease. Such studies typically report subjects in
common, many from large family pedigrees. These limitations of ascertainment,
bias and small population size have restricted accurate investigation of fundamental
clinical issues relating to EPP.
This thesis describes a prospective cross-sectional study of United Kingdom patients
with EPP, designed to describe in detail clinical features, assess liver and
haematopoietic function and to characterise vitamin D status. Genotyping was
additionally undertaken and statistical analysis of measured variables performed to
identify significant associations which might predict clinical status.
The study cohort included 223 patients from 193 families (114 females, 109 males
median age 34 years; range 5-87 years) most of whom were white Caucasians apart
from two. Of 178 patients with 'dominant EPP' (dEPP), 48% of women and 33% of
men were anaemic. Iron stores were decreased by two-thirds but normal serum
soluble transferrin receptor-1 and iron concentrations suggested that erythropoiesis
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was not limited by iron supply. Liver dysfunction was present in 25% dEPP and
significantly associated with total erythrocyte protoporphyrin (TEP) concentration,
male sex, age, anaemia and alcohol consumption, but not with genotype. Vitamin D
deficiency and insufficiency was present in 17% and 91% of 201 subjects
respectively seen over a seven-month period between January and July. Both
insufficiency and deficiency were significantly associated with the TEP and
inversely with the time in minutes to the onset of symptoms following sunlight
exposure. A new clinical EPP subtype was identified of seasonal palmar
keratoderma, characterised by low erythrocyte protoporphyrin concentrations and
recessive inheritance. This condition may carry a lower risk of liver disease than
other patients with recessively-inherited EPP. Investigation of individuals, clinically
presenting as EPP, but in whom no FECHmutation was identifiable, has identified a
new condition, X-linked dominant protoporphyria, which results from a gain-of-
function mutation of the C-terminal of 5-amino levulinate synthase 2, the initial rate-
regulating enzyme of erythroid haem biosynthesis. X-linked dominant
protoporphyria causes neither anaemia nor iron overload.
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Clinical, Biochemical, Haematological and Molecular
Epidemiology of Erythropoietic Protoporphyria. A United
Kingdom Cross-Sectional Study
1. Introduction
1.1 Statement of the problem
The porphyrias are disorders associated with inherited or acquired enzyme
deficiencies in the haem biosynthetic pathway. Erythropoietic protoporphyria (EPP)
was first described by Magnus in 1961.' The condition is caused by a partial
deficiency of ferrochelatase (FECH), the terminal enzyme of haem biosynthesis.
This leads to accumulation of its substrate, protoporphyrin IX (PP) in erythrocytes,
plasma, liver and skin. PP in the skin, through its photodynamic action, causes life¬
long acute photosensitivity of sun exposed areas, while its accumulation in the liver
9 T
leads to potentially fatal liver failure in 1-4% of patient series. ' In most families,
increased protoporphyrin formation sufficient to cause photosensitivity occurs only
in individuals who have inherited a low expression FECH gene polymorphism
(present in about 13% of the UK population)4 trans to a loss of function FECH
mutation on the other allele that abolishes or markedly decreases FECH activity.5
The clinical features of EPP, which are distinct from those of other cutaneous
porphyrias, have been described in various case reports and small series, none
containing more than 32 patients.6'7 Larger studies have focussed on particular
aspects of the disease, such as genetics8 or liver disease,2' but have omitted clinical
details. Information from such sources may be biased by selection and may not
reflect the full clinical spectrum. In addition, no study has addressed the psychosocial
consequences of EPP, despite the apparent severity of symptoms and substantial
changes to lifestyle necessary to avoid episodes of acute photosensitivity.
1.2 The porphyrias
The porphyrias are a group of metabolic disorders associated with inherited or
acquired enzyme deficiencies in the haem biosynthetic pathway resulting in
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excessive quantities of porphyrins or their precursors. This overproduction not only
results in products which are physiologically unuseful, but which are also toxic.
There are eight enzymes involved in the synthesis of haem from glycine and succinyl
CoA, four mitochondrial and four cytoplasmic, and in general, a specific enzyme
deficiency corresponds with a specific clinical type of porphyria (figure 1). Prior to
this study, the only enzyme in the synthetic chain in which deficiency had not been
associated with a porphyria was the first, 5-aminolevulinate synthase (ALAS).
Erythropoietic protoporphyria (EPP) is due to a relative deficiency of the final
enzyme in the haem biosynthetic pathway, FECH, resulting in accumulation of its
substrate, PP.

























































1.3 Historical perspective of the porphyrias 10
Porphyrias may have been clinically recognised for hundreds of years without
appreciation of the underlying disorder. For example Hippocrates recorded what was
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probably one of the first clinical descriptions of an acute porphyric attack.11 Legends
of werewolves, suffering from photophobia, hypertrichosis and skin mutilation were
believed to be based on the features of congenital erythropoietic porphyria. The
12 13
most famous suspected porphyria sufferer was King George III (1738-1820). '
The biochemical study of porphyrins commenced in the 19th century, following the
demonstration by Scherer that adding concentrated sulphuric acid to dried powdered
blood allowed separation of iron from the remaining material. When alcohol was
subsequently added to this iron-free blood, a purple-red colour appeared which was
subsequently named 'haematin'.14-16 By the latter half of the 19th century further
17
purification work of this blood derivative led to the observation of red fluorescence,
the introduction of the term 'hamatoporphyrin' - from the Greek for blood and
18
purple (aipa - haima + rropcpupoa - porphuros) - to describe the colour, and the
demonstration of the sharp near-ultraviolet absorption band of haemoglobin.19
The first accurate clinical description of a porphyria was made in 1874, with the
identification of haematin in the urine of the patient (diagnosed initially as "atypical
20
leprosy", but in retrospect as classical congenital erythropoietic porphyria (CEP)).
The biochemist who analysed the pigments from this first patient, perspicaciously
suggested its aetiology to be an error in haemoglobin synthesis, and not secondary to
anomalous haemoglobin degradation.21 The description in 1898 of two brothers with
skin photosensitivity and urinary 'haematoporphyrin' excretion led to the suggestion
of a close connection between the cutaneous manifestations and the urinary
pigment.22 Further understanding of the link between clinical diseases and porphyrin
pigments followed the introduction by the company Kast and Bayer in the late 1880s
of the chemically related hypnotics sulphonal and trional. Between 5 and 10% of
women treated with the drugs, developed acute porphyric attacks of abdominal pain,
pareses, and port-wine discoloured urine. At the time the urinary pigment was
23 24shown to be closely related to the sulphuric acid-derived haematoporphyrin, ' and
25it is now recognised that these cases were acute intermittent porphyria (AIP).
Subsequently, a number of other porphyrins were chemically identified, purified and
analysed. The connection of porphyrins to clinical disease was advanced by the
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extensive work of Gtinther on his laboratory assistant Mathias Petry, who suffered
from CEP. It was Gtinther also first introduced the term 'hamatoporphyrie' to
describe the group of diseases, and introduced a clinical classification (congenital,
acute idiopathic, acute toxic and chronic), which with some modifications, is still in
use today. Mathias Petry was subsequently employed by another German chemist,
Hans Fischer. On Petry's death, fluorescence microscopy of his bone marrow
erythropoietic cells at autopsy, revealed significantly elevated levels of porphyrin.
Fischer's further work, was seminal in developing understanding of porphyrin
chemistry and the haem biosynthetic pathway. He identified porphyrinogens as the
synthetic substrates, and introduced the terms uroporphyrin and coproporphyrin in
his description of the decarboxylation that occurs between the two intermediaries,
and he is credited with first using the stand alone term 'porphyrin'. Developing work
by Kammerer and Hijmans van den Bergh in the 1920's, he described the two
isomeric porphyrins and subsequently called the porphyrin described by Kammerer
protoporphyrin, demonstrating that it existed in 15 isomeric forms of which only No.
IX occurs in nature. He also conducted clinical experiments into the photosensitising
effects of the natural porphyrins and their excretion physiology.10
Additional work in the early 20th century led to understanding of the biosynthetic
relationships, and the introduction ofmore modern chemical nomenclature (e.g. uro-
and coproporphyrin, and the term porphyrin replacing haematoporphyrin). The
demonstration that porphyrins caused photosensitisation was shown in two classic
experiments: in the first, Haussmann added haematoporphyrin to cultures of the
protozoa Paramaecia - the organisms continued to grow normally in darkness, but
97 • •
were killed by exposure to bright daylight. The second was the self-administration
by Meyer-Betz of haematoporphyrin.28 Within 30 minutes of an intra-venous
infusion, he experienced liver discomfort and general pain, but no skin symptoms.
Exposure to sunlight the next day resulted in an immediate pricking, burning
sensation of exposed skin, followed by erythema, pain and oedema within 10-15
minutes. A photograph of his severely swollen face illustrates the photosensitivity,
that lasted for at least 6 weeks (figure 2).
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• 11 /-» 29Later milestones included the demonstration of inheritance, identification of
porphobilinogen,30'31 the emergence of quantitative porphyrin analysis,32'33 and thin
layer chromatography.34 The introduction in the 1950's of the Wood's light to both
biochemical and clinical practice (a source ofUVA from which visible light has been
excluded by a nickel oxide filter), allowed rapid screening of serum samples for
fluorescence.
Figure 2. Meyer-Betz after self administration of haematoporphyrin and
exposure to sunlight of the right face and left hand whilst seated on a
tram.
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During the 20th century the individual clinical conditions were more clearly
delineated and classified. For example, Giinther's chronic porphyria was renamed
porphyria cutanea tarda (PCT). New entities described included acute intermittent
porphyria (AIP),35 hereditary coproporphyria (HCP),36 and variegate porphyria
(VP). In 1926, the first known case of EPP was described as "hydroa aestivale
TO
without haematoporphyrinuria", although a formal diagnosis of EPP in this
TO
individual was only confirmed in the early 1960s. In 1953, a similar case of a 12-
year-old male was reported again with "atypical hydroa aestivale" without excessive
urinary porphyrin, but with elevated erythrocyte protoporphyrin and faecal
TQ
protoporphyrin probably also representing EPP, although some of the biochemical
results identified at the time were atypical for the condition. It was not until 1961
that the condition was clearly delineated, in a report of a 35-year-old man with light-
induced urticaria and maximal photosensitivity to short wavelength visible light at
400-4 lOnm, by Magnus et al.1 They demonstrated that it was the red cell component
of blood in which the majority of the elevated protoporphyrin was detected.
Significant numbers of other cases were quickly reported in the years that
followed.6,40"42 A case of liver dysfunction in EPP was reported shortly after the
initial description,43 followed by other similar cases of protoporphyric liver disease,
some of which were fatal.44,45
Table 1. Historical description of porphyrias
Porphyria Date of Description First Author
X-linked dominant protoporphyria 2008 Whatley46
ALA dehydratase porphyria 1983 Doss47
Acute intermittent porphyria 1951 Watson35
Congenital erythropoietic porphyria 1874 Schultz20
Porphyria cutanea tarda 1911 Gunther26
Hepatoerythropoietic porphyria 1969 Pinol-Aguade48
Hereditary coproporphyria 1955 Berger36
Variegate porphyria 1963 Dean37
Erythropoietic protoporphyria 1961 Magnus1
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1.4 Biochemistry of porphyrias and haem
Pyrroles are 5-membered aromatic compounds with a basic formula of C4H4NH
(figure 3a), formed by the condensation of glycine and succinyl-CoA. Porphyrins
are composed of four pyrrole molecules joined to produce a tetrapyrrole ring (figure
3b). Substitution of side chains to the basic pyrrole molecule alters the biochemical
and physical properties such as lipid solubility and absorption spectra. During haem
biosynthesis, other than protoporphyrin IX (a porphyrin), the actual substrates for the
enzymes catalysing haem biosynthesis are porphyrinogens, reduced forms of
porphyrins. Porphyrinogens are highly unstable molecules that rapidly oxidise to
porphyrins resulting in their irreversible removal from the biosynthetic pathway.
Figure 3.
a) A pyrrole ring.
H
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b) A tetrapyrrole ring consisting of a large ring composed of four
pyrroles, each a ring structure. All porphyrins are tetrapyrroles.
Porphyrins and metalloporphyrins are found in almost all living organisms and have
a range of functions. Their ring structure confers enhanced molecular stability, a
variety of redox levels for electron transfer, and acts as a powerful site for the
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chelation of transitional metals, greatly enhancing their catalytic capacity. This is
particularly evident when a metalloporphyrin binds to proteins, as in the catalase
enzymes. Porphyrins are sometimes described as the pigments of life, providing
through photosynthesis, a "free" energy source. Haem is involved in electron
transport systems and the metabolic utilisation of photosynthetic energy and energy
from food, and oxygen.49 Haem is a cofactor in the reduction of sulphite and nitrites,
and may participate in the oxidization of deleterious substances. The few organisms
which do not have porphyrins rely on complex organic molecules (themselves
produced by photosynthesis), or inorganic redox pairs such as hydrogen and sulphate
ions, where the hydrogen most commonly results from the action of other bacteria on
organic molecules. Thus porphyrin molecules, through their ability to provide
energy gradients, have been central to evolution as we know it, although whether
photosynthesis was a requirement for the origin of self-replicating life is less clear.
The Granick Hypothesis for the evolutionary development of porphyrin biosynthesis
suggested that the pathway was built in a forward direction.30 It states that each
pathway product had a function in it's time, but through mutations or chance events,
was superseded by the next more efficient or more useful molecule.50 This supports
the Oparin-Haldane hypothesis of life beginning in the oceans as the start of the
pathway consists of ionic, highly water-soluble simple molecules and finishes with
lipid-soluble complex molecules. Thus the location of each step in the biosynthetic
pathway recapitulates the sequence of evolution: ALAS is found in the mitochondria,
adjacent to the tricarboxylic acid cycle, the origin of succinyl CoA. The next four
enzymes are all in the cytosol, and their substrates are highly water-soluble. The
final three, where the substrates and products are progressively less water-soluble,
are in the lipid mitochondrial membranes. The negatively charged earlier soluble
products will not bind to the negatively charged cytosolic proteins, whilst keeping
the insoluble substrates close to their enzymes in the compartments of the
mitochondria prevents their loss through binding to hydrophobic proteins and cell
membranes.
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The haem biosynthetic pathway is essentially the sequential formation of a cyclical
iron metalloprotein capable of electron transfer, from less complex precursors,
catalysed by eight enzymes. It starts with the condensation of glycine and succinyl
Coenzyme A (CoA) to form 5-aminolevulinate (ALA) under the control of the
mitochondrial enzyme ALAS. For each molecule of porphyrin produced, eight
molecules of glycine and succinyl CoA are required. A series of enzymes (the next
four intra-cytoplasmic, and the remaining three within the mitochondrion) control the
conversion of ALA first to porphobilinogen (PBG), a pyrrole, hydroxymethylbilane,
a linear tetrapyrrole and then uroporphyrinogen III, the first cyclical tetrapyrrole in
the pathway. The first of two alternative biosynthetic forks occurs from
uroporphyrinogen III: subsequent formation of corrins, tetrapyrroles with two
pyrrolic rings joined directly, leads to synthesis of hydroxycobalamin (vitamin B12),
and the siderohaems and nickel complexes found in phylogenetically early bacteria.
The second biosynthetic fork occurs at the level of protoporphyrin, branching to
produce either haem or chlorophyll. Insertion of magnesium into the protoporphyrin
ring, catalysed by magnesium chelatase, followed by additional light-dependent
formation of a fifth ring from propionic acid side chains (cyclization), reduction of a
double bond in one of the other rings, and attachment of a phytol tail, convert the
molecule into chlorophyll. Non-photosynthetic organisms have lost this ability to
insert magnesium, and instead iron is inserted by ferrochelatase to produce haem. In
mammals, haem biosynthesis is most active in erythropoietic tissue, where it is
required for haemoglobin synthesis, and in hepatic tissue, where it forms the basis for
various haem-containing enzymes such as cytochrome P450, the catalases and
cytochrome oxidase. Thus the haem biosynthetic pathway is one of the most highly
conserved metabolic pathways, with identical steps in all cells of primitive bacteria,
plants and mammals. This high degree of conservation reflects the importance of the
pathway in producing critical components of living systems.
1.5 Protoporphyrin IX and ferrochelatase
Protoporphyrin IX (PP), the terminal porphyrin in the haem biosynthetic pathway, is
the substrate for the enzyme ferrochelatase (FECH). This enzyme is found on the
inner mitochondrial membrane and catalyses the insertion of ferrous iron into the
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centre of the molecule to form haem. The enzyme is synthesised in the cytosol as a
larger precursor form, and imported into the mitochondria, dependant on the
membrane potential. The human FECH maps to chromosome 18 q21.3 and spans
45kb over a total of 11 exons (a nucleic acid sequence that is represented in the
mature form of an RNA molecule after portions of a precursor RNA (introns) have
been removed).51 The complementary DNA (cDNA - DNA synthesized from a
mature mRNA template in a reaction catalyzed by the enzyme reverse transcriptase)
has an open reading frame of 1269 base pairs, which encodes a protein of 423 amino
acid residues. The leader sequence of 62 amino acids appears important for the
mitochondrial targeting;52 removal of which yields the mature enzyme of 369 amino
acids. The transcripts are identical in both erythroid and non-erythroid cells: in all
tissues there are two mRNA of different lengths, both of which generate an identical
FECH protein, and are produced by two different polyadenylation sites (site for
addition of a tail composed of multiple adenosine monophosphates - important for
the nuclear export, translation and stability of the mRNA).
The description of the three-dimensional crystal structure of FECH (figure 4)
enhanced understanding of the catalytic mechanism and allowed predictions of the
effects of mutations on enzymatic activity.53"55 The human FECH enzyme is a
homodimer (a protein composed of two identical polypeptide chains)
metalloenzyme, which in contrast to prokaryotic FECH, has an additional 30-50
amino acid residues at the carboxyl terminus. This may function by providing three
cysteine residues to co-ordinate with an iron-sulphur (2Fe-2S) cluster which acts as
an essential co-factor.56 Iron-sulphur clusters are found in a variety of
metalloenzymes involved in oxidation-reduction reactions, particularly mitochondrial
electron transfer. Although FECH activity is dependant on the presence of this
cluster, its exact function in FECH has yet to be clearly elucidated, as it apparently
does not provide a direct catalytic role: it has been postulated to mediate electron
• • 57transfer or play a structural role by maintaining the correct conformation. In
erythropoietic protoporphyria (EPP), FECH activity is less than 30% that of normal
• S8 • • •
subjects, which leads to accumulation of it's substrate, PP. The enzyme is active in
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cells producing haem, including erythroid precursors in the bone marrow and
hepatocytes.59'60
Radio-labelling studies suggest that in EPP the majority of PP (approximately 80%)
originates from the bone marrow, with most of the remainder generated by the
liver.61 This is evidenced post-liver transplantation in EPP by the demonstrated
reduction in excess protoporphyrin and improvement in symptoms in the presence of
comparable raised faecal protoporphyrin levels, suggesting increased excretion but
similar levels of production. 2' 3 In contrast, those EPP individuals who have
successfully received bone marrow transplantation have normal porphyrin
concentrations in erythrocytes, plasma and faeces.64'65
The concentration of PP in circulating erythrocytes falls as it diffuses across the cell
membrane into the plasma. Exposure of erythrocytes to light results in increased
release.66 As the PP molecule is relatively hydrophobic, due to the presence of only
two carboxylic side chains, the majority is bound to albumin, haemopexin and other
proteins, including lipoproteins, with only a low level being unbound. As a result,
PP is not excreted in the urine: it is excreted in bile, although a proportion is re-
/-o
absorbed through an enterohepatic circulation. Due to physical proximity, free and
protein-bound PP is taken up by endothelial cells membranes either through a
concentration gradient, membrane lipoprotein receptors or by direct contact with
erythrocyte membranes, resulting in a higher concentration than elsewhere in the
dermis.69 The lipoproteins may also be important in the uptake of PP by the liver,
through their specific receptors.69
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Figure 4. The three dimensional crystal structure of Bacillus subtilis
ferrochelatase showing an elongated shape of approximately 60 A. The
protein has two main approximately symmetrical domains (green and
blue) consisting of a central four-stranded p sheet flanked by a helices.
The parts of the chain in red build up the walls of a hydrophobic cleft
containing conserved amino acids - the presumed catalytic site,
(reproduced with permission from Al-Karadaghi et al.)53
(a) empty structure.
(b) containing the protoporphyrin IX - iron complex
If
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Excess PP in the skin and cutaneous blood vessels absorbs light maximally at 400-
410 nm (the Soret Band - an absorption band in the blue short wavelength region of
the optical absorption spectrum). Visible light of this wavelength passes through
window glass and penetrates deeply into the skin. Following absorption of light, PP
generates excited electrons with the capacity to transfer their energy to oxygen, or
generate free radicals and singlet oxygen. Subsequent tissue damage ensues from
complement activation, peroxidation of lipids and protein cross-linking in cellular
membranes.70"75
1.6 Regulation of haem biosynthesis
• • 76 77The chief regulatory step in haem production is ALAS, ' upon which haem exerts
a negative feedback, although factors that limit each of the other enzyme steps in
haem production have been described; for example a secondary control lies at the
level of PBG deaminase (PBGD), which is inhibited by both copro- and
protoporphyrinogen. ALAS is encoded by two different genes: ALAS2 on the X-
chromosome (Xpll.21) is expressed only in erythroid cells, and mutations of this
gene cause certain types of X-linked hereditary sideroblastic anaemia. ALAS1 is
located on chromosome 3 (3p21.1) and encodes an ubiquitous enzyme which is
readily induced by drugs and other compounds associated with acute attacks of
70 #
porphyria. Due to relative ease of tissue sampling, the majority of porphyrin
research has focused on hepatic tissue where 15% of the daily haem production is
based, mainly for use in cytochromes such as P450. Production here is much more
sensitive to intracellular haem levels, and is able to respond more rapidly. Erythroid
production of haem is linked to tissue differentiation and has a much slower turnover
than hepatic haem.
Haem regulates ALAS in three different ways. Firstly, synthesis of new enzyme may
be repressed; secondly, the transfer of the newly synthesised enzyme to the
mitochondria may be limited; thirdly, haem decreases the stability of mRNA for
ALAS.79'80 In hepatic cells, synthesis of ALA is inhibited by haem,76 through the
post-transcriptional reduction of ALAS mRNA half-life and blocking the
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translocation of ALAS into the mitochondrion. The transcription rate does not
80
appear to be affected.
ALAS2 mRNA contains an area in its 5' untranslated region termed the iron
responsive element (IRE). This RNA sequence allows specific binding of two iron
regulatory proteins (IRP1 and IRP2), which inhibit ALAS2 mRNA translation.81'82
IRP 1 and 2 are activated by iron deficiency whereas high intracellular iron
availability results in post-translational modification of IRP-1 and degradation of
IRP-2.83 This demonstration of a direct molecular mechanism for iron availability to
influence haem biosynthesis, and may be particularly relevant in the case of EPP
where oral iron supplementation can lead to differing clinical outcomes. Similar IRE
have been shown in the mRNA of ferritin and transferrin,84 indicating the probability
of multiple mechanisms through which control of porphyrin production is co¬
ordinated and regulated.
Each of the other enzymes in the haem biosynthetic pathway is coded by a single
gene, although most have features that allow enhanced expression during erythroid
differentiation. For example, the FECH gene in both erythroid and non-erythroid
cell lines transcription is facilitated by a single promoter (the region of DNA
regulating gene transcription, located 'upstream' of a gene, containing specific DNA
sequences and response elements that provide a binding site for RNA polymerase
and transcription factor proteins that recruit RNA polymerase). Two FECH
polyadenylation sites can produce two mRNAs of different length, both of which are
believed to be transcribed to functional FECH.85 However binding sites in the
promoter region, for example to the transcription factor Spl, appear to confer
preferential erythroid expression.86 These probably interact with other erythroid-
specific transcription factors such as GATA-1 and NF-E2, whose binding sites have
also been identified on the FECH promoter region, permitting tissue-specific
expression of FECH in erythroid cells. Furthermore, these transcription factors have
binding sites in the promoter regions of other genes such as (3-globulin, allowing co¬
ordinated production of haem and globin during erythroid cell maturation.
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Deficiency of one of the biosynthetic enzymes (excepting ALAS) or failure to
produce sufficient haem results in loss of negative feedback, and a consequent
enhanced production of porphyrins, particularly the deficient enzyme's substrate.
Accumulation of porphyrins leads to the clinical presentation of the specific
porphyria. The degree of water solubility of the substrates dictates the excretion
pattern: more water-soluble porphyrin precursors in the urine, while lipid soluble
compounds are mainly excreted via the bile in the faeces. Acute porphyrias
overproduce all the porphyrins and precursors proximal to the deficiency. In
contrast, the non-acute porphyrias are characterised by accumulation of porphyrins
immediately proximal to the defect in the pathway. The reason for this is not clear,
but may be due to a compensatory increase in PBGD and ALAS.
It is believed that the pathogenesis of all the inherited porphyrias has now been
defined at a molecular level, with observed genetic heterogeneity within each group.
However, some individuals have more than one haem biosynthetic enzyme affected,
presenting either as two forms of porphyria in one family, or two forms in one
patient. Examples of this concurrent porphyria include the Chester porphyria (AIP
and VP), and dual porphyria (VP and PCT). 87
1.7 Porphyrin-induced photosensitivity
All the porphyrias, except AIP and ALA-dehydratase deficiency, have skin
photosensitivity as a clinical feature. Porphyrins absorb light energy in the blue
spectrum (400-410 nm: the Soret range), raising electrons into an excited triplet state.
Energy can be dissipated to the singlet and ground states by emission, either in the
form of light in the red spectrum (600-660 nm), or in the presence of oxygen,
through the formation of free radicals (chemically highly reactive molecules due to
unpaired electrons) with the potential for tissue damage. Photoactivated
protoporphyrin IX (PP) and uroporphyrin (URO) in erythrocytes have been shown to
oxidise cellular membrane amino acids, leading to cross-linking of proteins. The
resulting inhibition of membrane-bound enzymes, increased membrane permeability,
and loss of structural flexibility cause loss of function, damage and cell destruction,
particularly from osmotic haemolysis74'88 In EPP the major source of cutaneous PP
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is the erythrocyte, and the concentration declines over the lifetime of the cells.69
Irradiation of erythrocytes increases the release of PP,66 probably through
photodynamic damage to porphyrin binding sites on globin resulting in lower affinity
and release through the plasma membrane. In vivo, erythrocytes are exposed to
intermittent Soret-band irradiation every time they pass through light-exposed dermal
capillaries. In vitro simulation of this has shown release of most of the PP and only
• 89minimal amounts of haemoglobin, suggesting the cells remain intact. PP binds to
several plasma carriers, such as albumin, low density lipoprotein, high density
lipoprotein,67'90 allowing PP to be internalised into cell lysosomes through the LDL
receptor, or transported to the liver via HDL, akin to cholesterol metabolism. It is
not known which out of the carriers or erythrocytes is the most important for the
delivery of PP to endothelial cells in the superficial cutaneous blood vessels, but
probably all contribute, either through direct proximity or specific receptor-mediated
uptake, resulting in a higher PP load in light exposed vessel endothelium. Studies
suggest that localisation of PP in plasma membranes results in photo-oxidation of
membrane-bound proteins with inhibition of cation transport as an intial event,
leading to cell lysis with lipid peroxidation as a later process.91 The observation of
reduced light tolerance on days following an initial exposure to intense visible light
is termed the "priming phenomenon", and probably reflects the photodynamic
release of PP on the first day, with subsequent uptake by endothelium and higher
local concentrations on subsequent days.89'92'93
In contrast to URO, photoactivated PP also induces calcium and protein kinase-
independent release of histamine and serotonin from cutaneous mast cells (present in
perivascular locations in the dermis) and loss of their membrane integrity in vitro72'94
This is markedly inhibited by catalase, a hydrogen peroxide scavenger, suggesting
peroxidation as a mechanism.94 It is likely that mast cells release other inflammatory
mediators at the same time as the histamine and serotonin, and that other cell types
are similarly damaged by photo-activated protoporphyrin to release pro¬
inflammatory cytokines. Thus while some aspects of photosensitivity experienced
by patients with PCT and EPP share common mechanisms, the EPP-specific
symptoms of burning, stinging, erythema and oedema may be explained by a direct
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effect of singlet oxygen or PP on sensory neurones and mast cells. Furthemore, the
relatively hydrophobic nature of PP and hydrophilic nature of URO may result in
differential tissue distribution and cellular damage.
Activation of complement is another important mechanism for photoactivated
porphyrin cellular damage. In vitro and in vivo irradiation of serum from patients
with PCT and EPP results in a decrease of both C3 and C5, generating the C5b-9
membrane attack complex and anaphylatoxins, chemotactic for leucocytes.95 This
finding is not seen in individuals with acquired photodermatoses such as solar
urticaria and polymorphic light eruption.71' 5 The exact mechanism of light-induced
complement activation by PP remains to be elucidated, but complement activation is
central to the inflammatory response, through the induction of chemotaxis, increased
vascular permeability, immunomodulation of T cells and the opsonisation and lysis
of cells.
These experimental studies are supported by ultrastructural studies of irradiated skin
from individuals with EPP showing degeneration of upper dermal vasculature, with
loss of the endothelial cell cohesion,96 degranulation of mast cells, and later release
• Q7 . t
of other organelle-bound mediators such as lysosomal acid hydrolases, in addition
to chemotaxis of polymorphonuclear leucocytes. 5
1.8 Classification and diagnosis of porphyrias
Flistorically classification of porphyrias has been based either on the major site of
excess production (hepatic: liver, or erythropoietic: bone marrow - the tissue
specificity resulting from a tissue-specific control of the haem pathway gene
expression) or in terms of the presentation: acute porphyrias characterised by central
and peripheral nervous system dysfunction (AIP, ADP); non-acute or cutaneous
porphyrias, characterised solely by cutaneous photosensitivity (PCT, EPP, CEP); and
a third group, mixed porphyrias, in which both acute attacks and photosensitivity are
present (VP, HCT).
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Formal diagnosis is made on the characteristic porphyrin profiles evident in serum,
erythrocytes, stool 98 and urine 99-101 (table 2). A defective enzyme (either due to
genetic or environmental factors) will not catalyse its respective substrate effectively
leading to accumulation of this substrate and it's precursors.
Table 2. Diagnostic features of the porphyrias










Acute intermittent porphyria f PBGD t porphyrin t ALA, PBG,
activity during attacks UROI
Congenital erythropoietic
protoporphyria
tUPO, zincPP t URO I, CP I
f UROS
activity
t URO I, CP I t URO I, CP




Hereditary coproporphyria t zinc PP t URO ISCP/CP ratio ISCP/CP ratio
Variegate porphyria porphyrin- during attack: t PP > CP III >
protein complex CP III, PBG, ALA CP I
Erythropoietic
protoporphyria
t free PP t PP PP > CP
1.8.1 Qualitative measures
The neuropathic porphyrias tend to be associated with excessive urinary porphyrin
precursor excretion in the urine during an acute attack. Urinary PBG and ALA are
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increased in AIP, VP and HCP, with increased ALA alone in ALADP and lead
poisoning. Urine, faeces and blood, after appropriate processing if necessary, can be
screened for porphyrins by exposure to a Wood's light looking for characteristic red
fluorescence. Urine can also be screened for PBG using Ehrlich's reagent (1%
sodium /?-dimethylaminobenzaldehyde in hydrochloric acid, a strong electrophile,
which reacts with the electron-rich a-carbon of indole/pyrrole rings to form a blue-
coloured adduct, allowing the detection of some indoles, pyrroles and related
nitrogen-containing compounds).
Plasma fluorescence scanning is used as the main simple qualitative diagnostic
technique to screen for individual porphyrins. The method relies upon the capacity
of porphyrins to fluoresce when irradiated with wavelengths near to 400nm,
producing characteristic emission spectra. The plasma sample is placed in optical
glass cuvettes for spectrofluorometry, and a fluorescence spectrophotometer is
zeroed against any buffering dilutant at an excitation wavelength of 405 nm (the
Soret range) and emission wavelength of 620 nm. The emission spectrum is then
scanned from 580 to 650 nm with the excitation monochromator set at 405 nm. The
plasma porphyrin fluorescence peaks can be recorded and can be characteristic for
individual porphyrias, for example a maximum at 634-636nm is characteristic for
free PP and 587 for zinc PP. The intensity of this peak may vary between individuals
and within individuals depending on disease activity and treatment. Thin layer
chromatography and cytofluorometry can also be used for screening samples.
1.8.2 Quantitative assays
Quantitation involves specific measurement of the porphyrin concentration in the
sample. Spectrophotometry and fluorometry are the current standard methods, and
as previously discussed, rely on the characteristic absorption and emission spectra of
the different porphyrins. The porphyrin in the plasma or urinary sample is extracted
using high performance liquid chromatography (HPLC), a highly improved form of
column chromatography. The solvent, instead of being allowed to drip through a
column under gravity, is forced through under high pressures of up to 400
atmospheres, making the process faster and allowing the use a very much smaller
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particle size for the column packing material. This greater surface area facilitates
interactions between the stationary phase and the molecules flowing past it, resulting
in better separation of the components of the mixture. The difference between the
porphyrins that allows separation on an HPLC system is the number of carboxyl
groups and hence water solubility. This affects their ability to interact with the
column particles, and the more soluble elute earlier from the column. The detection
methods in HPLC are highly automated and sensitive. In the detection of porphyrins,
the eluate being assessed is excited with Soret range light at 405nm, and fluorescence
monitored at 620nm. As discussed above, the fluorescence emission peaks are
characteristic for individual porphyrins, allowing individual porphyrins to be
identified from a sample, gives a qualitative diagnostic result. The amount of light
produced will depend on the amount of a particular compound that is passing through
the beam at the time, thus quantitation of porphyrins in a sample can be performed
• i • 102
against a known concentration of a reference standard.
Similar spectrophotometry against a known concentration of a reference standard is
used to quantify the total red cell PP levels, but first the PP must be extracted from
the erythrocytes first using ethyl acetate/acetic acid mixture and then hydrochloric
acid.
Quantitation of urinary porphyrin precursors can be performed by extraction and
separation using ion-exchange resins, formation of a coloured compound using
Ehrlich's reagent and assessment of this product colorimetrically. Erythrocyte
porphyrins are abnormally increased in EPP, CEP and HEP.
1.8.3 Enzyme assays
Enzyme activity studies can be performed using erythrocytes, leucocytes,
transformed lymphoblasts skin fibroblasts, or recombinant Escherichia coli, usually
employing a spectrophotometric or fluorometric analysis of an enzyme reaction
product.103,104 Although the presence of sub-normal enzyme activity is not always
associated with clinical expression, these investigations are particularly useful in the
investigations of families where an index case has been identified.
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1.8.4 Potential pitfalls in diagnosis
It is recommended that analysis for porphyria is carried out in a laboratory
accustomed to the appropriate technical methods and quality control. Failure to
adhere to this will inevitably lead to false negative diagnoses (which may also arise
from deterioration of samples in transit). Ideally samples should include plasma and
whole blood EDTA samples (more stable than serum samples), stored at 4°C before
testing and protected from light to prevent light-induced porphyrin degradation.'05
Increased urinary ALA is seen in hereditary tyrosinaemia. Excess urinary
coproporphyrin occurs in toxic syndromes or hepatic conditions. High erythrocyte
zinc protoporphyrin may be found in lead poisoning, iron deficiency and
sideroblastic anaemia; due to its inability to diffuse through the erythrocyte
membrane, plasma porphyrin levels are usually normal. Use of a qualitative
fluorescent scan prior to quantitative analysis helps to avoid false-positive results
from fluorescent drug metabolites with emission peaks near to those characteristic
for porphyrins. Mildly elevated levels of plasma porphyrins are also seen in some
disorders such as renal failure, cholestasis and the acquired immune deficiency
syndrome. In most of these free erythrocyte porphyrin concentration is usually
normal.
1.8.5 Diagnosis of erythropoietic protoporphyria
The most important diagnostic feature is elevation (often 50-100 fold) of
protoporphyrin (PP) in erythrocytes and plasma. A useful screen is the
demonstration of orange-red fluorescence in samples irradiated with violet light
during fluorescence microscopy or in a spectrophotometer. Increased levels of PP
are demonstrable in plasma, bile and faeces, but not in urine due to its hydrophobic
nature. However where liver disease is manifest, decreased excretion into the faeces
leads to lower faecal concentrations, elevated plasma levels and urinary excretion of
coproporphyrin. In vivo phototesting of skin in suspected cases shows swelling and
erythema to high doses of monochromatic violet light at 405 nm, but normal
responses to UVA and UVB.106 This response is maximal at between 6-12 hours,
unlike the more usual 24 of other photodermatoses.
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1.9 Clinical features of erythropoietic protoporphyria
1.9.1 Acute cutaneous manifestations of EPP
EPP is characterised by mild to moderate photosensitivity, with symptoms usually
present from early childhood. Patients present with intense itching, painful burning
or a stinging sensation following minutes to hours of sunlight exposure. In young
children these features may be accompanied by inconsolable crying or screaming.
Symptoms usually occur in spring and summer but some patients are also
symptomatic in the winter,107 and experience exacerbation by cold winds.106'108
The initial skin discomfort may be followed by cutaneous signs. These tend to be
subtle, to the degree that affected individuals may be considered to have a psychiatric
disorder.7'109 The lack of clinical signs or a relatively mild phenotype can lead to a
significant delay before diagnosis is reached.110"114 Unlike other cutaneous
porphyrias which show blistering, EPP is characterised by delayed skin redness and
oedema.44 Petechiae, purpura, crusting and blistering are only evident following
prolonged sunlight exposure (figure 5). Skin fragility, vesiculation, crusting and
hypertrichosis of other porphyrias are seldom seen in EPP. Some report the signs
coincident with the onset of the symptoms,115 whilst others have noted them
occurring later.7 The sensitivity tends to affect only sun-exposed skin, including
finger nails, and can also occur following exposure through normal window glass.7
The frequency of acute urticated erythema is reported to be a rare sign. Subsequent
purpura or bullae are dependant on the dose of light sustained and the individual
sensitivity.1 6 The localisation of the photosensitivity eruption is significantly
affected by clothing: lesions are most commonly observed on the face, neck and
upper chest, lower arms and hands.106
Erythropoietic Protoporphyria in the United Kingdom 23
Figure 5. Acute skin changes in EPP
a) Subtle purpura on radial aspect of an index finger of a 12-year-old.
b) Crusting over tip of nose and upper lip in an eight-year-old.
Cutaneous tolerance to sunlight is markedly reduced for several days after sun
exposure, even if the initial exposure did not progress to the oedematous or petechial
stage. This sensitivity has been termed the 'priming phenomena' and can be
explained by the photodynamic release of PP from erythrocytes in the dermal
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vasculature to vascular endothelial cells in response to relatively small repetitive
sunlight exposure.66'93 One paper reported white nails, onycholysis and occasional
nail shedding concomitant with acute skin changes.115 These have not been recorded
elsewhere.
1.9.2 Chronic cutaneous manifestations of EPP
Episodes of photosensitivity often commence during infancy before the child is able
to communicate effectively. The paucity of signs and limited awareness of EPP
among healthcare professionals typically result in misinterpretation of the cause of
the child's symptoms and result in delay in diagnosis. Thus repeated acute
photosensitivity reactions may occur, leading to the development of chronic skin
changes, characteristically restricted to the light-exposed skin of the nose, forehead,
cheeks and dorsae of the hands. Waxy or leathery scars particularly on the face or
hyperkeratotic thickening of skin is described, particularly over the knuckles (in one
series evident in 27%).106,116 Small shallow depressed scars may be evident on the
face, whilst stellate scarring may be evident, particularly over the hands. Radial
grooves (pseudorhagades) are seen on the lips and course wrinkles may be evident,
particularly around the eyes (figure 6).115 In some individuals, chronic changes are
so subtle that the skin appears normal.7'70'106'115 Two early case reports suggested
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hypertrichosis was a feature of the condition; ' this has not been supported by
later EPP patient series.
Improvement of symptoms has been reported in up to 45% of individuals with
increasing age, possibly through efforts to avoid sunlight exposure,44 although none
have resolve spontaneously.115'11 Late onset of EPP is rare. Only 13 patients have
been reported in whom symptoms started after the age of 40 years. In the majority,
this was due to acquired haematopoietic FECH mutations in the context of
• 190 199
myelodysplastic and myeloproliferative disorders. " There is however a report of
late-onset with a genotype known to cause EPP and a close family history: In this
case the authors postulate that this was due to the FECH mutation contributing
residual activity such that overall FECH activity was similar to that of asymptomatic
123
carriers.
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Figure 6. Chronic skin changes in EPP
a) Waxy thickening and linear scarring on a 36-year-old man's nose.
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c) Pseudolichenified hyperkeratotic thickening over the dorsum of a
35-year-old man's hand.
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e) Subtle macular scarring on the hand dorsum (same patient as (d)).
f) More pronounced macular scarring on the right cheek and neck of a
49-year-old lorry driver.
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g) Course wrinkles evident over lateral cheeks (same patient as (a)).
h) Course pseudorhagades in a 32-year-old teacher. Scarring is also
evident over the tip of the nose.
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compared to experimental models. Furthermore, application may miss certain sites
such as neck, temples and ears, and shedding due to rubbing, sweat or contact with
water or clothing requires reapplication every 2 to 3 hours.238 The topical cosmetic
tanning agent, dihydroxyacetone (DHA) can provide a degree of protection to
wavelengths greater than 370 nm and has been suggested as a potential adjunct to
i 239
sunscreen therapy.
Figure 7. Use of Dundee sunscreen (beige colour) and clothing to
protect against sunlight exposure.
Normal clear window glass absorbs wavelengths below 320nm (UVB). Lamination
provides partial protection against UVA(320-380nm),240 but does not protect against
the Soret band.234 Within houses, curtains and blinds in houses provide a cheap and
pragmatic solution for EPP photoprotection, but motor vehicles provide more of a
problem as current UK legislation requires 75% ofvisible light to come through front
and back windows and 70% visible light to come through side windows. Thus dark
tinted glass is illegal for windscreens and driver's side windows. A compromise can
be reached by applying window films such as CLS200XSR (Madico) or Dermagard
(Bonwyck) which block light up to 400nm, and allow visible light over 420nm
through. Within the 400-420nm range, there is an approximate 50% reduction in
passage of light. Yellow tinted museum films, such as TA81 XSR (Madico) or
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1.9.3 Haemopoietic effects of EPP
Microcytic anaemia has been reported in 20 - 60% of EPP patient series.7'106'115'124
In contrast to other inherited disorders of erythroid haem biosynthesis,125 the anaemia
is not dyserythropoietic (the erythroid cells are differentiating normally), there is no
iron overload, and there is evidence for iron-deficiency, with low serum ferritin and
serum iron levels,7'106'126'127 without iron loss.127 A mouse model of EPP, the
homozygous Fechm,Pas mutant, develops a similar microcytic anemia.128'129 At an
ultra-structural level there is consistent pathological iron deposits in the mitochondria
of bone marrow erythroblasts.127 Although it is probable that the anaemia of EPP
reflects limitation of haem formation by FECH deficiency, its mechanism and
relationship to disordered iron metabolism remains unclear.
1.9.4 Hepatic manifestations of EPP
In contrast to non-cutaneous porphyrias, acute abdominal and neurological attacks do
not occur, nor are drugs known to exacerbate EPP. The major non-cutaneous clinical
manifestation of EPP is hepatobiliary disease, caused by accumulation of PP in the
liver.130'131 Hepatic PP deposition manifests progressively as cholestasis, cirrhosis,
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rapid decompensation and death. " The exact mechanism of the PP toxicity in
the absence of light, 'dark toxicity', is unclear. There may be a direct effect of PP
crystal deposition in the liver: Canalicular secretion of PP appears to be the rate-
limiting step in its transport from plasma to hepatocytes and subsequently to bile and
faeces,135 and when this excretory capacity is saturated, rising intrahepatic
concentration of PP results in aggregation and deposition of solid pigment and
crystalline PP both within the hepatocytes and canaliculae, causing cholestasis,
accelerating PP deposition, and subsequent liver cirrhosis.136 However this may not
be the initial event in PP liver damage, as ultrastructural studies show abnormalities
of hepatocytes even in patients with clinically mild disease and normal hepatic
architecture.137 Furthermore, in rat models, PP appears to be toxic to the liver when
it is in a soluble form, decreasing bile flow, and histologically resulting in canalicular
distortion, dilatation and loss of canalicular cell microvillae in the absence of PP
deposition.138 Thus it was proposed that the cirrhosis and fibrosis may coincide with,
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or precipitate, the cholestasis. Studies show hepatocyte cell membrane ATPase
enzyme activities are significantly reduced in livers infused with soluble PP, perhaps
explaining the decreased excretory capacity of the liver in EPP, and the degree of this
• 139reduction appears related to the PP concentration within the infusion. A
mechanism might be the hydrophobic nature of the PP molecule and its lipid
solubility, resulting in change to the physico-chemical properties of hepatocyte and
canalicular secretory membrane lipid bilayers. The resulting effacement of
canalicular microvillae may additionally reduce the functional excretory area,
resulting in the cholestasis, which in the presence of an apparent unsaturable hepatic
uptake of PP, leads to increasing intracellular PP concentrations deposition and
fibrosis.135
The dark toxicity of PP may also be through its relation with hydrogen peroxide. PP
has been demonstrated to be associated with increased intracellular hydrogen
peroxide concentrations (perhaps reflecting increased oxidative stress on the cell due
to the mechanisms described above) and inhibition of hepatocellular proliferation,
both in a dose-dependant manner.142 Increased intracellular hydrogen peroxide may
exert a direct toxic effect on hepatocytes.143 However PP's generation of hydrogen
peroxide, in the presence of iron, also permits a Fenton reaction.14 'I41 The Fenton
reaction describes the oxidation of ferrous (II) iron by hydrogen peroxide to ferric
(III) iron, a hydroxyl radical and a hydroxyl anion (Fe2+ + H2O2 —► Fe3+ + OH* +
OH-), during which the presence of iron is catalytic. These generated reactive
molecules can result in lipid peroxidation and disruption of the structure and function
of cellular membranes and their associated enzyme systems.144
Clinically, by the time jaundice is clinically evident it is likely that hepatic damage is
advanced. At this stage the clinical presentation is said to resemble an acute
porphyria: in addition to significantly increased photosensitivity, neurological
dysfunction (motor neuropathy), abdominal symptoms, tachycardia and hypertension
may develop. Indeed, it may be this deteriorating photosensitivity which brings
some EPP sufferers into contact with the medical profession for the first time.9'1
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It is unclear why some individuals with EPP develop hepatic dysfunction whilst
others do not. The features of liver dysfunction in EPP have yet to be clearly
established, including its age of onset, with reports from children aged 6, 11 and 13
years.43'145'146 There appears to be a genetic basis in some cases with increased
incidence in AR inheritance,147"149 and in those with liver failure in affected
siblings.150"152 In one case, alcohol has been reported to be contributory to EPP
1 ST
related liver disease, while in another, serum y-glutamyl transferase (GGT)
appeared to parallel levels of TEP.154 Because the onset of liver disease cannot yet
be predicted, patients should be monitored with regular liver function tests (LFTs).
No large-scale epidemiological studies of unrelated EPP patients have been done to
assess the frequency of hepatic dysfunction in EPP. Results of previous studies are
difficult to interpret due to retrospective analysis, small sample size or selection bias
(table 3), however the incidence of abnormal LFTs in EPP has variously been
estimated to be between 0 and 36%.6'115'137
Data from these same studies has estimated rates for liver failure to be about 2-
4%.9'70'130 The majority of individuals with this complication were aged 30 years and
over,45'155'156 although it has also been reported in children.7'9'145'146 Once jaundice is
apparent, hepatic disease is usually so advanced that transplantation is required to
prevent death. There is also uncertainty about risk factors for liver disease in EPP.
Most studies on this topic consist of reports of one or a few patients with liver failure
and include the following: alcohol intake,153'157 hepatitis,9 haemolytic anaemia,
disturbed iron metabolism,124'158'159 and high erythrocyte and plasma protoporphyrin
concentrations,9'130'160 (probably secondary to developing cholestasis130'158).
In small series previous cholecystectomy in EPP, as a proxy for symptomatic
gallstones, have been reported to have a prevalence of between 6 and 12%, which
may be increased above that of normal populations.7'115'162 In white Caucasian
populations the prevalence of gallstones is variously reported as between 4 and 6%,
with a cholecystectomy prevalence of 0.6% in Italy.163'164 The use of
cholecystectomy rates for symptomatic gallstone disease by these studies allow only
an estimation of increase: Assessment of the true prevalence of gallstones in a large
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EPP series has not been conducted, and could prove difficult by objective means, as
ultrasonic diagnosis is required and asymptomatic gallstones are common. The
gallstones have also been reported to present at a younger age than would be
expected. However neither of these two apparent observations have been statistically
proven due to the low prevalence of EPP and the variable incidence of symptomatic
gallstones.70 Those gallstones which have been analysed have high levels of PP
(310-479pg/g compared to 0.14-4.06pg/g in normal individuals) with no apparent
difference in composition between the nucleus and the outer layers.7,44 This suggests
the stones to be initiated by a precipitate of PP, rather than by any alternative
compound such as cholesterol.
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2005 204 T 70 34% Reported: Current study -
AST/ALT (25% no active
dEPP) infection
1991 90 T Bi 22 24% Not Retrospective 2
AST/ALT reported Some patients
previously
reported9
1990 11 t 4 36% Not Retrospective, 137
AST/ALT reported small sample
size











1976 32 t AST Bi 1 3% Not retrospective 7
Alk Phos reported
1974 29 t AST Bi 0 0 Not Biochemistry 115
Alk Phos reported not performed
in all cases
1965 4 t Bi 0 0 Not 3 other cases 6
reported biochemistry
not performed
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1.9.5 EPP & pregnancy
Some women report significant improvement of their symptoms in pregnancy,8'115'165
apparently through a pregnancy-related reduction in erythrocyte PP levels.166'167 The
mechanism for this remains to be elucidated, but could result from a hormonal
influence on FECH expression, the dilutional effects on the vasculature of
pregnancy, or haemodynamic or hormonal changes causing diminished
protoporphyrin production, decreased efflux from erythrocytes, or enhanced biliary
excretion. Furthermore, as PP crosses the human placenta in a dose-dependant
manner, maternal PP may act as a substrate for the foetal FECH, leading to
suppression of foetal FECH and sequestration of maternal PP.168
1.10 Histopathology of EPP
The histopathological features of EPP affect only sun-exposed skin. Within the first
few days following sunlight exposure an acute inflammatory response is observed
with intercellular oedema in the epidermis and dermis and a dermal leucocytoclastic
neutrophil-rich infiltrate. Superficial cutaneous vessels appear selectively damaged,
with vacuolation, swollen organelles, cytolysis and loss of intercellular contact.96
Red cell extravasation may be seen within vessel walls and perivascularly.
Involvement of epidermal cells, fibroblasts and other dermal elements appears to be a
later event,96 suggesting that endothelial cells represent the initial target of the
photodynamic reaction.69 This observation has been explained by the relatively high
concentration of PP within endothelial cells and presence of high partial pressure of
oxygen, facilitating oxidative photodynamic damage.169
The most common chronic changes evident are epidermal hyperkeratosis, acanthosis,
but also sometimes atrophy. In the dermis, amorphous hyalin-like PAS-positive
deposits are observed, particularly around superficial vessel walls and papillary
dermis, caused by concentric reduplication of the basal lamina. These are thought to
represent carbohydrate-protein complexes from repeated acute damage and repair of
blood vessel basement membrane.17 '171 Immunohistochemically there is IgG
deposition (with occasional IgM) at the dermo-epidermal zone and around blood
vessels. Electron microscopy confirms extensive reduplication of the basal lamina of
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small upper dermal blood vessels from light-exposed skin, with occasional clumps of
dense amorphous material within the reduplication.172
Within the liver, most individuals, even those without serological evidence of
dysfunction, will show evidence of vacuoles containing characteristic needle-like PP
crystals.173 The histopathological changes range from essentially normal liver
architecture with PP pigment deposition within hepatocytes, Kupffer cells and
canaliculi, some widening of portal tracts and mild periportal fibrosis, to more
advanced cases demonstrate larger collections of PP crystals within hepatocytes,
Kupffer cells and free in canaliculi, where they appear to plug the lumen. Changes
include hepatocyte degeneration and necrosis, micronodular cirrhosis, bile duct
proliferation, cholestasis and porphyrastasis. Under polarised light, large quantities
of PP exhibit a 'Maltese Cross' appearance, while smaller deposits appear as brilliant
1 "71
reflections.
1.11 Prevalence of EPP
EPP is not specific for sex.8 The prevalence of the IVS3-48C low expression allele
shows clear differences between ethnic populations,174 with low levels in Afro-
Caribbeans (<1%) and north Africans (2.7%), and high levels in Japanese
populations (43%) compared to white Europeans (11%).175'176 It has been proposed
that the prevalence of symptomatic EPP in a population would be determined by the
frequency of the IVS3-48C polymorphism within the population.176 However the
true prevalence of the clinical condition is difficult to predict in the absence of large-
scale randomised population screening. Previous estimates have been based on
patients known to physicians, and probably significantly underestimate the true
incidence due to patients failing to seek medical advice, failure of physicians to
recognise the condition, or false negative investigations. Studies have estimated
prevalences between 1:200,000 (Sweden)177 to higher rates of 1:79,000 (Northern
Ireland)70 and 1:75,000 (Netherlands)106 for more well-defined populations. In view
of the overall underestimation of cases of EPP, these latter figures are probably more
accurate, although a founder effect is possible in these smaller populations, as
demonstrated among Swiss EPP families.178
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1.12 Genetic inheritance of EPP
Early case reports of EPP patients described between 10 and 25% of red blood cells
showing a transient red fluorescence when viewed under a fluorescence microscope.
Analysis for these 'fluorocytes' provided a simple qualitative screen for the condition
using light-protected dried or wet blood samples (with a differential diagnosis of iron
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deficiency anaemia, lead poisoning, HCP and CEP). However asymptomatic
individuals from EPP families were also shown to have peripheral blood fluorocytes
and that this asymptomatic group with fluorocytes outnumbered those clinically with
EPP.179 Studies of peripheral blood fluorocytes showed no gender predilection, that
the asymptomatic group with fluorocytes had normal or slightly elevated PP,
significantly lower percentage of fluorocytes than relations with EPP, and that they
occurred in half of the children and siblings of affected individuals following an
apparent autosomal dominant pattern.8'41 The EPP affected individuals appear to
represent a quarter of children in these families suggesting recessive inheritance.
Further pedigree and biochemical studies suggested that the genetics of the condition
were complex, as clear autosomal dominant parent-child transmission of the clinical
condition occurs in only 8% families,8'147'180 and FECH activities in overt EPP are
10-30% of normal enzyme activity: significantly less than the 50% predicted by
haplodeficiency (where a gene is mutant or absent on one diploid copy).5'58'60'181
Furthermore, FECH activities in asymptomatic siblings and offspring of EPP
individuals are decreased below normal, although not to the 30% level seen in
180
symptomatic cases. To explain these observations, a three allele hypothesis was
proposed comprising a normal allele if), an allele which led to the presence of
occasional fluorocytes in unaffected parents (F1-) and a third allele with a high
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population frequency (F).
The cloning, sequencing and characterisation of the human FECH gene, located on
the long arm of chromosome 18 and containing 11 exons spread over 45kb, allowed
examination of the genetic defects underlying the condition.51'103*182 A French EPP
family where the asymptomatic father had a deleterious FECH mutation which
reduced his FECH activity to 50% was studied. One of his children was
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symptomatic with EPP and had FECH activity of 25%. The mother was shown to be
heterozygous for an intronic single nucleotide polymorphism, IVS3-48T/C, and had
FECH activity of 75%. The affected son had received the C allele, while his
asymptomatic brother, who had also received the deleterious mutation from his
father, received the T allele and had FECH activities of 50%. Two sisters were
phenotypically and genotypically normal.183 This co-inheritance of a mutation which
considerably affects or abolishes FECH activity, trans to a wild-type hypomorphic
(reduced activity) allele causing a mild deficit in FECH activity causing symptomatic
EPP, confirmed the postulated 3-allele hypothesis: in this family the father is F*f the
mother Ff the daughters ff, the asymptomatic brother F*f and the symptomatic
brother F*F. This hypomorphic IVS3-48C allele (F) was subsequently shown to
result in aberrant splicing of the FECH mRNA (where RNA is modified by the
removal of introns and joining of exons), inserting a premature stop codon into the
FECH mRNA which is then more rapidly degraded than normal mRNA (by the
process of nonsense-mediated mRNA decay), resulting in decreased levels of
FECH.184 It is present in approximately 10% of white Caucasian populations,5'175
and in an unpublished study, the porphyria group in Cardiff have shown that IVS3-
48C allele is present in 108 of 111 unrelated EPP patients without liver disease. A
FECHmutation on both alleles explains the small subgroup of families in whom EPP
inheritance appears autosomal recessive (estimated to have a prevalence in the UK of
about 3% all EPP individuals).4'180'185"187 Reports of individuals with liver failure in
this subgroup of EPP subjects have lead to the suggestion that autosomal recessive
inheritance may put individuals at particular risk of more severe clinical features,
l 7,14 ,152 Rareiy5 0ther mechanisms must be involved in the aetiology of EPP as
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occasional patients are described in whom FECH activity appears normal.
Furthermore, late-onset EPP has been intermittently reported.189 In some individuals
this has been recognised to be in association with aplastic anaemia or
myeloproliferative disorders, resulting from FECH mutations in erythroid progenitor
cells.122'190'191
To date over 60 disease-specific deleterious FECH mutations have been reported,
with the majority being family-specific.9*192"194 A small minority of families have
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mutations that are shared by a limited number of other EPP families (possibly
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representing a founder effect). ' The majority of identified mutations are so-
called "null-allele" mutations, where the mutation leads to the formation of a
truncated, and therefore inactive enzyme completely lacking it's normal function,
and includes nonsense and frameshift mutations.196 In contrast, point mutations, in
which a single nucleotide is changed, resulting in a codon that codes for a different
amino acid, which have been identified in approximately 20% of EPP individuals.
They do not necessarily inhibit enzymatic activity, but, for example, may result in a
reduction of activity, or affect other characteristics such as thermal lability, a so-
called "missense mutation".104 FECH mutations in the central iron-sulphur cluster
seem to be of particular importance in affecting FECE1 activity.196
The significance of the different FECHmutations on clinical phenotype has not been
established, but while there is considerable genetic heterogeneity in those with liver
complications, all appear to have "null-allele" mutations which produce major
structural alterations in FECH,158'1 °'197 and this association has been reported to be
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statistically significant. These observations suggest that there may be a correlation
between genotype and protoporphyrin-induced liver disease with severe mutations
predisposing to this complication, although because the same mutations are found in
asymptomatic family members, other factors must also be critical to the development
of this severe phenotype. FECH activities are said to be particularly low in
autosomal recessive EPP, predisposing to severe liver disease;147 although
homozygous missense mutations do not appear to be associated with this
1 o/-
complication.
These genetic models of FECH activity are further complicated by the observation
that FECH exists as a dimeric molecule. Theoretically, the amounts of wild-
type/wild type, mutant/wild-type and mutant/mutant dimers in EPP individuals will
be 25, 50 and 25% in the same cell respectively. The observation that a majority of
EPP individuals exhibit less than 30% normal FECH activity could be explained by
FECH only being active when the dimer contains two wild-type subunits.
Heterodimers consisting of wild-type and mutated subunits have been shown to
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exhibit significant activity,199 however these molecules are inherently less stable, and
this explanation might explain the lower than expected FECH activity.200 No strict
correlations have been identified between genetic defects and either the erythrocyte
protoporphyrin levels, FECH activities or disease severity.
1.13 EPP & surgery
During surgery, EPP individuals are at risk of burn injuries to skin and intra¬
abdominal organs exposed to operating and other strong light sources emitting
wavelengths around 400nm (operating theatre lights' normal emission spectra is 300-
750nm), and circulating erythrocytes are more susceptible to photolysis, causing
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haemolytic anaemia. ' This is particularly the case in the setting of liver failure
when excess accumulation of protoporphyrin results in extreme photosensitivity,
massive haemolysis, and with at least one death attributed to such
complications.203'204 A number of measures can be implemented to reduce risks of
surgery: Firstly PP levels can be reduced by perioperative whole blood transfusions
to reduce haem synthesis and thereby PP synthesis, or omitting to use own-blood re¬
circulation cell savers. Secondly, all lamps in all rooms can be shielded using
yellow-coloured acrylate filter, such as TA81 XSR (Madico) or Bexfilm U
(Summerside Blinds), to cut off wavelength transmission below about 530nm and
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give almost complete protection from UV and visible violet light. Likewise,
windows adjacent to patient areas should have filters applied. The yellow filter can,
however, cause problems for both anaesthetists and surgeons, as blue objects appear
black, and other colours are perceived with a yellow hue.130 With a few notable
90ft
exceptions, the requirement to avoid anaesthetic agents is a fallacy in both the
anaesthetic and surgical literature (unlike the acute porphyrias, EPP is not associated
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with drug-induced crises).
Massive intra-operative haemolysis and severe polyneuropathy are two significant
peri-operative complications of surgery in EPP patients with liver failure. The
haemolysis, due to the photoactivation of PP by theatre light sources, releases further
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PP from erythrocytes, perhaps exacerbating the risk of subsequent neuropathy. '
The severe polyneuropathy, usually motor and which is seen both in the pre and post
Erythropoietic Protoporphyria in the United Kingdom 40
909 910 91 1
transplant period, clinically resembles Guillain-Barre syndrome. ' ' Elevated
PP has been postulated to cause a neuronal haem deficiency or may be directly
neurotoxic. The neuropathy does recovers slowly; peri-operative haematin infusion
in combination with plasmapheresis or dialysis with molecular adsorption (such as
212 214MARS or Prometheus systems) may help to prevent its development.
1.14 Vitamin D and porphyria
Vitamin D is an essential fat-soluble hormone required for bone integrity and
calcium homeostasis.215 Approximately 90% of requisite vitamin D is formed within
the skin as a result of sunlight photolysis of 7-dehydrocholesterol by ultra-violet B
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(UVB) radiation, before a temperature-dependent isomerisation to cholecalciferol.
White populations in the northern hemisphere tend to develop physiological vitamin
D insufficiency in winter and early spring.217 This propensity can be exacerbated by
a number of factors including increased ethnic skin pigmentation, occlusive clothing,
••218220institutional residency and decreased synthetic capacity with increasing age.
Although sunscreen use does appear to cause some reduction in 25-hydroxyvitamin
221 222 • • • •D levels, ' there is no equivocal evidence of sunscreen use causing insufficiency
or deficiency (in cases where this has been reported, other risk factors such as ethnic
skin pigmentation, institutional residency, age or occlusive clothing, have been
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present). " Increased incidence of various conditions such as diabetes mellitus,
hypertension, tuberculosis and some malignancies within populations at increasing
latitudes have led to suggestions that it may also protect against their
development.224"227
Previous studies of photosensitive patient cohorts with xeroderma pigmentosum (XP)
and Smith-Lemli-Opitz syndrome (SLOS) who actively avoid sunlight have failed to
990 OOQ
show convincing evidence of vitamin D insufficiency. ' There are case reports
and small series of individuals with photodermatoses such as occulocutaneous
albinism, coproporphyria, chronic actinic dermatitis (a case report of an elderly
Pakistani man resident in the UK, with several risk factors for insufficiency) and
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cutaneous lupus erythematosus which make such an association. " (Jury CS,
personal communication) Following a report in 1955 of a boy with coproporphyria
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and rickets there have been no further reported studies or cases commenting on
• .... • . 36vitamin D status in individuals with porphyria.
1.15 Therapeutic approaches in EPP
1.15.1 Patient information
One of the most helpful measures for EPP patients and their families is a detailed
explanation of the condition provided by a well-informed expert and complimented
by the provision of accurate and up-to-date written information. A wealth of
information can be found on the internet about porphyrias, but some of this is of poor
quality and most is focussed on porphyrias with acute symptoms. For example, the
excellent European Porphyria Association site (http://www.porphyria-europe.org/)
currently has nothing in the patient section about non-acute porphyrias, and has only
four lines of text describing EPP in the clinicians' section. Likewise, national
support organisations are available for porphyrias as a group of conditions (e.g.
British Porphyria Association http://www.porphyria.org.uk/), but tend to focus on the
acute and mixed group of porphyrias, with only a few providing quality information
and support for the cutaneous porphyrias such as EPP
(http://www.porphyriafoundation.com/). The Cardiff Porphyria Service maintains an
accurate website (http://www.cardiff-porphyria.org/), but this is directed mainly at
clinicians rather than patients. Using 'erythropoietic protoporphyria' as a search
term does return more specific information, but this ranges considerably in quality
from the good (http://www.netdoctor.co.uk/diseases/facts/erythropoietic.htm) to the
inaccurate (http://www.britannica.com/). Prior to this project, the New Zealand
Dermatology Society was the only major professional association to host a patient
information sheet about the condition (http://dermnetnz.org/systemic/erythropoeitic-
protoporphyria.html). There are currently no English-language EPP-specific patient
support groups, although such groups do exist in Germany and the Netherlands
(http://www.epp-deutschland.de/ and http:/1www.epp.info/).
1.15.2 General management
The cutaneous symptoms of EPP result from the interaction between visible light in
the Soret range (400-41 Onm), and protoporphyrin IX (PP). Hence, avoidance of
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strong light sources, particularly sunlight, through behaviour modification and
photoprotection should form the mainstay of treatment. This can be achieved using
clothing or sunscreens that include protection against the visible spectrum,
particularly the longer wavelengths. Avoidance of outdoor activities is
recommended, particularly in the middle of the day, and career guidance should
advocate an indoor occupation.233 Clothing such as hats, long-sleeved tops and long
trousers provide excellent photoprotection, particularly for closed-weaved, dark-
coloured fabrics.234 Thus socks and shoes should be recommended over bare feet or
open footwear such as sandals, and summer clothing avoided as this tends to have
insufficient protection.235 Some clothing manufacturers advertise their products
using a UV protection factor (UPF) rating, which unlike the SPF which only
measures protection against UVB, measures protection from clothing against UVB
and UVA. The UPF rating for a fabric/textile is the ratio of UV measured without
the protection of the fabric compared to with protection of the fabric. For example, a
fabric rated UPF 30 means that if 30 units of UV fall on the fabric only 1 unit will
pass through; thus by blocking or absorbing 29 out of 30 units of UV it is blocking
96.7% of UV. It has been suggested that photosensitive individuals wear fabrics
with a UPF > 30, as this has been shown to protect against UV-induced erythema and
yif. ,
the development of pre-malignant lesions in animal models. While it does not
automatically follow that UV-opaqueness equates to visible-light opaqueness, in
practice this is likely to be the case.
As the symptoms of photosensitivity in EPP are triggered by visible light in the Soret
range, sunscreens specifically effective against UVB (280-320nm) or UVA (400-320
nm) are inappropriate and ineffective protection. Opaque sunscreens containing
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titanium dioxide, zinc or iron oxide may be effective theoretically, but a thick
coating is necessary to achieve a sufficient degree of reflection (figure 7), and the
white appearance and greasy formulation are usually cosmetically unacceptable for
most patients. Decreasing the particle size into micronised form (10-50nm,
compared to 500nm of non-micronised form) increases cosmetic acceptability but
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shifts protection towards shorter wavelengths. In practice, sunscreen tends not to
be applied in sufficient quantities or frequency, resulting in reduced photoprotection
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compared to experimental models. Furthermore, application may miss certain sites
such as neck, temples and ears, and shedding due to rubbing, sweat or contact with
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water or clothing requires reapplication every 2 to 3 hours. The topical cosmetic
tanning agent, dihydroxyacetone (DHA) can provide a degree of protection to
wavelengths greater than 370 nm and has been suggested as a potential adjunct to
sunscreen therapy.239
Figure 7. Use of Dundee sunscreen (beige colour) and clothing to
protect against sunlight exposure.
Normal clear window glass absorbs wavelengths below 320nm (UVB). Lamination
provides partial protection against UVA(320-380nm),240 but does not protect against
the Soret band.234 Within houses, curtains and blinds in houses provide a cheap and
pragmatic solution for EPP photoprotection, but motor vehicles provide more of a
problem as current UK legislation requires 75% of visible light to come through front
and back windows and 70% visible light to come through side windows. Thus dark
tinted glass is illegal for windscreens and driver's side windows. A compromise can
be reached by applying window films such as CLS200XSR (Madico) or Dermagard
(Bonwyck) which block light up to 400nm, and allow visible light over 420nm
through. Within the 400-420nm range, there is an approximate 50% reduction in
passage of light. Yellow tinted museum films, such as TA81 XSR (Madico) or
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Bexfilm U (Summerside Blinds), give almost complete protection from UV and
visible violet light but are not legal on UK motor vehicles. Newer, non-tinted
propriety glass films (e.g. 3M prestige) designed to reduce UV transmission also
claim to absorb up to 99% light up to wavelengths of 410nm, and may prove useful
for school and home windows.
Individuals' symptom management has been well described in previous small series,
consisting of attempts to relieve the pain by cooling the skin using wet cloths or
towels, and scratching or rubbing to relieve the itch.106 Antihistamines are
commonly used first line agents for the pruritus and to reduce weal and flare.241
Because of the small unpredictable proportion of EPP individuals at risk of life-
threatening liver disease, it is good practice for affected individuals to avoid or
minimise exposure to factors which could exacerbate this propensity, such as
medication, excess alcohol and risk behaviour for hepatitis virus infection.
1.15.3 Interventional measures to reduce solar sensitivity
There are a number of suggested therapies for EPP, but for the majority, it is difficult
to assess efficacy due to lack of objective measurement.242 The main symptom of
EPP is pain; thus, assessment of severity is subjective and prone to placebo effect.243
In contrast, skin phototesting objectively induces skin erythema; however skin
erythema does not necessarily correlate with individuals' self-assessment of pain.244
Antioxidants are molecules capable of removing free radical intermediates and
inhibiting other oxidation reactions, through donation of hydrogen, formation of a
complex between the radical and the antioxidant (free radical acceptor), loss of
electrons or an increase in their oxidation state. The resulting antioxidant free radical
is generally stable and does not initiate another free radical due to the stabilisation of
and delocalisation of radical electron (resonance stabilised) within an aromatic
molecule, or through conformational change of the molecule. This 'quenching' of
reactive oxygen species keeps them at an optimum levels for biological functions,
whilst at the same time preventing oxidative damage to cellular components such as
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DNA, proteins and lipids. Antioxidants have been shown to have an inhibitory effect
on porphyrin-induced cellular phototoxicity in vitro,245 and one such compound, P-
carotene, is a standard therapeutic agent used in EPP. There is sound theory for its
use, as photosynthetic organelles in plants utilise carotenoids to quench the excited
singlet oxygen formed by the porphyrin chlorophyll during rapid energy and electron
transfers.246 It also absorbs light maximally at 450-470nm, and may therefore, act as
a chromophore, reducing some of the light that would activate PP.247 Clinical trials
in bacterial and animal models suggested benefit; P-carotene was approved for use in
EPP by the United States Food and Drug Administration in 197 5.248 The initial
uncontrolled trial found an increased sunlight tolerance in 84% of subjects,249
however discolouration of the skin at therapeutic doses makes blinded assessment
difficult and subsequent trials have found a similarly high response rate to placebo.243
The only controlled cross-over trial of P-carotene (which assessed subject's
recordings of time spent outside during placebo and P-carotene treatments) did not
show a significant therapeutic effect.250 The small numbers used in the trial (13)
could have resulted in failure to detect a small effect, and there was no objective
measurement used of exposure to sunlight. Furthermore, following publication of
the trial, the treatment's main proponent, Dr Mathews-Roth, suggested that doses
higher than the lOOmg daily use in the trial (and which she had initially proposed)
were lower than optimal. Unfortunately the preparation has not been tested again at
these higher doses. Thus if P-carotene has any effect at lower doses, this is probably
small, and has not been proven to be effective at higher doses. The maximum daily
oral dose is age-related (1-4 years: 60-90 mg, 5-8 years: 90-120mg, 9-12 years: 120-
150mg, 13-16 years: 150-180mg, age 16 and over: 180mg), although a maximum of
300mg/day has been used safely. Approximately 80% of individuals on maximal
dose P-carotene report significant prolongation in the time they can spend outside
before developing the symptoms of EPP, although one to two months may elapse
before this benefit is noticed. Approximately 20% of EPP individuals did not find P-
carotene helpful, and if there is no improved tolerance to sunlight by 3 months at
maximal dose, it can be concluded that P-carotene is not effective in that
• 948 9S1 •
individual. ' The main side effects are carotenaemia, manifesting as striking
yellow-orange discolouration of the skin, most marked on the palms and soles. Less
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commonly, gastro-intestinal side effects such as nausea, abdominal discomfort and
diarrhoea occur. There are conflicting reports of |3-carotene and the risk of systemic
malignancy. Epidemiological studies of (3-carotene dietary supplementation of
individuals at high risk of lung cancer (smokers and asbestos workers) found more
cancers in the intervention group compared with placebo,252'253 while another looking
at all cancers found neither an increase or a protective effect.254 The currently
recommended formulation of P-carotene supplementation is a 'beadlet' preparation
(Lumitene) which has superior bioavailability over crystalline formulations.
Increased intake of carotenoid-containing foods would not attain the serum levels
recommended, and could result in toxicity from other food constituents. Previous
use of preparations containing the carotenoid pigment canthoxanthine in combination
with P-carotene is no longer recommended due to lack of photoprotection, and risk of
retinal deposition of canthoxanthine granules.
Vitamin E (a-tocopherol), similar to p-carotene, shares the ability to quench singlet
oxygen. Case reports have suggested possible efficacy,156'157 but in vivo studies have
7 9SS
failed to show clinical benefit as a systemic photoprotective agent. ' " N-
acetylcysteine (NAC) is an agent that increases levels of glutathione, an endogenous
antioxidant. The mechanism of action is unknown, but may involve the quenching (a
process which decreases the intensity of a reaction through charge or energy transfer
reactions) of radical oxygen molecules, or increased levels of glutathione to attenuate
porphyrinogen oxidation. Case reports suggest efficacy in reducing the cutaneous
symptoms,256"258 however a small cross-over double blinded trial in EPP showed no
benefit.243 The chemically similar L-cysteine has been suggested to have a beneficial
259effect in EPP; again the mechanism is thought to be an antioxidant function.
Subjective and objective increased tolerance to sunlight of EPP individuals can be
induced using narrow-band EfVB (TL-01) phototherapy in spring to 'harden' the skin
over the summer period.260'261 The mechanism of action is not fully understood but
may result from UV-induced skin thickening and melanogenesis. Long-term risks of
phototherapy are a disadvantage, but are probably more than offset by the cumulative
minimal UV exposure of EPP individuals due to their expert and rigorous sun-
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avoidance behaviour. PUVA has also be used successfully, but as the wavelengths
of UVA more closely approach those of visible violet light, and therefore increase
the risk precipitating EPP symptoms, UVB is probably to be preferred.
Subcutaneous administration of synthetic a-melanocyte stimulating hormone (MSH)
induces skin tanning without excess UV exposure.262'263 An open-label trial in five
EPP patients has suggested significantly increased tolerance to artificial light and
increased cutaneous melanin density.264
Case reports suggest utility or possible utility of a number of other agents such as
pyridoxine,265 zinc (as zinc protoporphyrin is less phototoxic than metal-free
protoporphyrin),266 and dietary fish oils (the mechanism is unknown although the
• 267
high omega-3 polyunsaturated fatty acids may act as an antioxidant). Other non-
anti-oxidant treatments approaches have focussed on trying to reduce the
enterohepatic circulation of PP excreted by the liver but then subsequently
reabsorbed. In the context of incipient or actual liver decompensation, when levels
of PP are significantly elevated, cholestyramine has been reported to reduce blood
levels of PP and reduce photosensitivity. Treatment may also be associated with
• • 968
histological evidence of a reduction in hepatic crystalline deposits of PP.
1.15.4 Suppression of haematopoiesis
Haematological investigations of EPP patients often suggest an iron-deficient
197 •
picture, although the mechanism remains uncertain, as no studies have examined
the aetiology. It seems unlikely that individuals with EPP are losing iron; the
mechanism probably involves either failure to adequately absorb iron from the gut,
or failure to utilise it (suggested by electron microscopic demonstration of iron
deposition in EPP erythroblast mitochondria).127 The role of iron supplementation in
EPP is controversial and the literature limited, consisting mainly of small series and
case reports (table 4). Clinically iron has been reported to normalise liver function
96Q 979
and erythrocyte protoporphyrin levels " however others report symptomatic and
biochemical deterioration of EPP following supplementation1'9'273 with improvement
following the discontinuation of treatment. Theories for the beneficial effects of iron
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supplementation in EPP include reduced enterohepatic circulation due to chelation
with protoporphyrin in the intestine, increased non-enzymatic intracellular chelation
with protoporphyrin, or facilitated chelation by residual active ferrochelatase due to
increased intracellular iron concentrations.269 Conversely deterioration following
supplementation may result from stimulation of haematopoiesis and increased
production of protoporphyrin, interaction with other products such as the oral
contraceptive, which predispose to cholestasis, or induction of photodamage by
• • ?7T
acting as a catalyst in oxygen free radical formation.
A clinical observation of decreased photosensitivity following transfusions with
washed packed red blood cells, led to the observation that this was accompanied by a
• • 07n 071
decline in free erythrocyte PP levels in EPP individuals. ' Transfusions (usually
in the setting of decompensated cirrhosis) of packed red cells or haematin have been
reported to reduce both photosensitivity and biochemical markers of the condition
07fl 070
such as free PP and TEP, " however others have reported there is no benefit in
• 010
preventing progressive hepatic deterioration and of symptomatic deterioration
following such treatment.274 The mechanism for action of packed red cell
transfusions may be through suppression of endogenous bone marrow erythropoiesis
and PP synthesis, as has been demonstrated in sickle cell anaemia and thalassaemia,
07c 07A
or through a dilutional effect. ' Improvement in symptoms logically results from
the reduced free PP and TEP levels, although a direct link between these parameters
and degree of photosensitivity has not previously been demonstrated. However this
therapeutic approach carries significant risk of transmission of blood-borne viral and
prion infections, is not generally used, except in the setting of fulminant
protoporphyric liver disease.
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1.15.5 Gene therapy treatment for EPP
Since the underlying abnormality in EPP is a reduced level of ferrochelatase activity,
mainly in the bone marrow, the definitive treatment for the condition would be to
augment FECH levels to 50% or above that of the wild-type population. Human
FECH has been transferred using a retrovirus into the haematopoietic stem cells of a
missense FECH EPP mouse model. Transplantation into irradiated recipient EPP-
model mice, resulted in elevated erythrocyte protoporphyrin levels falling to within
the normal range, and clinically correction of the skin photosensitivity, compared to
non-transplanted mice, although pre-existing liver dysfunction and cirrhosis was not
977 •
reversed. As greater than 50% of haematopoietic stem cells required correcting to
reverse the EPP phenotype, and there was no substantial in vivo selection of the
transfected cells compared to FECH-deficient cells, ex-vivo preselection of a high
proportion of transfected cells is necessary, for the current time making this
technique impractical in EPP. Unfortunately human experiments of gene therapy
using retroviral vectors for haemophilia B detected vector in participants' semen,
raising concern about germline modifications, and those in children with severe
combined immunodeficiency (SCID) had a higher than expected level of leukaemia
in the recipients. Thus human gene therapy is currently facing a period of further
experimentation, particularly to find alternative vectors, before additional in vivo
• 970
trials can be conducted.
The identification of both the mutant FECH and the low activity wild-type FECH
has enabled useful genetic counselling for the first time. If the partner does not
possess the low-expression variant, the chances of children having the condition is
very low, whilst if the variant is present, the probability is 25% for each conception.
Potential parents who previously might have opted not to have children or
experienced considerable anxiety prenataly can now make an informed choice.
1.15.6 Treatment of hepatic failure
For EPP patients who progress to cirrhosis or acute liver failure, liver transplantation
970 t ,
has been established as a successful treatment. By 2007, sixteen patients in
Europe and 20 in the USA had received transplantation.64 However the underlying
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metabolic aetiology is not corrected and liver disease may recur in the graft.
Complications of this technique include perioperative light-induced tissue damage
and motor neuropathy. Furthermore rapid decompensation of liver function may
occur in those developing fulminant hepatic failure, manifesting as an EPP crisis,
where the acute decline in hepatic function is accompanied by a marked increase in
erythrocyte and plasma PP, with severe abdominal and back pain. Light-induced
tissue damage is prevented by screening all light sources with a filter to remove
wavelengths of 400-410 nm.280
It is standard practice to use a number of therapeutic interventions simultaneously for
EPP patients with decompensating liver disease; clinical or biochemical
981
improvement can be difficult to ascribe to any one therapy. Haematin, usually
combined with plasmapheresis, has been used to treat crises and neuropathy by
979 989
reducing PP levels. ' In acute porphyrias there is evidence that haematin reduces
98*2
excess production of porphyrin by the bone marrow. Plasmapheresis decreases
free plasma PP by plasma exchange, but does not treat protein-bound PP.
Replacement with extracorporeal albumin dialysis (molecular adsorbents
recirculating system (MARS) and the Prometheus system) increase the proportion of
PP removed.214'284
Oral cholestyramine has been reported to be successful in reducing TEP, normalising
serum transaminases and improving hepatic architecture on biopsy, both as
monotherapy and in combination with oral iron or vitamin E.156'268 These effects are
probably related to its demonstrated effect on increasing faecal PP excretion,
• • • 985
probably through interruption of the enterohepatic PP circulation.
A case of oral iron supplementation has been reported to improve the biochemical
parameters of liver dysfunction, possibly through enhanced conversion of excess
98f. ,
protoporphyrin to haem. However, others have reported deterioration both
biochemically and symptomatically when this approach has been tried for other
patients.159 The mechanism for these observations has yet to be elucidated.
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Chenodeoxycholic acid was reported to lower erythrocyte and plasma protoporphyrin
• 1 "37 987 •
and reduce faecal excretion, ' perhaps through a reduction in synthesis or assisted
9 88
conversion to haem. Rat studies have suggested that ferrochelatase activity in
hepatocytes could be altered through dietary manipulation with fatty acids,
98Q • 9A7
particularly those diets rich in triolein oil, or dietary fish oils.
Thus, the most effective treatment for liver failure is currently liver transplantation,
through the removal of the hepatic contribution to excess protoporphyrin production,
and reinstitution of efficient protoporphyrin excretion.146'203 As the underlying bone
marrow ferrochelatase deficiency remains, transplanted patients are at risk of
developing damage in the new liver. In such a situation, some advocate chronic
• 282intravenous haem-albumin and plasmapheresis to support the transplanted organ.
Bone marrow is primarily responsible for protoporphyrin over-production and the
resulting hepatic complications. Bone marrow transplantation (BMT) has been
977 9Qfl
shown to be successful in an EPP mouse model, ' and as an unintentional effect
in a human following transplantation for acute myelogenous leukaemia.65 One
further individual successfully received bone marrow, rather than liver,
transplantation, following the development of severe progressive protoporphyrin
hepatic failure, with resolution of his serum liver biochemistry and improvement in
histological liver architecture.64 A further case of successful liver transplantation
followed by bone marrow transplantation has recently been reported, with the
i*i* 291rationale of protecting the engrafted organ and preventing recurrent liver disease.
However because of the significant associated risks, experience of the therapeutic
use ofBMT in EPP remains limited.
1.15.7 Follow-up for EPP patients
Evidence upon which to base recommendations for the management of EPP
individuals, particularly with regard to predicting and treating liver disease, is
lacking. This is made more difficult by the widely varying incidences for liver
disease given by previous studies, and no proven evidence for liver function tests
being a useful tool to identify significant liver disease. Unsurprisingly therefore,
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recommendations for surveillance to identify liver disease vary. Mathews-Roth
recommended liver biopsy in any patient with abnormal liver function, even when
this was minimal, or in those with markedly raised erythrocyte or plasma porphyrin
levels (TEP > 2000 pg/dl; plasma protoporphyrin > 50 pg/dl).292 Mooyaart
suggested annual measurement of serum liver function before the age of 20, and
biennial subsequently, with liver biopsies at a minimum of 5-year intervals.161
Sarkany and Norris measure liver function at six monthly intervals, on the basis of
9Q-1
the speed at which deterioration can progress. Thunell advocates annual follow-up
with more frequent visits for those with increasing TEP >30 pg/dl and referral to a
hepatologist if there is evidence of abnormal liver function.108 Harper recommends
an annual follow-up including vaccination for hepatitis A and B, monitoring liver
function and porphyrin levels, and liver biopsy in the presence of elevated results.294
A recent review has proposed the following programme for non invasive monitoring
of liver function, albeit without a suggested frequency:131
1. Investigations to exclude other causes of hepatic dysfunction (viral hepatitis,
haemochromatosis).
2. Liver function tests (including AST, ALT, Alk Phos and GGT).
3. Red cell (TEP) and plasma protoporphyrin levels.
4. Non-specific serum markers for hepatic fibrosis (YKL-40, Fibrotest,
Fibroscan and serum aminoterminal propeptide of type III procollagen).
5. Ultrasound scan for gallstones.
6. CT and MRI studies of the liver.
They also suggest indications for liver biopsy in the following EPP patients:
1. Those with null mutations or autosomal recessive disease in countries where
FECH genotyping studies are available.
2. In the presence of a family history of EPP-related liver disease.
3. Those with other risk factors for liver disease (viral hepatitis,
haemochromatosis, alcohol excess, non-alcoholic fatty liver disease).
4. Abnormal liver function tests.
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5. Evidence for hepatic decompensation (worsening of photosensitivity, liver
function tests, rising protoporphyrin levels).
6. Patient anxiety or preference.
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2. Methods
2.1 Ethical committee approval
The study was conducted in accord with the World Medical Association Declaration
of Helsinki ethical principles for medical research involving human subjects and its
subsequent amendments. Multicentre research ethics committee (MREC) approval
was obtained from the north-west MREC, Manchester (MREC No. 03/8/065 - 13th
October 2003) for a 'no local researcher' study. Following their instructions, 84
local research ethics committees for areas in which study subjects were resident were
informed of the study, the name of the subjects' local consultant, and sent a copy of
the MREC approval letter.
2.2 Statistics and sample size
A minimum sample size of 150 patients was selected following discussion with the
Department of Epidemiology, Statistics and Public Health, University of Wales
College of Medicine (Mr R. Newcombe, Reader). At prevalences of 20% for
abnormal LFTs and 20-30% for missense mutations, estimated statistical power is
about 88%. Statistical analysis was performed by the study investigator using an
SPSS package version 12 under the guidance of this department. All independent
factors were analysed using Spearman's correlation coefficient for continuous
quantitative data, or the Mann-Whitney test for nominal data, to identify significant
associations (where significance was taken to be p<0.05), or where the association
approached significance (p<0.1). Linear regression analysis was subsequently used
to investigate associations between these factors.
For statistical analysis of liver function test status, results were graded both into a
binary normal/abnormal and into a 4-category ordinal variable (normal, A (elevated
yGT, isolated increase in serum alkaline phosphatase, bilirubin < 34 U/L), B
(elevated AST </= 68, ALT </= 60) and C (AST > 68, ALT > 60). As the majority
of variables had skewed distribution, non-parametric data analysis was performed: a
Kruskal-Wallis test (KWT) for one-way analysis of concordance and the Mann-
Whitney test (MWT) for independent groups.
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2.3 Identification of cases of erythropoietic protoporphyria
All available EPP patients were identified from databases or patient records held in 5
British supra-regional referral centres for photodermatoses:
1. Department ofMedical Biochemistry and Immunology, University Hospital of
Wales, Cardiff.
2. St John's Institute ofDermatology, St Thomas' Hospital, London.
3. Departments of Biochemistry and Dermatology, Hope Hospital, Salford.
4. Department of Biochemistry, The General Infirmary, Leeds.
5. Department ofDermatology, Ninewells Hospital, Dundee.
Inclusion criteria
• Age at least 5 years
• Biochemical diagnosis of EPP
Exclusion criteria
• Age less than 5 years
• Haematological or hepatic malignancy
The referring consultant for each patient was identified, either from the records, or by
telephoning the referring hospital or department. Each of these physicians was sent
details of the study, informing them of the ethics approval and asking if they would
allow their patients to be contacted and invited to take part in the study. Consultants
were asked to reply to the dermatology department in Cardiff using a postage-paid
envelope, confirming the current contact details of their patients. To minimise travel
by patients, the consultants were also asked if they would allow the use of their local
out-patients department for the study investigator to see their patients. In situations
were patients had moved areas, participating consultants were asked if they minded
their patients being seen at a different hospital. Following permission, patients
were sent a postal study invitation consisting of a covering letter (stating that their
local consultant's and the local ethical committee permission had been sought), a
study information sheet, a reply form to indicate whether they did or did not wish to
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participate and a stamp addressed envelope. If the individual's consultant felt this
would be perceived as 'cold-calling' and might cause distress, the patient invitation
letter was sent to the consultant to allow them to insert a personalised covering letter.
2.4 Organisation of patient visits
With secretarial help provided by the Department of Dermatology, University of
Wales College of Medicine, groups of patients in each locality with available first
degree family members, were asked to attend the local NHS out-patient facility,
following the prior agreement of the unit. Patients were allocated appointments at 30
minute intervals. With the prior agreement of the local biochemistry department,
serum blood samples were centrifuged prior to transportation back to Cardiff for
analysis.
2.5 History taking
History taking for details of photosensitivity was standardised by use of a proforma
(appendix III). The questionnaire was constructed for completion by the
investigator, as part of an interview with the subject (or subject and their parents, if
subjects were children). The same investigator saw all the study subjects to
minimise inter-observer variability. The questions were constructed to be clear and
concise. Some questions were relatively focused, with a yes/no format, or with a
limited number of choices. Other questions were deliberately open-ended to ensure
that clinical information of relevance was not overlooked, and all comments made
during the interview relating to EPP were recorded. Every effort was made to avoid
ambiguous or leading questions.
The clinical proforma was divided into four main sections:
• General questions relating to the photosensitivity and the appearance of any
associated eruption.
• Questions relating to photoprotective measures and treatments taken to prevent
the photosensitivity.
• Questions concerning the individual's previous medical history.
• Questions about their family history and social background.
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2.5.1 Photosensitivity
i. How old were you when you first experienced problems with EPP?
ii. What were these initial symptoms?
crying /screaming /burning / itching / tingling /other
iii. How old were you when the diagnosis was made?
iv. Who made diagnosis? GP/dermatologist /paediatrician /
gastroenterology /other doctor /other person
v. What symptoms do you have now after sun exposure?
nil /crying /screaming/burning / itching / tingling /other
vi. How long does it take for the symptoms to start after sunlight exposure?
vii. How long does it takefor the symptoms to settle?
viii. Does your skin have any visible changes immediately after sunlight
exposure?
nil /redness /swelling /eczema /bruising /blistering /crusting /other
Are there any visible changes later on?
nil / redness/swelling/ eczema/ bruising/blistering/crusting/ other
ix. Apart from the skin symptoms, do you feel unwell in any other way after
sunlight exposure?
nil /fever /generally unwell /can't sleep /feel down / irritable /other
x. On the second day of sun exposure, are the symptoms the same, better or
worse?
xi. Is your skin sensitive to sunlight through window glass?
xii. Is your skin more sensitive on windy days?Y/N
xiii. Do your nails ever get affected by the sunlight?Y/N
xiv. Is your skin is more fragile /difficult to heal than others? Y/N
xv. Do you think your skin sensitivity changes over the summer or stays about
the same?
xvi. Do you think there has been any change in sensitivity as you've got older? Y/
N Ifyes, improved /deteriorated, and any thoughts why?
xvii. Is your skin ever sensitive over winter (November - February)? Y/N
Ifyes, how often /circumstances etc
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xviii. Does your sunlight sensitivity interfere with your daily activities in summer?
Y/N
The age of onset of a photosensitivity reaction is important to establish. Onset in the
first year of life and associated with first exposure to sunlight, would suggest a
congenital photosensitivity syndrome. In contrast, onset later in life suggests an
acquired form of photosensitivity (e.g. porphyria cutanea tarda) although there have
been reports of late-onset or late presentations of EPP.
Because of the relative lack of obvious physical signs, problems with diagnostic
samples being insufficiently light protected and a general lack of knowledge of the
condition, there is a perception that individuals with EPP may suffer a delay in
obtaining a formal diagnosis. By asking about the age at presentation and diagnosis
and by whom the diagnosis was made, we sought to identify diagnostic delay and
whether a perceived lack of knowledge amongst health professionals is bourn out by
the initial diagnosis being mainly by secondary care professionals, particularly
dermatologists.
To determine the interval between going into direct sunlight and the onset of the
eruption, patients were told to imagine a day in June with little cloud cover.
According to the majority of dermatology textbooks, EPP is a condition in which
there is a paucity of visible signs, particularly acutely, although there are reports of
individuals who experienced one or more presentations from redness, swelling,
eczema, bruising, blistering or crusting. We sought to investigate the veracity of
these statements. The list of possible signs was not read out to the participants, but
used to assist with the recording of replies. As the majority of previous clinical
descriptions have focused on the acute cutaneous symptoms, we also sought to
discover if individuals experienced any other symptoms when acutely affected, the
degree to which the reported priming phenomenon is experience,119 and other aspects
of the sun sensitivity such as sensitivity to sunlight through glass (glass filters out
UVB, and photosensitive eruptions triggered by sunlight transmitted through glass
are therefore usually a manifestation of sensitivity to UVA or visible light) and the
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effect of wind (once briefly mentioned in a previously report,106 and spontaneously
by a number of the EPP individuals on whom the proforma was piloted). This effect
may well be the cooling effect of wind on the skin, reducing the burning perception
and allowing a longer exposure to sunlight.
A single case of onycholysis in an EPP patient following sun-exposure has been
reported,115 so a proforma question aimed to discover if this had been a chance
finding, or was an experienced shared by other individuals with the condition.
Activation of protoporphyrin in the skin by light results in the formation of reactive
oxygen species, and damage to surrounding structures such as vascular endothelium
and beyond that, the dermis. One might expect such damage to result in skin
fragility, as in other cutaneous porphyrias, although this has been said to be
uncommon by a major dermatology textbook.295
Some photosensitivity syndromes improve with repeated exposure to sunlight (the
so-called "hardening response"), and this forms part of the rationale for their
treatment with phototherapy. We sought to establish the proportion of individuals
with EPP who had noticed this phenomenon.
Again to check to veracity of a statement in a major dermatology textbook that the
natural history of the photosensitivity in EPP "often (improves) spontaneously after
the age of 10 or 11 years", the proforma asked for participants' personal
295
experience.
Over the winter months in the UK, the lower angle of the sun in the sky results in a
greater proportion of sunlight being absorbed in the atmosphere. Combined with the
shorter day lengths, it would be reasonable to speculate that photosensitivity is not a
significant problem at this time of year. An open question sought to test this
hypothesis.
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A final rather non-specific question was asked about whether the condition interferes
with daily activity in summer. The purpose of this question was to provide an
overall global picture of the impact of EPP and whether the results of this question
would correlate with and provide a degree of validation for the score from the quality
of life questionnaires.
2.5.2 Photoprotection
xx. Do you regularly try to avoid sunlight? Y/N
xxi. What kind ofthings do you do?
stay inside /seek shade/go out in evening /at night/other
xxii. Do you regularly wear special clothes to go out in sunlight? Y/N
hat/high collar /long sleeves /trousers /gloves /other
xxiii. Do you use sunscreen?Y/N
xxiv. What type and sun protection factor (SpF)?
xvv. How often? daily /at weekends/less often
allyear /in any sunny weather /over summer only /abroad only /other
xxvi. Are you aware what the star ratingsfor sunprotection mean? Y/N
xxvii. Have you tried any of thefollowing, and were they helpful?
antihistamines currently /previously /never helpful /not helpful
f-carotene currently /previously /never helpful /not helpful
Dundee sunscreen currently /previously /never helpful /not helpful
cysteine currently /previously /never helpful /not helpful
phototherapy currently /previously /never helpful /not helpful
sunbeds currently /previously /never helpful/not helpful
fake tan currently /previously /never helpful/not helpful
other treatments
xxviii. Who is involved in the care ofyour skin problem?
No-one / GP/ dermatologist /paediatrician /gastroenterologist /other
How often does each ofthese people see you?
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Clothing is an important aspect of photoprotective measures, and is a helpful
indicator of how severe a photosensitive eruption has been in the past and the degree
to which it can impact on aspects of daily living.
Most members of the general population are aware of the SPF (sun protection factor)
ratings for sunscreens, a laboratory-conditions rating which can be used to give a
rough estimation of increasing protection the product affords against UVB. In the
last 10 years an additional star rating (from 0 to 5) has been introduced by some
manufacturers to give an indication, relative to the product's SPF, of the protection it
affords against UVA. However individuals with EPP are more sensitive to longer
wavelengths of UV into visible light, so an ideal sunscreen would require high
reflectant properties against visible light in combination with high SPF and star
rating.
Although a number of different therapeutic options have been reported, there are no
large-scale trials assessing efficacy. Some treatments such as hospital phototherapy
are not easily accessible, and others may be associated with side effects. The
questionnaire sought to obtain the range of treatments that subjects had used or were
currently using, and their views on overall usefulness. In addition the final open-
ended question sought to obtain other therapeutic measures that individuals might
have been tried.
There are currently no national guidelines on how often and by whom EPP patients
should be followed up, although authors have made suggestions.131 A question was
included to identify the current UK situation.
2.5.3 Previous medical history
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other liver disease Y/N details:
liver treatment Y/N details:
arthritis Y/N details:
haematological cancer Y/N details
other
xxx. Are you allergic to anything?Y/NIfyes, what?
xxxi. Are you currently taking medicines and tablets? Y/N Ifyes, what?
In common with a general medical history, participants were asked about other
previous medical conditions in an open format. A number of specific conditions
were then mentioned; these being conditions that were either study exclusion criteria,
or conditions associated with EPP or liver dysfunction. A standard drug history was
taken.
2.5.4 Family and social history
xxxii. Are there any illnesses that run in yourfamily?Y/N Ifyes, what?
Family tree: parents/siblings/marital status/children
xxxiii. Women only: Does your sensitivity change with your menstrual cycle?Y/N
Ifyes, how?
xxxiv. If you had children, did you find any change in the EPP during your
pregnancy?Y/N Ifyes, how?
xvxv. Place ofbirth: UK/northern Europe/Mediterranean Europe / other
xxxvi. What wouldyou describe your ethnic origin as?
Caucasian / indo-asian /far east asian /afro-caribbean / other:
xxxvii. Are you working? Y/N And ifso, what is your job?
xxxviii. Was your choice ofprofession influenced by your skin ? Y/N
xxxix. How much alcohol do you drink in an average week?
Estimated units beer /wine/spirits /other
xl. Have you ever noticedyour skin more sensitive after drinking alcohol Y/N
xli. Do you smoke? Y/N And ifyes, how much per day?
xlii. Vegetarian /Non-vegetarian?
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A family history and medical history was sought to investigate for associations.
There are a number of reports of EPP symptoms improving during pregnancy,
although the mechanism for this is unknown.8'115,165"167 Questions were asked to
investigate this association, and to examine if this observation might be hormonally-
mediated, and evident on a monthly cyclical basis.
Self-reported ethnicity was asked for: Although EPP appears to occur in all
populations, there have been reports of increased incidence in certain ethnic groups
(Professor Elder, personal communication), and it is possible that skin pigmentation
provides additional protection against symptom onset in the UK following UV-
exposure.
Whilst part of a general social history, a question on choice of profession was also
included to assess if this was influenced by having EPP, and if any participants had
occupations that resulted in them working outdoors. Alcohol and smoking were
enquired about as part of a general medical history, but also because alcohol might
be used as an analgesic during acute episodes, and for its potential to cause
hepatotoxicity. Dietary preference was sought, as vegetarians, particularly strict
vegans, might be more likely to have iron deficiency than omnivorous individuals.
2.6 Examination
Light-exposed skin was examined at the end of the history taking, particularly the
face, neck, arms, hands and nails, but also any other affected skin volunteered by the
subjects. Examination findings were grouped into acute (e.g. erythema, oedema,
eczema, purpura, vesicobullous and crusted erosions) and chronic EPP signs (e.g.
excoriations, thickened skin, hyperkeratosis, yellowing, excessively wrinkling, and
scarring (varrioliform/pitted/stellate etc)), and other signs (e.g. evidence of liver
dysfunction such as spider naevi or flap). The cutaneous signs were graded into a
simple mild / moderate / severe.
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2.7 Quality of life measurement
Skin conditions have been shown to exert profound effects on an individual's quality
of life (QOL), through the disruption of family and social relationships, interference
with sport, leisure and work, and adoption of specific clothing. Although there have
been considerable advances in understanding the molecular genetics and treatment of
porphyrias, little research has assessed the psychosocial consequences of these
conditions. QOL was measured using previously validated dermatology-specific
296
quality of life tools, the dermatology life quality index (DLQI - appendix vii) and
the children's dermatology life quality index in a cartoon format (CDLQI - appendix
297 • ...
viii) . Each of these consists of ten questions, scored up to 3, giving a maximum
possible score of 30: an increasing score indicates a more impaired QOL. They have
both previously been validated using populations with dermatological conditions,
and in normal individuals, for repeatability, internal consistency and sensitivity to
change, and subsequently used in studies examining individuals, both adults and
children, with a range of conditions including acne, atopic dermatitis, psoriasis,
• ... 9QO
urticaria and vitiligo, and in a variety of languages.
2.8 Blood samples, initial processing and transport
24 ml of blood was drawn from each patient into six tubes: two EDTA, one of which
was light-protected, and four serum gel tubes, for the following analysis:
1. EDTA full blood count
2. EDTA (light protected) plasma porphyrin screen
4. Serum sample
3. Serum sample
whole blood protoporphyrin screen
whole blood protoporphyrin quantification
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serum iron







stored for future analysis
serum calcium
parathyroid hormone
Light-protected EDTA samples were placed in a thick brown envelope, which was
then wrapped around the tube several times, secured with an elastic band, and kept in
a darkened environment. Each serum sample was taken to the local biochemistry
department, centrifuged at 3,000 r.p.m. for 8-10 minutes to allow the sample to
separate, with the cellular component at the bottom of the tube bellow the gel, and
the serum component in the area above the gel. The resulting serum was then stable
to transport back to Cardiff. Depending on the location of visit, the samples and
request forms were either sent to the porphyrin laboratory in Cardiff by post, or
transported by car. Postal boxes used were Royal Mail first class postage pre-paid,
diagnostic specimen containers (UN3373), which allowed transport of the six
specimen tubes wrapped in a sealed plastic bag and wadding, in a water-tight inner
compartment, with the request forms in an outer compartment. The reinforced outer
plastic box was of a size suitable for postage through most post-boxes (figure 8).
All analyses were undertaken in the laboratories of the University Hospital of Wales,
Cardiff. Automated processes were used for all the investigations listed above other
than the porphyrin analysis and the DNA extraction and analysis.
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Figure 8. The Royal Mail first class containers used for posting
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2.9 Biochemical analysis of samples
2.9.1 Routine automated biochemical analyses
Assessments of liver function were performed in the biochemical laboratories at the
University Hospital of Wales, Cardiff, using the automated processes. The
quantitative analysis of 25-hydroxyvitamin D (25-hydroxy cholecalciferol - 25-OH-
D) was measured by radioimmunoassay following solvent extraction from stored
patient's serum using a commercially available assay (125I radioimmunoassay,
DiaSorin, Stillwater, Minnesota, USA) in the Department of Medical Biochemistry
and Immunology, University Hospital of Wales. 25-OH-D is the predominant
circulating form ofvitamin D, is more stable than 1,25-OH-D and is considered to be
the most reliable index of vitamin D status. Serum 25-hydroxyvitamin D
concentrations less than 10 and 20ng/ml (25 and 50nmol/L) were used to identify
those vitamin D deficient (VDD) or insufficient (VDI).299
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2.9.2 Plasma porphyrin screen
As porphyrins can absorb light energy and release this in the form of light emission
in a different spectrum, a simple screen for porphyrins in samples can be undertaken
by fluorescence emission detection. Plasma, diluted 10-fold in phosphate buffered
saline is exposed to an excitation wavelength of 405nm light and screened for
emission wavelengths between 550 and 650nm. Increased concentrations of
coproporphyrin and uroporphyrin give a peak at around 615nm, protoporphyrin a
peak at around 632nm, and protein-bound porphyrin, found only in variegate
porphyria, a peak at around 626nm.
Figure 9. Plasma fluorescence emission of EPP sample compared to
quality control sample (EPP patient sample in red, control sample blue).
550 570 590 610 630 650
Wavelength (nm)
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2.9.2.1 Patient samples
5ml venous blood collected into heparin or potassium EDTA. An aliquot was
centrifuged and the plasma removed. Samples were stored frozen at -20°C.
Sample processing was in the main undertaken by Mrs Jacqueline Woolf.
2.9.2.2 Equipment
1. Fluorimeter: Perkin-Elmer LS-50B luminescence spectrometer incorporating
a R928 red sensitive photomultiplier (Hamamatsu 928).
2. Disposable soda glass cuvette tubes, 50 x 7.5 mm. Supplied by Kernicks
Samco (code GO 10/24).
2.9.2.3 Materials and reagents
Phosphate buffered saline pH 7.3 (Oxoid BR 14a)
Dissolve one tablet in 100ml distilled water.
2.9.2.4 Method procedure
1. Thaw samples and QC (quality control sample).
2. Add lOOul plasma (QC and patient samples) to 900ul phosphate buffered
saline in a soda glass cuvette. Mix by inversion.
3. Switch on fluorimeter, mertec disc drive, VDU and printer.
4. Click the 'FL Winlab' icon.
5. Call up 'LS50b setup' and change the excitation filter to 'clear (auto cut-off
off)' and the emission monochromator to '515nm cut off. Exit from the
LS50b setup programme.
6. Click on 'pscan,mth' from the list of filenames: the 'setup parameters' screen
will appear. At the 'result file' name box overwrite the day and month. Also
select 'auto increment filename' and 'auto clear curves'.
7. The setup screen should be pre-set to scan emission between 550 and 650nm
at an excitation wavelength of 405nm. The slit widths are both lOnm and the
scan speed 240nm/min. Close the 'sample information' box.
8. At the 'spectrum 1' space overwrite the name of the sample or lab number.
9. Place the sample in the cuvette holder and close the lid.
10. Click on the traffic light icon. The light will turn red and the 'view scan'
screen will appear when the scan begins. When it has finished, the light will
turn green.
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11. Turn off the fluorimeter and exit from the scan application.
12. To processing the scans, click on 'view' and from drop-down menu choose
'new graph window'. Click on 'file' and from the drop-down menu choose
'open'. Find the filename to be processed and double click on it. This will
put the file into the new graph window. Adjust the ordinate by clicking on
the second icon. Identify any peaks by clicking on the 7th icon and choosing
'peak' and 'OK'. If the trace appears negative close the graph window.
Continue processing scans until a positive or borderline scan appears. Adjust
the abscissa and identify the peaks as above but also click on 'file' and
choose 'print'.
13. To calculating peak intensity, draw a tangent to the curve on the print out.










If peak intensity is <5 FU (fluorescence units), this is reported as :
No porphyrin detected by fluorescence emission spectroscopy.










If peak intensity is >4FU, this is reported as: Fluorescence emission spectrum shows
a porphyrin peak at Xnm. If the intensity is >100FU, report as: Fluorescence
emission spectrum shows a prominent porphyrin peak at Xnm
2.9.2.5 Clinical interpretation of results
Table 5. Clinical interpretation of fluorescent emission results
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Porphyrin peaks at about 615nm may also be seen in chronic renal failure and
cholestasis. A negative screen does not exclude porphyria.
2.9.3 Whole blood protoporphyrin screen
2.9.3.1 Principal of method
As in 2.9.2, this process uses the ability of protoporphyrin to absorb light
energy in the Soret range and release this in the form of light emission in a
different spectrum, to screen fluorimetrically for the presence and relative
quantities of erythrocyte free and zinc protoporphyrin in whole blood
samples. Zinc and free protoporphyrin have similar excitation maxima of
415 nm and 409 nm, but different emission maxima of 587 and 630 nm
respectively. However, as analytical procedures in which acidic conditions
are used the zinc protoporphyrin is removed, this method uses ethanol, a
neutral extractant, to allow analysis for both.
The erythrocyte free protoporphyrin may be raised in EPP, and rarely in some
sideroblastic anaemias and some homozygous porphyrias. The zinc
protoporphyrin may be increased in lead poisoning, iron deficiency and some
anaemias.
2.9.3.2 Patient samples
5 ml light-protected venous blood collected into potassium EDTA containers.
2.9.3.3 Equipment
1. Fluorimeter: Perkin-Elmer LS-50B luminescence spectrometer
incorporating a R928 red sensitive photomultiplier (Hamamatsu 928).
2. Soda glass durham tubes, 7.5 mm, supplied by Kernicks Samco (code
GO 10/24).
2.9.3.4 Reagents
1. Phosphate buffered saline pH 7.3
2. 95% ethanol
2.9.3.5 Method procedure
Add 50 pi of whole blood to 200 pi phosphate buffered saline in an eppendorf
tube and mixed thoroughly by vortexing. Pipette 50 pi of this diluted blood
into a fresh eppendorf tube containing 1 ml 95% ethanol, mixed for 15
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seconds then immediately centrifuge at 14,000 rpm for 2 minutes. Pipette
supernatant into a disposable glass cuvette. Setup the fluorimeter to scan
emission between 550 and 650 nm at an excitation wavelength of 415 nm.
The slit widths are both lOnm and the scan speed 480 nm/minute. The
sample is placed in the cuvette holder, the fluorimeter lid closed, and the
traffic icon selected. During processing the green light turns red, and returns
to green when the process is complete. The results are displayed on the
fluorimeter VDU screen by selecting 'view', 'new graph window', 'file', and
'open' the filename to be processed. Double clicking the filename will place
it into the new graph window. Clicking 'view' followed by 'horizontal
cursor' allows the cursor to roughly estimate the FU response of zinc and free
protoporphyrin peaks. A zinc protoporphyrin peak of <17 FU and a free
protoporphyrin of <5 FU is reported as 'not increased (mainly zinc
protoporphyrin)'. When a positive or borderline scan appears, roughly
measure the peaks as about, but also click on 'file' and chose 'print'. Using
the print out, measure the heights and intensity of the curves on the graph
scale. A free protoporphyrin peak of >6 FU or zinc protoporphyrin of >17
















In erythropoietic protoporphyria, and rarely in some sideroblastic anaemias
and some homozygous porphyrias, there is an increase in erythrocyte free
protoporphyrin. In lead poisoning, iron deficiency and some anaemias, zinc
protoporphyrin is increased.
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2.9.4 Whole blood porphyrin quantitation
2.9.4.1 Principal of method
This method of quantifying porphyrins in whole blood uses comparison of the
fluorescence of the sample against a standard molar coproporphyrin solution
sample fluorescence. The samples are measured at the emission maxima of
the porphyrins (in the case of coproporphyrin, the fluorimeter is calibrated
using 595 and samples tested for protoporphyrin at 603nm respectively).
2.9.4.2 Patient samples
5 ml venous blood collected into potassium EDTA. The haematocrit is
measured on a small sample of blood to enable the results to be expressed
with reference to the volume of packed erythrocytes. The sample can then be
frozen at -20°C and is stable for many months.
2.9.4.3 Equipment
1. A Perkin-Elmer LS-50B luminescence/Spectrophotometer incorporating a
R928 red-sensitive photomultiplier. The proto factor is determined for
the fluorimeter.
2. Cuvettes: Quartz glass tubes, 50 x 7.5mm supplied by Kernicks Samco.
Code GO 10/24.
2.9.4.4 Materials and reagents
1. Phosphate buffered saline pH 7.3 (Oxoid BR14a)
Dissolve one tablet in 100ml distilled water.
2. Ethyl acetate 3:1 (BDH 10108 Analar)
(BDH 10001 Analar)3. Glacial acetic acid
Mix 6ml of ethylacetate with 2ml glacial acetic acid in fume cupboard.
4. HCL1.5M (BDH 10307 Analar)
Dilute 129ml concentrated HCL to 871ml of distilled water.
5. HCL5M (BDH 10307 Analar)
Dilute 429ml concentrated HCL to 571ml of distilled water.
6. Coproporphyrin I standard (Sigma COP-1-5)
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2.9.4.5 Precautions and hazards
Ethyl acetate: glacial acetic acid mixture 3:1
• Area should be well ventilated
• Eppendorf tubes containing small volumes of ethyl acetate (pi) should be
capped.
2.9.4.6 Method procedure
1. Equilibrate samples and coproporphyrin standard to room temperature,
protected from light. Mix well before using. Fill in data sheet and turn
on spectrophotometer to allow lamps to warm up.
2. Label Eppendorf tubes and add 60pl phosphate buffered saline (PBS) to
each.
3. Pipette 8pl whole blood into PBS and vortex mix.
4. Add 400pl ethylacetate/acetic acid while vortexing and continue to vortex
mix for a further 15 seconds to break up clumps and vortex mix.
5. Centrifuge all tubes for 2 min. in Eppendorf centrifuge at 12,000 rpm.
6. Decant supernatant into clean Eppendorf tubes.
7. Add 800pl 1.5M HCL and mix for 1 minute.
8. Centrifuge for 2 min. at 12,000 rpm. Leave to stand in the dark for at
least 30 minutes.
9. Transfer approximately 1ml lower (aqueous) layer with a Pasteur pipette
into labelled disposable glass cuvettes.
10. Measure absorbance of stock coproporphyrin standard against a bank of
1.5M HCL on the spectrophotometer by scanning between 350 and
450nm and using the 'trace' function to obtain the maximum absorbance.
Record on a datasheet and attach a copy of the standard trace.
11. Prepare working copro standard in a soda glass cuvette. Add 1 Oul of
stock standard to 1ml 1,5M HCL and mix by inversion.
12. Switch on fluorimeter and set up the 'PSCAN' programme:
• Excitation wavelength = 405nm
• Emission wavelength = 550-650nm
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• Ex an Em slit widths = 1 Onm
13. Scan the standard, QCs and samples and print out each one with the peak
maxima.
14. Measure the peak heights and use the FU scale on the right hand side of
each printout to work out the FU change.
2.9.4.7 Calculation of results
Erythrocyte porphyrin =
A400 x 1 x 1000 x FU(sample) x 0.94 x 1000 x 1000 x 1.3
0.489.101 FU(std) 1000 8 1000 Hct
= A400 x FU (sample) x 3.07 umol/RBC
FU(std) Hct
Components of equation:
1. Concentration ofworking standard
_ A400 x _1_ (Dil of stock std) x 1000 nmol/1
pm (0.489) 101
2. FU (sample) = fluorescence units of sample
FU (standard) fluorescence units of standard
3. 0.94 = change in volume after addition of 500 pi organic phase to
1000 800 pi of 1.5 M HCL
4. 1000= Converts pi to ml
8 Volume in pi of blood assayed or 160 volume of plasma assay
5. Hct = Haematocrit
2.9.4.8 Reference range
Total erythrocyte porphyrin 0.4-1.7 pmol/L
2.9.4.9 Clinical interpretation
If the total porphyrin concentration is increased the proportion of zinc
protoporphyrin to protoporphyrin is assessed (method: whole blood
protoporphyrin screen). The presence of a major peak at 587nm (zinc
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protoporphyrin) excludes protoporphyria. An increased zinc protoporphyrin
can be caused by lead poisoning or iron deficiency, particularly if there is no
evidence of protoporphyria. The coefficients of variation of the quantitative
erythrocyte protoporphyrin assay are 9.8% at a level of 1.1 pmol/L red blood
cells and 11.1% at 39.6 pmol/L red blood cells
2.10 Haematological analysis of samples
Full blood count, ferritin, serum iron, total iron binding capacity and transferrin
saturation were determined in the Department of Haematology, University Hospital
of Wales using automated processing. Serum iron (sFe),300 total iron binding
capacity (TIBC),300 serum ferritin (sFn) (Elecsys 2010, Roche Diagnostics, IN,
USA), soluble transferrin receptor-1 (sTfR) (R&D Systems, Abingdon, UK) and
erythrocyte protoporphyrin301 were determined as described. Other measurements
were by standard automated methods. Data obtained previously for 611 male first
time blood donors were used for comparisons.302
2.11 Virological analysis of samples
Samples were processed by the Public Health Laboratory Service, Cardiff for
evidence of hepatitis B antibody and surface antigen, and hepatitis C. If either of the
hepatitis B tests were positive, an IgG core antigen was also sought.
2.12 Mutational analysis of the FECH gene
Samples were processed by Dr Sharon D. Whatley in the Department of Medical
Biochemistry and Immunology, School of Medicine, Cardiff University, Cardiff.
Genomic DNA was extracted from whole blood using the QIAamp DNA purification
kit (Qiagen, Crawley, UK). For identification of FECH mutations and SNPs, all
exons with 20 - 300 bp flanking sequence and 1300 bp of the promoter region of the
FECH gene were PCR-amplified and sequenced (primers and conditions in table 6).
For sequencing, PCR-amplified double-stranded DNA was purified from agarose
gels using the QIAquick gel extraction kit (Qiagen, Cawley, UK) before being cycle
sequenced using fluorescent ddNTPs (BigDye) and an ABI Prism 3100 Genetic
Analyzer (PE Biosystems, Warrington, UK). The presence or absence of mutations
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was confirmed by sequencing both strands. Partial or complete FECH gene deletions
TAT
were excluded in apparent homozygotes by quantitative gene dosage analysis.
Nucleotides are numbered from the cDNA sequence of human FECH (GenBank
accession number D00726) with the A of the ATG initiation codon as '+1\
PCR is the technique to amplify samples of DNA to facilitate analysis. It works on
the basis of thermal cycling (heating and cooling) of the sample DNA with a DNA
polymerase enzyme, sense and antisense primers, and mononucleotides. The sample
DNA is denatured by heating to 95°C. At 55-69 °C the primers anneal to their target
sequences. At 72 °C the polymerase extends the primers copying the sample DNA.
The sample DNA and the copy are denatured at 95 °C and the cycle begins again. In
each round of denaturation, not only is the original template replicated, but also all
the copies made in previous rounds. Thus the amount of product is doubled in each
round (20 rounds of PCR would amplify the target sequence one million fold).
Primers are short fragments of DNA complimentary to the DNA template target
region. The selectivity of PCR depends on having primers that will anneal only to
the desired target and not to any other sequence in the whole genome. The necessary
specificity is achieved by using short primers (usually 18-22 nucleotides) and taking
the annealing temperature to the highest temperature at which the primer will still
bind. If the temperature is too low the primers may be able to bind to mismatched
targets, and if too high they will not hybridize at all. Where possible the choice of
primers was according to the advice in the HotstarTaq PCR handbook (Qiagen):
1. Primers should be 18-30 bases in length.
2. G/C content should be between 40-60% of the total.
3. The two or three bases at the 3' ends should not be complementary to reduce
primer-dimers formation.
4. Primers should end (3') in a C,G,CG or GC. If G/C bases are both the 5' and 3'
ends they should be the same base.
5. Avoid runs of three or more C or G bases at the 3' end in GC rich sequences.
6. Avoid self-complementarity (> 4 bases) that may cause primer-primer binding or
intra primer secondary structures (e.g. hairpin loops).
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In our analyses, both DNA strands were sequenced to confirm the identified
mutation.
Gene dosage is the number of copies of a gene present in a nucleus. Humans (being
diploid) ordinarily have two copies of each gene, one on each chromosome.
Abnormalities of dosage may occur due to deletion or duplication of a gene or part of
a gene. PCR can be made quantitative (quantitative gene dosage analysis) by using a
primer tagged with a fluorescent dye. PCR is carried out only during the linear phase
of amplification and the amount of product measured using a fluorescence sequence
analyser. The amount of product is compared with an internal standard and to a
group of normal individuals to estimate the number of copies of the gene in the
patient's sample.
Table 6. The primers required for each region of the FECH gene, their
concentrations and PCR programmes:
Region of gene Primers Primer sequence pmol/pl Programme
Exon 1 F37104 GTGGTGGGGAGCGGGCTTCT 65.1 Hot 64°C + Q
FECH g2 GATCCTGGCCCTGGCGGC 100
Exon 2 F33401 TTACCTGCCTGCAGAGAAATGC 76.3 Hot 65°C
F34928 CCTGTTGCAGGGAAGGATCC 78.5
Exon 3 F33402 AAGTGTGACAAATCAACCGTTG 74.5 Hot 55°C
FECH g6 TTGAGAGACACACATGTCAATG 100
Exon 4 F33403 AACATTTCTCAGGTTGCTAAGCT 48.1 Hot 49°C
FECH g8 TTCATAACTACTTCGAAAGAACTA 100
Exon 5 F34929 CTCTTGAGGCTCTCTTATGCC 79.8 Hot 65°C
FECH g10 AI I I I IGCCAGCACCGIAIC 100
Exon 6 F37105 CCACCGTGCCTGGCCGACATAC 90.1 Hot 66°C
FECH g12 ATGAGAAGCTGATTCACACTAGA 100
Exon 7 F33406 TTTCCTTCCATTTCTTTCTTCC 94.5 Hot 46°C
FECH g14 GAAATCACCCAATCCTCTATCA 100
Exon 8-9 F34931 GACCTTAGAGATGATTGACAG 73.8 Hot 55°C + DMSO
FECH g18 GATGGAAAAAGGCAGATGG 100
Exon 10-11 F38652 GAAGGGACATAAGAATTGAGG 56 Hot 59°C
F38653 CCATCAAGAGTCCAATCCTC 83.8
Intron 3 F69723 GTGTTGTGTGTCCTGAATCTT 57.3 Hot 60°C
F69724 GAATGGTGCCAGCTTACTAAA 70.5
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2.13 Prokaryotic expression of missense mutations
Prokaryotic organisms (mainly unicellular and bacteria) do not have nuclei and
instead have a single loop of chromosomal DNA bound to protein in an area called
the nucleoid. Thus, while eukaryote DNA is tightly bound in chromosomes within
the DNA, the eukaryotic DNA loop is more accessible to retroviral insertion of study
gene DNA, allowing exploration of its expression, and in the case of EPP,
exploration of the effect of a variety of FECH mutations on the enzyme's activity.304
The effect of mutations on FECH activity was determined using the bacterial
expression vector pHisTF20E.56 Mutations were created using the Quickchange
mutagenesis protocol (Stratagene) with 50ng of vector and 12 cycles of 30sec
denaturation at 95°C, 30sec annealing at 55°C and 8min extension at 68°C. Primer
sequences are available from the authors. After digestion with Dpnl to eliminate the
template vector DNA, the PCR products were used to transform chemically
competent E. Coli JM109. Colonies were screened by automated fluorescent DNA
sequencing.
For each mutation, a single bacterial colony was grown in 5ml of LB broth
containing lOOpg/ml carbenicillin for 6h. A 25pl aliquot was then used to inoculate
25ml LB (lOOpg/ml carbenicillin) and the culture grown at 37°C for 18h. Cells were
harvested by centrifugation at 6000g for 15 min and resuspended in 1.5ml of 50mM
Tris/HCl [pH 7.6] containing 20% glycerol and ImM PMSF. Cells were disrupted
by sonication on ice (3x 30sec) and centrifuged at 13500g for 2min. The
supernatant, which contains the recombinant FECH, was stored at -70°C. FECH
17S •
activity was determined as described by Gouya et al. A blank without cell lysate
was included and endogenous bacterial FECH activity was assayed using an empty
vector control. Protein concentrations were determined using the BCA protein assay
(Pierce).
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3. Results
3.1 Results of case identification
The details of 401 UK patients with biochemically proven EPP were identified. Four
of these individuals were under the age of five years, and were therefore excluded
from the study. Three hundred and eighty nine replies were obtained from the
patients' referring physicians. Of these, we were requested not to contact six
patients, and were informed that 15 patients were deceased, one had emigrated to
Australia, and that two additional patients had declined to take part (total = 24).
Furthermore the physicians had either no records of the patients or no contact details
in a further 17 cases. Three hundred and forty eight patients (or their consultants)
were subsequently sent the study pack containing the invitation to participate, a reply
sheet and a reply-paid envelope.
Replies were received from 223 following the initial mail shot, of which 215
indicated that they would like to take part (initial response rate 61%). One patient
declined to take part, five letters were returned due to the patient no longer being
resident at that address, and two replies stated that the patients to whom the letters
had been addressed were dead. Follow-up letters were sent to the 122 non-
responders (three patients were not sent a follow-up letter due to their inclusion
towards the end of the trial recruitment period). Of this second posting, a further 39
patients replied to say they would like to take part, five declined to be included in the
study, and there was no reply from the remaining 78. In addition, four further
patients with EPP clinically but not known to the databases, were referred by other
members of their family who had been invited to participate. Thus we obtained 258
individuals who wished to take part (final response rate 74%). Appointments were
arranged for 254 of these study individuals (4 were not included due to study time
constraints) and 223 subjects were seen by the study investigator. The remaining 32
either found the appointment time inconvenient or failed to attend.
Erythropoietic Protoporphyria in the United Kingdom 83
3.2 Proforma results
3.2.1 Study participant characteristics
The study cohort contained 223 subjects (median age 34 years; range 5-87 years)
with a history of acute photosensitivity. There were 114 females (median age 33.5
years, range 5-87 years) and 109 males (median age 35 years, range 5-77 years); the
age distribution was similar in both sexes. All were white Caucasians apart from 2
Indo-Asians (originally from Pakistan and Iraq, both male and skin type IV).
3.2.2 Age at onset of photosensitivity
The median age at onset of symptom was 1.1 years (range birth to 12 years), usually
at the time of first major exposure to sunlight (figure 10). However diagnosis was
often delayed; the median age at diagnosis was 12 years (range 6 months to 86 years)
with the diagnosis not being made in 38 subjects (19%) until after the age of 29 years
(figure 11). The majority of subjects (81%; 180) were diagnosed by a dermatologist.
Other diagnoses were made by general practitioners (6%; 13), the subject themselves
(4%; 8), family members (4%; 8) (brother 1, sister 2, father 5), paediatricians (3%;
7), unknown (2%; 5), a biochemist (1) and a haematologist (1). Of the eight self-
diagnoses, six recalled recognising the symptoms either after reading a magazine
article (4), after researching in a medical library (1), or seeing a television
programme (1) about EPP.
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Figure 11. Age at which diagnosis of EPP was made in study cohort.
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Age diagnosed (years)
3.2.3 Symptoms of EPP
The cutaneous sensation following sunlight exposure was frequently said to be
difficult to describe. The most frequently used terms included burning (85%),
tingling (33%), prickling (4%) and stinging (3%). Descriptions of the sensation
convey the severity: Tike burn on a candle flame or bonfire', Tike being scalded and
lots of red hot needles under the skin', Tike putting hands into a hot deep fat fryer,
but under the skin, or getting into a chip pan at boiling point', 'having boiling water
from a kettle or oil being poured all over the skin', Tike a thousand pins and
needles', 'itching like stinging nettles', 'burning like blood boiling', 'burning like hot
pins' and Tike iron burn all over'.
The median time for onset of symptoms following sunlight exposure was 20 minutes
(lower quartile 10 minutes, upper quartile 60 minutes, range immediately to 12
hours/asymptomatic in the UK), and was significantly shorter in females than males
(median 15 and 30 minutes, P = 0.018). The median time to resolution was three
days (lower quartile 1, upper quartile 4 days, range immediately to 4 weeks).
Asked if they noticed any additional symptoms when they were affected (out of 220):
78% had problems sleeping (171), 30% irritability (66), 19% excessive temperature
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sensitivity (41), 12% feeling down or depressed (26), 11% tired (24), 6% nausea
(13), 5% malaise/generally unwell (10) and 3% headache (7). Fifteen percent of
subjects (34) said they did not have any other symptoms apart from those of the skin.
Only 25 of 199 subjects (12.5%) felt that their photosensitivity had changed with
age; 14 subjects had improved and 11 subjects had become more sensitive. Other
features of the cohort's EPP are summarised in table 7.
Table 7. Photosensitivity features of the EPP study cohort.
Symptom No. of subjects questioned No. with symptom
Photosensitive through glass 220 202 (92%)
Priming1 219 186 (85%)
Exacerbation by wind 202 137 (68%)
Skin fragile/slow to heal 115 75 (65%)
Improvement during summer 194 109 (56%)
('hardening of skin')
Photosensitive during winter 165 73 (44%)
(November - February)2
1
Photosensitivity worse the day after sun exposure.
Contributory factors: sunny weather (95%), snow (28%), wind (26%), water reflection (8%),
seaside (5%), increased exposure to artificial light (1%).
The priming phenomenon was noticed by 85% (186/219), sensitivity to sunlight
through glass by 92% (202/220), and exacerbation of the skin sensitivity by the wind
(or in some cases stimulation of similar symptoms despite lack of sunlight) in 68%
(137/202). Sixty five percent (75/115) felt their skin was more fragile or more
difficult to heal when compared with others, 56% (109/194) that their skin sensitivity
improved (hardened) over the summer. When asked if their skin had ever been
sensitive over a UK winter (November - February) 44% said yes (73/165) and 56%
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no (92/165). The circumstances that were most commonly associated with winter
sensitivity were sunny weather (95%) with snow (28%) wind (26%) or water (8%;
e.g. whilst sailing) as contributing factors. Other factors included being at the beach
(5%), or the increased exposure in the winter to artificial light sources (1%). Five
percent described occasions when they had been affected in overcast conditions,
even whilst raining, in winter.
3.2.4 Menstruation & pregnancy
Twenty eight (47%) of 59 gravid female subjects reported an improvement in
symptoms during pregnancy. Nine subjects spontaneously described this as "very
significant" or that they became "asymptomatic", with anecdotes of having a tan for
the first time in their lives, or tolerating foreign sunny holidays. None reported
deterioration, and several of the women who had not noticed a change commented
that they had been pregnant mainly over winter or were too apprehensive to expose
themselves to sunlight to test for a pregnancy-related change. Two women who had
not noticed change were both seen in the study at an early stage of their first
pregnancies and early in the year. Menses-related worsening of photosensitivity was
reported by 8 (10%) of 81 menstruating females; 6 of these were gravid; 5 of whom
had noticed an improvement in their sensitivity during pregnancy. No improvement
during menses was reported. Three subjects mentioned their symptoms had
improved since the menopause and none had noticed any post-menopausal
worsening of photosensitivity.
3.2.5 Signs of EPP
Two hundred and eleven subjects (95%) said that the onset of symptoms was not
associated with any immediate visible change to the skin. Immediate changes
reported were reddening (7 subjects), swelling (3 subjects), purple discoloration and
blanching (one subject each). Visible changes were generally related to the duration
of exposure; minimal exposure tended not to result in visible changes, whilst
prolonged exposure resulted in signs. Those most commonly reported included:
swelling (179 subjects, 80%), reddening (45 subjects, 20%), blistering (37 subjects,
17%), crusting / eczema (32 subjects, 14%), petechiae and/or bruising (20 subjects,
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9%) and fissuring (10 subjects, 4%). Thirteen of 103 subjects (13%) had noticed
changes in their nails during acute episodes. Twenty two subjects (10%) reported no
visible change at any time. Sixty one subjects estimated a median time for onset of
swelling post-exposure of 6 hours (lower quartile 2, upper quartile 12 hours, range 15
minutes to the next morning).
3.2.6 Photoprotective measures and previous treatments
When asked if EPP interfered with their daily activities on sunny days, 92% (204)
said "yes" and 8% said "no" (18). The main activities to avoid sunlight exposure
were staying inside 65% (144), seeking shade 32% (71), and only going out in the
evening or early morning 12% (26). Of the 18 subjects with no daily interference,
some took care to avoid sports (1), foreign travel (2) or to limit time outside when
attempting to hardening the skin (2).
Special clothes were worn by 87% (194) of subjects to protect themselves from
sunlight, whilst 13% (28) wore no special clothes. These were most commonly as
follows: 91% long sleeves (174/191) (two subjects sewed extra fabric to sleeves to
make them longer), 78% trousers (149) (long skirts or dresses additionally 6), 75%
hats (143) (where specified 29 baseball or cap, 14 brimmed, 5 foreign legion-style, 2
Arabic head-dresses), 50% gloves (95) (6 cotton, 4 leather, 1 each yachting and
cycling) - for driving 18 and sport 7 (football, gardening and bowls). Other clothing
included 3% UV-opaque bathing suits (6), 10% shoes and socks that covered feet
(20), 4% sunglasses (8), 2% scarf (6), letting hair grow 3 and growing a beard 1, and
1 each of hooded tops, pillow case to drive, balaclava, face mask to play golf, plaster
on nose.
When asked if they used a sunscreen, 31% (70) replied "no", citing a number of
reasons such as: tried most of them and none seem to work, sunscreens are too thick,
cosmetically unacceptable, makes it feel like I'm frying, feels like they make my skin
worse - stings and don't like greasy sensation, feel they aggravate the skin by
making it itchy, they are messy and expensive, don't use them as always covered up
with clothes. Of the 69% who used a sunscreen, the most frequent used was the
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Tayside Pharmaceuticals' Dundee Reflectant Sunscreen, used by 25% of subjects,
most commonly the beige colour, followed by conventional sunscreens with sun
protection factor (SPF) 60 (23%), 50 (13%), 30 (13%), and 25 (11%). There was no
obvious preference for any one brand of sunscreen manufacturer. Dundee sun cream
was used regularly by 25% of the subjects, of whom 98% felt it was useful. Of the
25% who had previously used it, only 33% thought it to be helpful. Poor cosmesis
was frequently mentioned in connection with this product. The range in the
frequency of sunscreen application was between weekend or occasional use only, to
8 times a day (9% occasional use/use at weekends, 77% daily, and 14% more
frequently than once a day). The circumstances in which the sunscreen was applied
ranged from "only when abroad", to "all year" (6% abroad only, 61% in sunny
weather, 24% all summer, 9% all year). Only 14% were aware of the UVA star
rating of sunscreen.
Other commonly used treatments for EPP are shown in table 8. Seven percent of
subjects currently used antihistamines, of which 50% thought them helpful, and 50%
not. Forty five percent had previously used them, of whom 14% thought them
helpful, and 86% not. Forty seven percent of subjects had never tried antihistamines.
Table 8. Treatments used for EPP.
Treatment % Currently Using % Previously Used % Never Used
Antihistamines 7 45 47
Beta carotene 28 56 24
Dundee Cream 25 25 50
L-Acetyl Cysteine 1 0.5 98
UVB Phototherapy 9 16 75
Tanning Parlours 2 15 83
Beta-carotene was used currently by 28% of whom 77% thought them to be helpful
(median dose 180 mg, range 60-390 mg). Fifty six percent (124) had previously
taken it, 24% of whom had felt it helped (median dose 240 mg, range 60-360 mg),
and 16% had never tried it. Although not specifically asked, the main reason given
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by those discontinuing it (other than efficacy) was an unacceptable orange
discoloration of skin and body fluids (34), difficulty taking the tablets (5), retinal
crystals from the canthoxanthine preparation (5) and media coverage of possible
risks ofmalignancy (2).
L-acetyl cysteine was used by 3 subjects (1%), all of whom thought it helped. Two
subjects had previously taken it, one thought it helpful and one did not (dose taken
by all five was 500mg tablets twice daily).
Hospital phototherapy was used by 21 subjects (9%) at the time of the study, and all
thought it helpful (due to geographical factors, one patient was using home
phototherapy provided and monitored by a hospital department). Thirty five (16%)
had previously used phototherapy (49% of whom thought it useful) and 166 (74%)
had never had it. Commercially available sunbeds were currently used by 5 subjects
(2%), all of whom found it helped. Thirty three (15%) had previously tried sunbeds,
53% of whom had found it useful, and 144 (83%) had never used them. Use of
phototherapy was not statistically associated with use of commercial sunbeds
(Spearman's correlation = 0.032; n = 222; P = 0.639).
The other measures most commonly used by subjects for symptom relief included
immersion in cold water (51; 37%), wet cloths or flannels (47; 21%), use of a fan
(12; 5%), putting affected areas on cold walls, metal or under pillows (11; 5%),
drinking alcohol (10; 4%), emollients (8; 4%), ice packs (7; 3%), and emersion in hot
water (7; 3%). Other treatments that small numbers found helpful included sleeping
(8), analgesics (7), cold drinks cans kept in the fridge applied topically (7), fish oils
(3), air-conditioning (3), antioxidants e.g. green tea and vegetable juices (3), sleeping
tablets (2), blood transfusion (2), anaesthetic spray (1), acupuncture (1), oral iron
supplementation (1), systemic steroids (1), cannabis (1) and make-up (1).
Treatments that were said not to work included Chinese herbalist (1), zinc tablets (1),
calamine lotion (3), topical steroid creams (1) and fish oils (1). Prescribed drugs
which had been of no benefit included: a cystic fibrosis drug, mepacrine, activated
charcoal and cholestyramine.
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A large minority of the subjects (30%) were not seen regularly by any doctor for
their EPP. None of these subjects had any monitoring of blood tests either for liver
function or blood count. The majority of subjects 127 (57%) were under the care of
a dermatologist, with either annual (54%), twice yearly (35%), three times yearly
(4%) or four times yearly (7%) reviews. Eight subjects were under the care of a
biochemist, seven were under a general practitioner, five were under a paediatrician
and three were under a haematologist, all with annual reviews. Three subjects were
under joint care by both a dermatologist and a gastroenterologist, and were seen
twice yearly, and two subjects, one under the care of a hepatologist, and one under a
gastroenterologist were seen weekly. Ninety-eight percent of those under the care of
a dermatologist and all of those under the care of the biochemist, haematologists,
gastroenterologists and hepatologists had blood checks at least annually. The six
subjects, under the care of a general practitioner and paediatrician did not have
regular blood tests.
3.2.7 Subjects' previous medical history
Asked about other illness and operations, 109 (49%) could not recall any other
previous problems, and a further 60 (27%) had a single condition only. The most
commonly reported conditions included: asthma 13, hayfever 12, hypothyroidism 11
(4.7% population), eczema 8, heart murmur 6, hiatus hernia 6, keratoderma 5,
hypertension 4, ischaemic heart disease 4, peptic ulcer 4, osteoporosis 4, arrhythmias
4, appendicectomy 3, irritable bowel 3, chronic fatigue 3, congenital cardiac
anomalies 3, hyperthyroidism 3, peripheral vascular disease 2, liver failure 2, low
platelets 2, ureteric anomalies 2, Perthe's disease 2, psoriasis 2, obstructive
pulmonary disease 2, cardiac failure 2, stroke 2. Conditions which affected only one
individual were: Osgood-Schlatter's syndrome, cataract, breast fibroma, colon
carcinoma, rheumatoid arthritis, iritis, prostatic hypertrophy, prostatic carcinoma, leg
ulcer, mechanical heart valve, rhinoplasty, onychomycosis, ovarian cyst, dyspraxia,
pancreatitis, PLE, SLE, polymyalgia rheumatica, horse-shoe kidney, acne,
acrodermatitis enteropathica, coeliac disease, vitiligo, Crohn's disease, thyroid cyst,
leishmaniasis, pituitary gland tumour, ulcerative colitis, scleroderma, spastic
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diplegia, testicular seminoma. Specific conditions were asked about: anaemia 18%
previously, iron deficiency 22%, gallstones 9%, cholecystectomy 7%, hepatitis 1
patient, other liver problems 2 subjects (liver failure secondary to EPP), arthritis 7%,
haematological malignancy 0%.
Ten percent of subjects gave a history of sensitivity to medication, most commonly
penicillin and erythromycin. Fifty percent of subjects were taking medication at the
time of the study, 51% of whom were taking only a single preparation. The
medications taken most commonly were: beta-carotene 62, antihistamines 15,
thyroxine 12, proton pump inhibitors 11, oral iron 10, paracetamol 9, NSAIDs 7, oral
contraceptive 7, aspirin 7, cholesterol lowering agents 6, antidepressants 6,
antidepressants 6, ACEI 5, beta blockers 5, fish oils 4, antimicrobials 4, opiates 4, H2
receptor antagonists 3, L-acetyl cysteine 3, warfarin 3, systemic steroids 3, calcium
channel blockers 3, calcichew 3.
3.2.8 Family history
The 233 subjects came from 193 families. One hundred and twenty-five subjects
(56%) had no family history of photosensitivity; 89 from 60 families had affected
relatives (only 29 of whom were seen in the study) and a further 9 subjects were
uncertain. In the 60 families with more than one affected individual, the disease was
manifest in one or more siblings in 33 families, in seven of which a more distant
relative was also affected. There were thirteen instances of parent to child
transmission of photosensitivity, with transmission through three consecutive
generations in two families. In 16 families only relatives more distant than first
degree were affected.
Fifty four subjects from 24 families were related to another study subject. Forty one
were siblings (20 families), and 3 parents with 4 affected children (3 families - one
of these also included in the siblings families count). An affected great grandmother
was also seen with one sibling pair, and the remaining 2 families were an uncle-
niece, and a pair of first cousins. Thirty one (14%) of subjects had a family history
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of another condition; the most commonly reported being ischaemic heart disease
(13), diabetes (8) and hypothyroidism (3).
3.2.9 Social characteristics
Two hundred and twenty one were white Caucasian, the other two Indo-Asian
(ethnically Pakistani and Iraqi), and all but four had been born in the United
Kingdom (the exceptions being Canada, Germany, Iraq and Malawi). One hundred
and twenty seven (56%) of the subjects were in employment, and a further 60 (27%)
were either in school or were further education students. Half of those in
employment felt their choice of profession had been significantly influenced by their
skin.
Thirteen percent smoked tobacco (median 10 cigarettes/day, quartiles 4, 20, range 1-
50), and 64% (143) of the study population, and 80% of those over the age of 16
drank alcohol regularly. The median number of units consumed was 7 per week
(quartiles 1, 14.5, range 1-70), in the following formats: 55% wine, 50% beer, 26%
spirits and 0.5% cider. Fourteen percent said they noticed their skin being more
sensitive to the sun after drinking. All subjects apart from one ate meat regularly; the
exception was a non-vegan vegetarian.
3.2.10 Skin examination
Only three subjects, all children, had acute changes at the time of examination; all
three had erythema, mainly over the nose, cheeks, dorsae of hands and fingers, lower
lips and upper helix of the ears (Figure 5). Thirty four (15%) subjects had no
changes evident on any light-exposed skin (16 females, 18 males; median age 37
years, range 5-87 years). Scarring was the most commonly present chronic change,
affecting mainly light-exposed skin of the face (149 subjects, 67%) and hands (138
subjects, 62%) (Figure 6, Table 9). The observer-perceived severity for mild and
moderate face and hand signs was in roughly equal proportions (face 31% and 29%
of subjects respectively, hands 30% and 27%). Only a minority of subjects had
scarring that was assessed as severe (face 6%, hands 5%). Other chronic changes
such as thickening of knuckle skin and lip rhagades were observed less frequently.
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Table 9. Percentage of cohort with evident cutaneous changes on light-
exposed skin
Face Hand Knuckle Nail
none 21 27 37 0
mild 37 35 34 0
moderate 35 32 25 1
severe 7 6 3 0
Compared to those with no thickening, the cohort with severe and moderate knuckle
thickening were older (38 vs 34 years), had a higher proportion of male sex (63% vs
37%) and alcohol consumption (11.6 vs 7.6 units a week), shorter time to sensitivity
following sunlight exposure (47 vs 52 minutes), but similar TEP (26.9 vs 25.3 pmol
L"1).
3.3 Quality of life analyses
Two hundred and twenty completed QOL questionnaires were obtained, comprising
176 DLQIs (age range 16-87, mean 39.6) and 44 CDLQIs (age range 5-16, mean
11.1). Scores were not significantly influenced by age or sex (table 10).
The mean total DLQI score was 13.95 (SD +/- 6.715, range 0-29, n = 176). It is
possible to interpret the meaning of DLQI scores by applying simple validated
descriptive score bands. Six adults scored 0 or 1 (3%) indicating no effect on their
life over the preceding week and 15 scored 2-5 (9%), indicating a small effect: in
total only 21 subjects (12%) scored 5 or less, indicating no or little effect on their
QoL. Thirty two (18%) scored 6-10, indicating a moderate effect, 92 (52%) scored
11-20 indicating a very large effect and 31 (18%) scored 21-30 indicating an
extremely large effect. Thus 123 of 176 adults (70%) scored over 10, indicating at
least a very large effect on their QoL over the preceding week. The highest scoring
DLQI questions were 4, 5 and 6, relating to clothing, social/leisure activities and
sport. All six adults (4 female, 2 males; mean age 47.5 years, range 20-77 years)
with a DLQI score of 0 or 1 had mild symptoms and were part of the group who felt
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EPP did not interfere with daily activities (3.2.6); in three of these EPP was not
diagnosed until over 43 years after the onset of symptoms.
The mean total CDLQI score was 13.02 (SD +/- 4.027, range 5-21) and the highest
CDLQI questions were 5, 1 and 9, relating to social/leisure activities, skin symptoms
and sleep. No child scored less than 5, and 80% (35) scored greater than 10.
Table 10. Total DLQI and CDLQI scores in EPP
Age range Sex Number Mean age QOL score
(years) of subjects (years) (mean & range)
6-151 F 22 10.9 12.8 (5-20)
M 22 11.3 12.9 (6-21)
F & M 44 11.1 12.8 (5-21)
16-352 F 40 27.3 14.4 (0-29)
M 37 26 13.9 (4-25)
F & M 77 26.7 14.1 (0-29)
36-552 F 33 43.6 13.2 (0-25)
M 36 44 13.0 (1-29)
F & M 69 43.8 13.1 (0-29)
56-872 F 17 62.8 16.1 (4-27)
M 13 62.3 15.3 (0-27)
F & M 30 62.6 15.76 (0-27)
16-872 F 90 40 14.2 (0-29)
M 86 39 13.8 (0-29)
F & M 176 39.5 14.0 (0-29)
^DQLI questionnaire; 2DQLI questionnaire
The relationships between three potential indicators of severity of disease and QoL
were assessed. There was a positive correlation between TEP and adult DLQI scores
(rs = 0.228; P = 0.002; n = 174) but not between TEP and CDLQI scores (rs = 0.025;
P = 0.888; n = 35) (Figure 12). In contrast, there was a stronger correlation between
times to onset of symptoms for CDLI scores (rs = - 0.422; P = 0.004; n = 44) than for
adult DLQI scores (rs = -0.233; P = 0.002; n = 176). There was no significant
relationship between age at onset and either DLQI or CDQLI score.
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Figure 12. Relationship between total erythrocyte protoporphyrin (TEP)
and quality of life (QoL) scores for 220 subjects with EPP.
QoL: DLQI scores for 176 adults (grey diamonds) and CDQLI scores for 44


















rs=0.228; P = 0.002




3.4.1 Overall cohort results
Blood samples were obtained from 210 subjects for analysis. Overall, the mean
haemoglobin was 12.54 g/dL, (range 8.6-17.5, quartiles 11.7, 13.37), with 34% (70)
of subjects having levels below the normal range, in roughly equal proportions
between males and females (34 of 107 (32%) females and 36 of 101 (36%) males).
The RBC was normal in all females and abnormal in only two males who were both
also anaemic. The haematocrit was abnormal in 3 females and 4 males (all of whom
were anaemic). Overall 37% of subjects had a low MCV, and 47% a low MCH
(abnormal MCV 77 (42 females, 35 males; 39 anaemic, 38 not anaemic), and 98
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abnormal MCH (58 females and 40 males, 51 anaemic, 47 normal Hb, 19 anaemic,
normal MCH). Low ferritin was seen in 42% subjects (1 male: 3.2 females), low
serum iron in 35% (1 male: 1.8 females), and a raised TIBC in 17% (1 male: 1.4
females). Low ferritin (P < 0.0005), low serum iron (P = 0.027) and low transferrin
saturation (P = 0.019) were all significantly associated with anaemia. A related-
samples /-test showed significance between low haemoglobin and MCV beyond the
.05 level: t(207) = -211; P = 0.00 (two-tailed); 95% confidence interval (-80.09, -
78.61), and anaemia and MCH: t(207) = -174.67; P = 0.00 (two-tailed); 95%
confidence interval (-25.56, -24.99).
3.4.2 Haematological analysis in dominant EPP
One hundred and ninety two subjects had one FECH mutation with one or two
FPC//IVS3-48C alleles and were classified as dominant EPP (dEPP);175 14 of these
were excluded because they had diseases likely to affect iron metabolism, leaving
178 samples for more detailed analysis.
3.4.2.1 Red cell indices
By WHO criteria, 73 (41%; 95% CI: 34 - 48%) of our subjects with dEPP were
anaemic. All had a mild microcytic, hypochromic anaemia; 48% of females and
33% of males being affected. The anaemic subjects did not form a separate
subgroup. In both sexes, haemoglobin (Hb) (females: 11.9 ± 1.0 g/dL; males: 13.3 ±
1.0), mean cell volume (MCV) and mean corpuscular haemoglobin (MCH) were
normally distributed with a shift in their means towards lower values (Table 11); the
mean Hb for males being 1.2 g/L lower than in the general population (Fig 13a). This
downward shift in Hb leads to some subjects falling within the definition of anaemia.
Erythrocyte protoporphyrin concentrations (females: 21.9, 4.1 - 75.3 pmol/L; males:
25.5, 8.9 - 77.3 prnol/L) showed no correlation with Hb.
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Table 11. Red cell indices in 178 subjects with dominant EPP
Female Male
All Anaemia No anaemia All Anaemia No anaemia
(n = 98) (n = 47) (n = 51) u II 00 (n = 26) (n = 54)
Hb 11.9 ± 1.0 11.1 ± 0.6 12.7 ± 0.5*** 13.3 ± 1.0 12.2 ± 0.5 13.8 ± 0.7***
(g/dL)
Hct 0.361 ± 0.340 ± 0.380 ± 0.398 ± 0.366 ± 0.414 ±
0.027 0.018 0.019*** 0.033 0.019 0.026***
RBC 4.5 ± 0.3 4.4 ± 0.3 4.6 ±0.3** 4.9 ± 0.4 4.6 ± 0.3 5.0 ± 0.3***
(x1012)
MCV 80 ± 5 77 ±5 82 ± 4*** 82 ± 5 80 ±6 83 ± 5**
(fL)
MCH 26.6 ±2.5 25.5 ± 2.2 27.7 ± 2.2*** 27.4 ± 1.6 26.7 1.9 27.7 ± 1.3**
(pg)
Figures are mean ± SD for 98 females aged 6-87 years, median 35 years; 80 males aged
8-87 years, median 36 years. Anaemia was defined as Hb less than 12.0 g/dL (females) or
less than 13.0 g/dl_(males) for adults and less than the lower limit of the age-related Hb
range for children.32 For comparison of anaemia vs. no anaemia groups: **P < 0.01; *** P <
0.001.
3.4.2.2 Iron status
Both sexes showed evidence of iron depletion (Table 12). Differences in sFn and
transferrin saturation (TS) between women and men suggested that more of the
former had iron depletion due to iron loss in addition to abnormalities caused by
EPP. Therefore, we restricted detailed analysis of iron indices to the 67 male subjects
(Hb 13.5 ± 0.9 g/dL) aged over 15 years who had never received iron supplements.
The main abnormality was a marked shift in sFn towards lower values (Fig 13b)
(Table 13); sFn correlated with Hb (rs = 0.415; P < 0.001). Because protoporphyrin
is hepatotoxic and accumulates in the liver in EPP, and liver cell damage may
increase sFn, we assessed liver cell function by measuring liver enzymes. One or
more of these was increased in 17 (25%) subjects; sFn correlated with y-glutamyl
transpeptidase (rs = 0.507; P < 0.001) and alanine aminotransferase (rs = 0.392; P <
0.001) but not with aspartate aminotransferase.
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A second notable feature of iron depletion in dEPP was the finding that sFe (Table
12) and sTfR (18.6 ± 5.1 nmol/L) (Fig 13c) concentrations are normal. The normal
sTfR. was consistent with the degree of depletion of iron stores indicated by sFn and,
together with the normal sFe, suggested that erythropoiesis is not limited by iron
supply.306
Table 12. Iron status of 178 subjects with dominant EPP.




All subjects Iron insufficient
(%)
All subjects Iron insufficient
(%)
sFe (pmol/L) 11.9 (1 -38.7) - 14.2 (1 -29.5) -
TIBC (pmol/L) 65.4 ± 7.6 - 63.0 ±6.7 -
TS (%) 19 (2-58) 61 24 (2 - 49) 15**
sFn (pg/L) 13 (2-186) 44 33 (8 - 246) 27*
Figures are means ± SD or, for sFn, medians and ranges. Iron insufficient was defined as TS
<16% and/or sFn < 15 pg/L. For comparisons of percentages of male and female subjects: *
P< 0.05; ** P< 0.001.
Table 13. Comparison of indicators of iron status in male subjects with
dEPP and male first-time blood donors
Serum iron indices EPP subjects First-time blood donors
(n = 67) (n = 611)
sFe (pmol/L) 15.1 ± 6.6ns 16.7 ±6.0
TIBC (pmol/L) 63.0 ± 6.9* 54.5 ±10.0
TS (%) 23.9 ±10.3* 31.1 ±10.9
sFn (pg/L) 37 (10- 119)* 101 (35-220)
Figures are means ± SD or, for sFn, medians and 95% ranges. EPP subjects are males
aged 16-77 years who have never been prescribed iron supplements. Blood donors are
male, first time donors aged 17-62 years from South Wales;301 samples for analysis were
obtained prior to first donation. * P < 0.001 compared with donors; nsnot significant. Only
TIBC showed any correlation with sFn (rs = - 0.412, P < 0.001).
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Figure 13. Haemoglobin, serum ferritin and serum soluble transferrin
receptor-1 concentrations in male subjects with dominant EPP.
a) Haemoglobin concentrations in 66 male subjects with dEPP aged 16
or over (■) and in a sample of 5206 men aged 16 or over from the
English population307 (□ ) .
11.9 12.9 13.9 15A
Hemoglobin (g/dL)
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b) Serum ferritin concentrations in 66 male subjects with dEPP aged 16
or over (■) and in 612 male first-time blood donors from south Wales








c) Serum soluble transferrin receptor-1 concentrations in 61 male
subjects with dEPP aged 16 or over (18.6 ± 5.1 nmol/L) (■) and in 225
haematologically normal male and female subjects from the United
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3.5 Biochemical assay of liver function in dEPP
Table 14. Liver dysfunction in reported EPP patient series.
Paper Definition of Subject Percentage Virology Comment
Reference abnormal Number (No.) with
liver abnormal
function liver function
Holme fYGT, AST, 182
ALT
25 (45) All Current study
negative
Frank Not stated 90 27 (24) All Retrospective analysis
negative Possible selection bias
Doss Not stated 55 35(19) Not Retrospective analysis
reported Possible selection bias
DeLeo7 T AST Bi 32 3(1) Not Retrospective analysis
reported
Schmidt115 t AST Bi 29 0 (0) Not Biochemistry not
reported performed in all cases
Rademakers137 | AST, ALT 11 36 (4) Not Retrospective analysis
reported Small sample size
Mooyaart t yGT, AST,
ALT, LDH, Bi
22 (2) Not Small sample size
reported
Peterka t Bi 0 (0) Not Small sample size
reported 3 other cases with no
biochemistry
TOTAL 412 23 (95)
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From the overall study population of 223, 210 complete blood sample sets were
obtained. Six result sets were withdrawn from the biochemical analysis for the
following reasons: two subjects with malignancy (one colonic carcinoma, one
testicular seminoma), one subject with liver failure, one recipient of a liver
transplant, and two subjects with alcoholic liver disease. Of the remaining 204
sample sets, 182 were identified with mutation-positive dEPP (100 females and 82
males, median age 35 years, range 6-87). The precise mutations identified were: 24
missense (M), 10 of which were P334L missense mutations (MP), 75 null (N), and
83 splice (S), 44 ofwhich were IVS3+2T>G splice mutations (SS).
Serum liver function tests were out-with normal limits in 25% of subjects (45/122) in
keeping with results from previous EPP patient series (table 14). Total erythrocyte
protoporphyrin (TEP) was higher in males (mean 29.6 |Jmol L"1) than females (mean
23.6 pmol L"1). Mean TEP was higher in this cohort with dEPP (mean 29.3 [Jmol L"
') than those subjects with EPP inherited in an autosomal recessive pattern (rEPP;
mean 10.8 [Jmol L"1).309 Alcohol was drunk regularly by 132 subjects (73% (84% of
the 157 aged 16 or over)). The median number of self-reported units consumed per
week was 10 (quartiles 0, 14, range 0-70).
One hundred and seventy two subjects (95%) had no hepatitis B surface antigen and
antibody, 8 had surface antibodies, but were negative for surface and core antigen,
(suggesting hepatitis B vaccination - five were employed as health care
professionals) and 2 were positive for both surface antibody and core antibody but
negative for core antigen and e antigen (suggesting either latent or previous infection
with no current replication). Neither of these two subjects had abnormal liver
function results. None had evidence of infection with or exposure to the hepatitis C
virus.
By creating a category of normal/abnormal AST/ALT, non-parametric analysis
suggested associations with male gender (Mann-Whitney exact P = 0.004), TEP
(p=0.03), haemoglobin (p=0.049), serum ferritin (P - 0.002) and GGT (P < 0.0005).
Entry of these and borderline significant variables into a regression analysis revealed
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significant associations with: male gender (P = 0.002), TEP (P = 0.029),
haemoglobin (P = 0.01), haematocrit (P = 0.017), ferritin (P = 0.03), albumin (P =
0.009) and GGT (P < 0.0005). Adjusted R2 = 0.179 and ANOVA significance
p<0.0005. There was no significant association between genotype and LFTS.
3.6 Assay of Protoporphyrin
Total erythrocyte porphyrin (TEP) was increased in the 211 subjects from whom
blood was obtained (mean 26.1 pmol L"1, range 2.0 - 159.2 pmol L"1; normal
subjects less than 1.7 prnol L"1). Erythrocyte porphyrin, mainly free protoporphyrin
and plasma porphyrin (fluorescence emission maximum 626 - 634 nm), was
increased in all subjects. TEP and was significantly higher in males (mean 29.3 pmol
L"1, range 2.0 - 159.2 prnol L"1) than females (mean 23.1 pmol L"1, range 2.3 - 75.3
pmol L"1) (P = 0.003). There was a slight increase with current age but this did not
reach statistical significance in either sex (P = 0.096).
TEP results from analyses prior to this study were available for 113 study subjects
(mean time from previous sample 5.9 years, range 0.5-12, mean TEP at time of study
26.41, mean previous TEP 27.59). There was no statistically significant difference
between the two TEP groups (Wilcoxon test P = 0.628), suggesting no change in
TEP with age.
3.7 Assay of 1,25 dihydroxy Vitamin D
Two hundred and ten samples were collected over a 7-month period between January
and July, representing a period with minimal and maximal vitamin D levels in
normal populations,310 at latitudes ranging from 51°N to 57.5°N, and analysed for
serum 25-hydroxyvitamin D. Nine subjects were withdrawn from the analysis due to
non-white skin coloration (2 - both vitamin D insufficient (VDI)), systemic
malignancy (2), renal failure (1), hepatic failure (2), post-orthotic liver transplant (1)
and one patient taking ergocalciferol.
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Eighty percent of the cohort regularly avoided sunlight, 87% wore long-sleeve
occlusive clothing daily, 9% used a sun screen at least once daily all year and 68%
used sunscreen once daily or more frequently in sunny weather. No subjects had
ever had their vitamin D status checked by their physicians. Five subjects reported
coexistent osteoporosis, but other than analgesics, were not taking any other
treatments for this. Three subjects took fish liver oils daily as a health supplement,
one of whom also took a calcium supplement. One further patient took calcium
supplementation. Excepting a non-vegan vegetarian, all subjects were omnivores; a
more detailed dietary history was not taken.
The mean serum hydroxyvitamin D was 18.32 ng/ml (range 4.9-51.4, quartiles 11.5,
23.5). One hundred and twenty six subjects (63%, 58 males, 68 females) were VDI
of whom thirty four subjects were vitamin D deficient (VDD) (17%, 15 males, 19
females). Of three subjects taking dietary fish oil supplements, one was VDI.
Twenty one subjects were receiving ultra-violet B (UVB) phototherapy to induce
'hardening' of their skin to sunlight sensitivity; 6 (29%) were VDI and none were
VDD.
The mean monthly serum 25-hydroxyvitamin D rose over the study period January to
July from 15.5 to 21.3 ng/ml (Figure 14). In the winter months of January and
February 70% of subjects (19/27) were VDI and 44% (7/27) were VDD: In the
summer months of June and July 45% (34/75) were VDI and 37% (28/75) VDD.
There appeared to be a slightly smaller proportion of children aged 16 or under VDI
or VDD compared to the overall population (3/34 - 11%, 18/92 - 20%).
One hundred and eighty one complete sample sets were available for analysis of
calcium, phosphate and PTH biochemistry. Thirteen subjects (7%) were deficient in
adjusted serum calcium (11 VDI, ofwhom 3 were VDD) and forty one (23%) had an
elevated serum phosphate (21 VDI, of whom 3 were VDD). Hyperparathyroidism
was seen in 12 subjects of whom 9 were VDI (2 VDD) and the remaining 3 had
serum 25-hydroxyvitamin D at the lower end of the normal range of between 21 and
23 ng/ml.
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Figure 14. Boxplot of serum 25-hydroxyvitamin D by month of sampling
(deficiency <10 ng/ml, insufficiency < 20 ng/ml). The boxes contain
results between the upper and lower quartiles and the dark bars within
























Statistical analysis (Mann-Whitney test) suggested VDI was associated with total
erythrocyte protoporphyrin (TEP) (P = 0.009) and inversely associated with the time
in minutes to the onset of symptoms following sunlight exposure (P = 0.008). VDD
was associated with the age of symptom onset (P < 0.0005), TEP (P = 0.02) and
inversely with minutes to symptom onset (P = 0.03). There was no association with
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calcium deficiency, raised phosphorus or elevated PTH, although elevated PTH
approached significance with VDI (P = 0.57).
3.8 Autosomal recessive EPP
3.8.1 Palmar keratoderma is an uncommon feature of EPP.
From the study cohort, 7 rEPP subjects from 4 families had marked thickening of the
palmar epidermis (palmar keratoderma). Subsequent to the close of the study, 2
further individuals with this uncommon phenotype were identified resulting in 5
males and 4 females, aged 8 to 63 years, from 6 families (Table 15), giving
prevalences for palmar keratoderma in EPP of 3.3% for all subjects and 2.6% (95%
confidence interval: 1.0 - 5.1%) for families.
In all subjects, keratoderma had been present since early childhood and in 7 subjects
had developed before the diagnosis of EPP was made. In 3 subjects the development
of mild palmar keratoderma was preceded during infancy by a scaly rash, mainly on
the dorsum of the hands, initially thought to be eczema; a third patient had areas of
hyperpigmentation and lichenified skin over her knees, neck and elbows which were
present before the onset of photosensitivity and have persisted. Keratoderma was
worse in summer and often resolved in winter. In one patient, occlusion of the skin
with a plaster cast for 6 weeks following a wrist fracture led to almost complete
resolution of the keratoderma. These features have not previously been reported for
other palmoplantar keratodermas311 and were felt to represent a distinct rEPP-
specific presentation.
The keratoderma ranged in severity from waxy keratoderma over the whole palm to
mild keratoderma of the first interdigital web (Fig 15, Table 15). Palmar
keratoderma was sharply demarcated at the wrist with, in most cases, minimal
transgredience onto the extensor surface, and without an erythematous border (Fig
15). Two subjects had mild onycholysis but otherwise nails were not affected.
Sweating appeared unimpaired and there was no malodour. Two unrelated subjects
also had mild plantar keratoderma (Table 15). Keratoderma was not particularly
marked at sites of pressure or punctuate in pattern. No patient reported blistering,
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hyperhydrosis, periodontitis or other teeth abnormalities, visual or auditory
impairment.
In one patient, a very small punch biopsy of the hand had previously been obtained.
The limited amount of epidermis present was slightly thickened and spongiotic and
there were some prominent upper dermal vessels with a hint of PAS-positive hyaline
change. There was not enough epidermis to determine whether the keratin layer was
thickened.
The severity of photosensitivity varied within families but was similar to that in
subjects with EPP without keratoderma (average time to symptom onset 24 minutes,
quartiles 6, 45).312 All became photosensitive between the ages of 3 and 17 months.
Symptoms started within 1 - 30 minutes after exposure to sunlight and quality of life,
assessed by CDLQI or DLQI scores, was severely impaired in the 6 subjects in
whom it was measured (mean DLQI 11, CDLQI 12).
Four subjects from 3 families had neurological abnormalities. Three subjects (P7,
P8, P9) had slight or moderately severe cognitive and motor developmental delay,
without regression since early childhood, and one of these suffered from fits until the
age of 2 years. Older siblings in both families had neither EPP nor developmental
delay. One patient (P4) presented in his early thirties with a spastic paraparesis
which has progressed; extensive investigations to identify a cause were negative.
Haemoglobin concentrations and biochemical tests of liver function were normal in
all subjects, except for one female patient who had a haemoglobin concentration of
11.9g/dL.
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Table 15. Recessive EPP with keratoderma: clinical features.







1 P1 F 8 1.4 sib1 Confluent waxy palmar keratoderma
with fine peeling; sharp cut-off at
wrists.
P2 M 10 1.0 sib1 Keratoderma and peeling of first
interdigital web and patchy keratosis
and peeling over palmar surface of
digit joints and pulps.
II2 P3 F 58 0.5 sib Palmar keratoderma with sharp cut¬
off at wrist; transgredience to involve
first interdigital web; focal plantar
keratoderma with fissuring over heels
and MCT joints
P4 M 52 0.4 sib Mild keratoderma of first interdigital
web
III P5 M 27 0.3 Confluent palmar keratoderma with
peeling; lateral aspects dry, white and
cracked; slight onycholysis;
keratoderma medial aspect of forefoot
and great toes.
IV P6 M 63 <1 Marked keratosis of first interdigital
web and radial border of index fingers
with fissuring at index finger joints
V P7 F 17 0.25 Waxy keratoderma over the whole
palm; mild fine peeling; more obvious
in summer, regresses in winter; sharp
cut-off at wrist. Nail dystrophy.
VI P8 M 13 0.25 sib Mild keratoderma of first interdigital
web
P9 F 12 2.0 sib Mild keratoderma of first interdigital
web
1
Great grandmother has EPP without keratoderma (see text). 2Consanguineous parents.
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Figure 15. Palmar keratoderma in EPP.
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3.8.2 Erythrocyte protoporphyrin concentrations are lower in EPP with
keratoderma than in EPP without keratoderma.
Erythrocyte porphyrin concentrations in the nine subjects with keratoderma were
significantly lower (median 7.4 pmol/L, range 2.0-15.5 pmol/L; normal subjects, 0.4
- 1.7 pmol/L) than in 203 subjects without keratoderma (median 22.8 pmol/L, range
4.1-159.2 pmol/L) (Mann-Whitney test P <0.001). When two members of the same
family were affected, erythrocyte porphyrin concentrations were similar. The
percentage of free erythrocyte protoporphyrin (41 - 91%) was increased in all
subjects but in those with the lowest TEP was only approximately equal in amount to
zinc-protoporphyrin. In contrast, the plasma protoporphyrin concentrations in the
subjects with keratoderma (median 55.0 nmol/L, range 13.4 - 115.1nmol/L; normal
subjects, less than 10.5 nmol/L) did not differ significantly from those in 11
randomly selected subjects with EPP without keratoderma (median 68.4, range 18.8
- 396.0) whose erythrocyte porphyrin concentrations ranged from 12,4 to 159.2
pmol/L (median 30.1 pmol/L). Faecal total porphyrin excretion was substantially
increased (median 1198 nmol/g dry weight; range 523 - 1940 nmol/g; normal
subjects, less than 200nmol/g) in the seven subjects in whom it was measured, with
protoporphyrin accounting for greater than 80% of the total.
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3.8.3 EPP with palmar keratoderma is inherited in an autosomal
recessive pattern
Three subjects had no family history of overt EPP or palmar keratoderma. In
families II and VI, two siblings had EPP with keratoderma but no other relative had
either condition. In family I, two of three siblings had EPP with keratoderma; the
third had neither condition but their maternal great grandmother had a lifelong
history of photosensitivity without keratoderma. Photosensitivity and keratoderma
always occurred together when more than one member of the same generation had
EPP.
Mutational analysis showed that all subjects with EPP and palmar keratoderma were
either compound heterozygous or homozygous for FECH mutations and that only
one patient (family III) had inherited the hypomorphic FECH IVS3-48C allele (Table
16). All but one of the mutations were missense; 4 of these (c.0302T>C; c.0854A>G;
c.0898G>T; c.0502C>T) are novel. Mutational analyses of families II and VI have
been reported.4 Both subjects in family I were compound heterozygotes for a
missense mutation and a mutation (IVS3+2T>G) that is known to impair splicing of
313*
exon 3. In their maternal grandmother, this mutation was trans to an FECHIVS3-
48C allele; a genotype that has been identified in other patients with the typical
dominant form of EPP (Whatley SD, unpublished information). Mutational analysis
of 184 unrelated subjects without keratoderma identified 2 additional subjects with
recessive EPP; one , a 14-year-old boy, had been reported previously with regard to
his abnormal liver function.4'149 The other was homozygous for both a novel
mutation (c.0502C>T; P168L) and the hypomorphic IVS3-48C allele.
Five of the eight missense mutations that we identified were expressed in a
prokaryotic expression system and their effect on FECH activity determined (Table
17). These activities, together with those previously reported for the 3 other missense
mutations,4 were used to calculate the FECH activities in our subjects (Table 17) on
the assumption that they were similar to those expressed by these alleles in human
tissues.
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Table 16. EPP with palmar keratoderma: FECH genotypes with
predicted FECH activities.
Family Allele Mutation Effect FECH IVS3-48 Predicted FECH
activity (%)
r 1 c.0302T>C L101P T 2.74
2 IVS3+2T>G Splice T
defect
n1 1 c.0416A>T Q139L T 18
2 c.0416A>T Q139L T
in 1 c.0503C>T P168S TorC 5.63
2 c.0854A>G Q285R C orT
IV 1 c.0820G>A D274N T 5.9
2 c.0898G>T V300L T
V 1 c.0707G>A C236Y T 6.4
2 c.0820G>A D274N T
VI1 1 c.1137C>G K379N T 25
2 c.0707G>A C236Y T
Previously unreported mutations are shown in bold; 1both affected siblings had the same
genotype; 2assuming no activity from the IVS3+2T>G allele; 3assuming IVS3-48C cis to
P168S (see text).
Table 17. Prokaryotic expression of mutant and wild type FECH alleles
FECH allele FECH activity(nmol/h/mg) Percent wild type activity







Predicted FECH activity was calculated from data in Table 18 and Whatley et al, 2004.4
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3.9 X-linked dominant protoporphyria (XLPP)
Mutational analysis fails to detect FECH mutations in about 7% of EPP families of
which about 3% are homozygous for the wild type FECH IVS3-48T allele (rEPP).314
We studied 8 families (Fig. 16) in which at least one individual had acute
photosensitivity clinically indistinguishable from that of dEPP and who genotypicaly
were not rEPP. Three families were identified from this study and the remainder
through collaboration with colleagues in Paris, London and Cape Town.315 They
were of western European (4 families), Jewish, north African, Indo-Asian or
Sudanese origin (one family each).






Family E Family F Family G Family H
O □ = patient with EPP clinically. O □ = patient with EPP clinically and liver
disease.
Clinical information was not obtainable for subjects C I, 3 and 4 or E 1,1 and 2. All subjects
with liver disease had symptoms attributable to liver disease which was confirmed at autopsy
or by needle biopsy as being protoporphyric liver disease in all except patient H 1,1 for whom
a diagnosis has not been established. Patient E II,3 was previously described by Eales, L,
Day, RS, Pimstone, NR. Ann Clin Res 1979; 10: 205-213. For families A - D, haplotyping
showed no linkage of disease to FECH and was uninformative for family E. Haplotyping of
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families A - C was consistent with a disease locus on the X chromosome; other families
were not haplotyped.
We differentiated these subjects from others with mutation-negative EPP by showing
that the percentage of erythrocyte PP that was present as its zinc chelate (ZnPP) (19-
65%, median 44%) was markedly greater than in dEPP (4-13%, median 8%) (Fig. 17
and Table 20). Erythrocyte PP concentrations were also higher in our subjects, being
increased 24-fold (range: 6 - 103-fold) compared with 14-fold (range: 4 - 44-fold) in
171 subjects with mutation-positive dEPP (Mann-Whitney test P <0.001) (Fig. 17).
Lymphocyte FECH activity was normal, indicating that PP accumulation was not
caused by FECH deficiency resulting from a mutation of the ubiquitously expressed
FECH gene (Fig. 18 and Table 20).
Figure 17. Spectrophotometric illustration of free erythrocyte
protoporphyrin concentrations in mutation negative EPP subjects
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A 1,2 2 F 86.3 45 30 4.5 delAGTG
11,4 4 M 51.2 27 52 4.2
111,9 9 F 20.1 10.6 57 4.3
111,10 10 F 38.4 20.2 61 4.0
B 1,2. 2 F 52.4 27.6 57 3.8 delAGTG
II,6 6 M 178.6 94 39 5.3
II,7 7 M 195.6 103 36 4.9
C II,7 7 F 56.7 29.8 40 4.1 delAGTG
111,10 10 F 37.1 19.5 34 3.7
D II,4 1 F oCD 24.0 27 - delAGTG
III,6 2 F 109 64.1 37
N
CDCD
III,7 3 F 41.2 24.2 41 -
E II, 4 1 F 5.6 5.6 65 - delAGTG
II,7 2 M 11.1 11.1 45 -
III,9 4 F 9.3 9.3 61 -
111,10 5 F 8.1 8.1 65 -
111,12 6 F 27.3 27.3 47 -
F 1,3 1 M 22.6 13.3 64 - delAT
II,7 2 F 61.7 36.3 46 -
II,8 3 F 40.8 24.0 42 -
G 1,2 1 F 35.2 20.7 - - delAT
III,6 2 M 22.5 13.2 58 -
H 1,1 1 M 159 93.5 19 - delAGTG
Reference ranges for erythrocyte PP are less than 1.9 pmol/L erythrocytes (families A-C),
less than 1.0 pmol/L (family E) and 0.4-1.7 |jmol/L (families D, F-H). 1Free PP and ZnPP
determined separately; reference ranges less than 0.2 pmol/L and less than 0.8 pmol/L
respectively. Reference range for lymphocyte FECH activity: 5 .0 ± 1.5 (mean ± 2SD) nmol
zinc mesoporphyrin/h/mg protein;2 indirect FECH assay, reference range: 42-92%, mean
68%, n = 22. There was no significant difference between erythrocyte PP in males and
females (P = 0.37, Mann Whitney test).
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Figure18.PedigreeoffamilyA. FC,lymphocyteFECHactivityinn lzinc- esoporphyrin/h/mgprotein; PP,erythrocyteprotoporphyrininpm l/lit epackederythrocyt s.
Involvement of FECH was further eliminated by showing that the disease did not
segregate with FECH haplotypes (Fig. 18). Because abnormal expression ofmRNA
for mitoferrin has been implicated in the pathogenesis of a similar form of
protoporphyria,316 we sequenced SLC25A37 in all 8 probands, but were unable to
identify disease-specific mutations.
Parent-child transmission of overt disease is uncommon in dEPP.8 Our families were
unusual in showing an apparent dominant pattern of inheritance with an absence of
father-son transmission that suggested X-linkage (Figures 16 and 18). X-linkage was
confirmed in 3 families using microsatellite markers for two candidate genes, GATA1
and ALAS2, on the X chromosome (Fig. 19).
Figure 19. X chromosome microsatellite markers used for haplotyping
and the X chromosome haplotypes associated with disease in families
A-G.































































































Sequencing of genomic DNA excluded a mutation in GATA1 but identified two
different deletions in exon 11 ofALAS2 (c. 1706-1709delAGTG; p.Glu569GlyfsX24
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in 6 families and c. 1699-1700delAT; p.Met567GlufsX2 in 2 families) that predicted
alterations of the 19 -20 C-terminal amino acids of ALAS2; either their replacement
by a 23 residue sequence that extends the enzyme by 4 amino acids or their deletion
(Fig. 20). These deletions segregated with photosensitivity (LOD score 8.13) and
were absent from 23 unrelated FECH-mutation negative subjects, 106 unrelated
dEPP subjects, and 100 normal subjects. The c. 1706-1709delAGTG mutation
occurred on 5 different haplotypes indicating that it has arisen on at least 5 separate
occasions. This recurrent mutation involves a direct 4 base repeat in the coding
sequence ofALAS2, such sequences being more prone to deletion (Fig. 20a). These
data indicate that the deletions in ALAS2 that we have identified are responsible for
the disease in our families. They identify a previously unrecognised disorder, X-
linked dominant protoporphyria (XLPP) that, in contrast to dEPP and other
autosomal dominant porphyrias, has close to 100% penetrance.
Figure 20. a) Sequence analysis of genomic DNA from male subjects
showing deletions in the ALAS2 gene.
Del Contr Del
b) Alignment of ALAS C-terminal sequences; arrows indicate the effects of
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All previously described mutations in ALAS2 have caused XLSA with frame shift
(insertion or deletion of a number of nucleotides, not divisible by three, disrupting
the triplet reading frame of the DNA) or other null ALAS2 mutations (mutations
which prevent the DNA being transcribed into RNA and / or translated into a
• 317 ifunctional protein product, which are embryonically lethal in males). The
mutations appear to be in the catalytic site of ALAS2, and reduce mitochondrial
enzyme activity levels, resulting in dyserythropoiesis, with ring sideroblasts in the
marrow, a microcytic hypochromic anaemia and a secondary (erythropoietic)
haemochromatosis.318 In contrast, in our families, both sexes were affected and
subjects had neither anaemia (haemoglobin: 12.2 - 17.5g/dL) nor iron overload
(Table 21). In one subject with iron deficiency caused by a gastric ulcer, treatment
with iron led to a 3-fold decrease in TEP with little change in ZnPP concentrations;
other subjects showed the mild disturbance of iron metabolism characteristic of
dEPP,319 consistent with the hypothesis that accumulation of protoporphyrin rather
than FECH deficiency is responsible for this abnormality.129 Five (16%) subjects
had overt liver disease (Fig. 15), suggesting that XLPP, like autosomal recessive
i "jc
EPP, carries a higher risk of liver disease than dEPP. Liver disease was
commoner in males (P = 0.008, Fisher's exact test), and one obligate carrier was
asymptomatic (Fig. 15, II, 4 in family G), but otherwise we found no evidence that
X-inactivation led to milder disease in females; there was no significant difference
between erythrocyte PP concentrations in males and females (Table 19).
The 26 C-terminal amino acids of ALAS2 are highly conserved among species that
have two ALAS genes (Fig. 19) but are not present in ALAS from Rhodobacter
capsulatus (ALASrc), the only ALAS for which the crystal structure has been
320
reported. The conservation of this sequence and its absence from ALAS1 suggest
an important, but unknown, erythroid-specific function. It does not appear to be
directly involved in catalysis and a missense mutation in this region (S568G) that
T90
produces XLSA probably acts by inducing a general conformational change.
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Table 19. Haematological and iron indices for subjects with X-linked
dominant protoporphyria
Family/Patient Sex PP Hb sFn sTf sat sTfR
(pmol/L) (pg/dL) (Mg/L) (%)
A 1,2 F 45 14.1 65 23 2.24
11,4 M 27 15.7 104 39 1.44
111,9 F 10.6 13.8 21 33 1.32
111,10 F 20.2 12.8 77 22 1.05
B 1,2 F 27.6 12.4 46 16 2.59
II,6 M 94 14.3 24 7 2.47
II,7 M 103 12.2 10 4 2.83
C II,7 F 29.8 13.8 154 3 1.41
111,10 F 19.5 13.0 19 12 1.24
F 1,3 M 22.6 17.5 28 24 18
G III,6 M 22.5 12.4 12 16 17
Reference ranges: serum ferritin (sFn) 15 - 250 pg/L; serum transferrin saturation (sTf sat)
20 - 45 %; serum transferrin receptor (sTfR) 0.8 - 1.6 mg/L (families A-C); 8-30 nmol/L
(families F and G).
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4. Discussion
4.1 Case identification and prevalence of EPP
The study provides quantitative data about the frequency of clinical features (Tables
7 and 9). Differences, particularly in the frequencies of clinical features, between
our data and that from previous descriptions of EPP7'115'166 are probably best
explained by the larger number of patients in this study, the inclusion of a higher
proportion of patients (32%) over the age of 40 years and possibly geographical
location. Furthermore these results may be less susceptible to observer variation and
participation bias, as all the subjects were seen by the same observer and selection
bias was minimised by recruiting as high a percentage of known UK cases as
possible.
We identified 389 living individuals within the UK with EPP and an additional 30
affected family members not included in the databases that we searched. This gives
a minimum prevalence for EPP in the UK (population 59.8 million) of 1 in 143,000,
close to the previously reported UK prevalence of 1:130,000321 and higher than
1:200,000 reported in Sweden177 but lower than the 1:79,000 and 1:75,000 for
Northern Ireland and the Netherlands, where there is some evidence for founder
o nr\
effects. ' The true UK prevalence probably lies between these figures given the
difficulty in obtaining a diagnosis reported by many of our patients, and our
identification since the study ended of new cases that were symptomatic before the
study period. Although it seems reasonable to assume that we studied just over half
the total number of UK patients, some selection bias may have been introduced by
using databases held by specialist referral centres and because only 76% of those
invited volunteered to participate.
4.2 Clinical presentation of EPP
This study clearly defines for the first time the clinical features of EPP in a large
cohort. The clinical onset is very much in early childhood, usually at the time of first
significant sunlight exposure. All 223 patients in this study developed symptoms
before they were 13 years old, although a few patients did not seek medical advice
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until they were much older. This was an unexpected finding because other series
have included patients whose disease became manifest only during their teens or
later,7'115 and there are several reports of adult onset of EPP,110 distinct from those
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caused by somatic mutation of the FECH gene in haematopoietic cells. In
contrast, the median age at diagnosis was 12 years and the diagnosis was not made in
a third of our patients until they were 20 years of age or older. This has obvious
implications for management and complications. Although laboratory methods for
the diagnosis of EPP have improved over the past three decades, analysis of our data
shows little change in the median time to diagnosis for each decade from 1965.
Dermatologists diagnose most EPP individuals, with only a minority diagnosed by
either GPs or Paediatricians, the healthcare professionals from whom most of these
individuals will have first sought advice. While it is possible that GPs and
Paediatricians refer individuals with such symptoms to Dermatologists to make the
diagnosis, both the delay in diagnosis and participants' comments regarding the
diagnostic process suggest that there is considerable ignorance of the condition in
these professional groups. Thus there is a need for an increased awareness of EPP
among GPs, Paediatricians, and also in the wider community, as 8% of our patients
were self-diagnosed or diagnosed by a family member after seeing or reading
information about porphyria.
Clinical aspects of EPP which this study has confirmed include the previously
reported priming phenomenon, nail changes in response to light exposure,115 acute
symptoms usually in the absence of visible signs (swelling/oedema appear on
average after 6 hours), and knuckle skin thickening. This latter sign appear more
common in males than females and while this may relate to a direct sex effect, more
probably reflects the increased light exposure of men's hands during differential
occupational and leisure activities. The study also confirms the improvement in
photosensitivity during pregnancy. Two novel findings related to this last
• ... • • 7Qobservation were the identification that TEP was higher in males than females, and
the experience by some women of more severe symptoms around the time of their
menses. These add to the evidence that sex hormones influence EPP, although the
mechanism for the effect remains unclear. There are reports that TEP decreases166'1 7
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or remains unchanged during pregnancy.165 The human ABCG2 multidrug
transporter protein regulates intracellular protoporphyrin concentrations in erythroid
and hepatic cells,36 and its expression in human placental cells is increased by
progesterone and 17P-oestradiol,37 an effect that might lead to removal of
protoporphyrin from the maternal circulation during pregnancy. Other suggestions
include a hormonal influence on FECH expression, the dilutional effects on the
vasculature of pregnancy, enhanced biliary excretion during pregnancy or foetal
1 68
detoxification ofmaternal PP.
Photo-induced hardening of the skin was reported in over half of participants. This is
an important observation as it suggests that iatrogenic hardening using phototherapy
(available in most Dermatology units) could be a helpful therapeutic modality if
commenced in Spring, similar to treatments for polymorphic light eruption, to
provide increase photo-tolerance over the summer months. Furthermore, such
treatment would have an additional benefit of UV-induced endogenous vitamin D
synthesis, as a further novel finding of this study was the identification that a large
proportion of EPP individuals are vitamin D insufficient or deficient throughout the
year, leaving individuals at risk of important clinical consequences. However three
quarters of the study cohort had never been offered phototherapy, perhaps reflecting
concerns of both patients and clinicians of using such treatment when the condition is
precipitated by light radiation at a closely related wavelength.
Some of the study's findings suggested that several earlier reported features of the
condition may not be correct. Subjectively there was no significant participant
reported reduction in symptoms with increasing age and objectively, no reduction in
DLQI scores with age. In contradistinction, there may be a trend to increasing
sensitivity with age due to the association between TEP and increasing age.
Participants' comments on this issue were generally that with increasing age they
were better able to judge situations and avoid activities at times when symptoms
might be induced.
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Although there is a perceived increased in hypothyroidism in our EPP study
population (4.7% versus 3.3% in a normal British population (Tayside)),322 a chi
square test failed to detect a significant difference (x = 1.19; df = 1; P = 0.274).
In contrast, gallstones have been reported to be more common in individuals with
EPP than might be expected;7'323 in our population 9% had gallstones and 6%
previous cholecystectomy (1% men and 5% women). It is recognised that gallstones
are often asymptomatic and may only be discovered incidentally, and that the
incidence of gallstones and cholecystectomy rises with age. The mean age of our
study population was 34 years, and the mean age of the Scottish population in 2000
was 38.76 (General Register Office for Scotland) and in England in 2001 was 38.6
(2001 census, Office for National Statistics), suggesting that normal British
populations have a similar mean age to our study population. Previous studies of
large normal British populations in Bristol324 and Teesside325 reveal cholecystectomy
rates of 1.67 - 1.3% for men and 3.5 - 4.1% for women respectively. While there
appeared to be no significant differences in cholecystectomy rates between the
Bristol and Teesside populations (%2 = 0.06; df = 1; P = 0.803), there appeared to be a
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significance difference in rates between the EPP population and the Bristol (x =
7.72; df = 1; P = 0.005) and Teesside populations (x2 = 7.57; df = 1; P = 0.006).
Closer analysis showed no difference in rates in males with EPP versus those
resident in Bristol (x2 = 0.64; df = 1; P — 0.424) or Teesside (x2 = 1.52; df = 1; P =
0.218), but there appeared to be an increased rate in females with EPP over those in
Bristol (x2 = 9.55; df = 1; P = 0.002) or Teesside (x2 = 7.53; df = 1; P = 0.006). The
explanation behind this observation is not apparent. Due to the small numbers of
men with EPP (3) who had undergone cholecystectomy, statistical analysis of this
group may not be accurate. The increased rate in women with EPP may be a true
reflection of an increase of symptomatic gallstone disease in the condition, or a
reflection of the preconception that individuals with EPP are more likely to have
gallstones leading to over-investigation and over-treatment.
Management of study individuals' EPP was often not optimal, possibly reflecting a
relative lack of knowledge amongst physicians, perhaps resulting from the dearth of
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robust studies. Although all individuals knew about sunscreen use to limit
photosensitivity, it was striking that the majority of those currently using sunscreen
were using propriety products which would be unlikely to protect effectively against
those visible wavelengths precipitating acute symptoms. Furthermore, nearly a third
did not use any sunscreen. Regular follow-up of EPP individuals would provide an
opportunity for physicians to educate them, suggest treatment options (including
phototherapy discussed above), and undertake regular blood investigations such as
liver function tests (LFT), serum 25 hydroxy vitamin D and possibly for FBC and
iron status (sFn and sTfR) to assess for possible complications. However 30% of the
study cohort was under no regular review of any medical practitioner. Although
there are no published follow-up guidelines for EPP either within the UK or
internationally, it would seem sensible for individuals to have at least an annual
review with a medical practitioner who has knowledge of the condition. An example
of an important area for education is the consumption of alcohol. Not only was
alcohol intake associated with abnormal LFTS, but 4% of the cohort used excess
alcohol intake as an analgesic approach during symptomatic episodes. While it may
be argued that there is no current evidence linking alcohol or abnormal LFTS and the
development of liver failure in EPP, it would seem prudent to limit intake of
additional hepatotoxins in the presence of TEP, an endogenous hepatotoxin.
Forty percent of participants recounted a family history of the condition, most
usually in siblings, but also parent-child inheritance and in more distant relations. In
only 2 families was transmission recorded in an apparent dominant pattern, between
at least 3 consecutive generations. Both these families were subsequently discovered
not to have classical EPP, but instead the novel XLPP, suggesting a good family
history is a useful discriminating feature between the two conditions.
4.3 Quality of life in EPP
The substantial impact of EPP on the lifestyle of most patients is indicated by their
QoL scores (Table 10) which were unexpectedly high in comparison with those for
other skin diseases generally regarded as more severe, such as severe eczema and
epidermolysis bullosa (Table 20).298 In contrast, relatively asymptomatic but
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visually disfiguring conditions scored much lower. There are no published studies
of QoL in other cutaneous porphyrias, although the impact of non-cutaneous
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symptoms in acute porphyrias can be marked. The high scores, with EPP having a
very large effect on QoL in 70% of adults, are partly explained by high scoring in the
social and leisure categories. This may reflect the lifestyle restrictions imposed by
the need to avoid exposure to sunlight, whereas in most other skin disorders
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symptom-related questions score highest. ' Children, who may be less aware of
the social implications of their illness, tended to score higher on questions about
symptoms and sleeping, reflecting their reduced control over sunlight exposure and
the pain experienced when avoidance is not possible. Thus the main effect of EPP
on QoL comes from the morbidity produced by acute and prolonged pain following
sunlight exposure together with the social consequences of the measures needed to
avoid this. This very significant impact of having EPP on an individual's QoL has
probably not previously been fully appreciated by clinicians.
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The previously reported trend for higher DLQI scores in younger adults was not
seen in EPP (Table 10). Indeed, scores did not improve with age, again in keeping
with our observation above of no subjective change with age and a trend for higher
TEP levels to be associated with increasing age, refuting the earlier suggestion of the
condition improving with age (which may have been more a reflection of better
ability to avoid sunlight in adulthood).115
Table 20. Comparison of previous DLQI and CDLQI study mean scores
Condition Adults Children
EPP (current study) 14.0 12.8
Acne 5.7329
Atopic eczema 4 14330-16.2331 7.7-12.721'24
Epidermolysis bullosa simplex 10.725 1525
Epidermolysis bullosa - dystrophic 7 5332 1 1.5332
Erythrokeratoderma variabilis 5.326 2.7526
Psoriasis 4.5330-13.9331 5.4329
Melanocyte naevi 2 3329
Vitiligo 5.627
Unaffected population 0.38329
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4.4 Haematological analyses
Part of the previously reported wide variation in incidence of anaemia can be
explained by the use of different definitions7'70'106'115'124,127 Using WHO references,
41% of the dEPP subjects were anaemic, all with a microcytic, hypochromic pattern.
In both sexes haemoglobin, mean cell volume (MCV), and mean corpuscular
haemoglobin (MCH) were normally distributed with a shift in their means towards
lower values. This is similar to a downward shift in haemoglobin (Hb) previously
noted in Dutch EPP patients,8 which leads to some patients falling within the
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definition of anaemia. FECH activity in dEPP is about 35% of normal. Our data
show that this decrease is sufficient to produce in all patients a mild defect of
erythropoiesis that impairs haemoglobinisation. Defective erythropoiesis persists
throughout life and our findings and previous reports ' suggest that it may not be
corrected by oral iron unless there is evidence of co-existing iron loss.
The study showed a marked shift in serum ferritin (sFn) towards lower values,
correlating with Hb. Since sFn correlates with mobilizable iron stores,334 the
downward shift in sFn by approximately two-thirds (Figure 13b; Table 12) suggests
that iron stores in dEPP are decreased to a similar extent or a little more if the effect
of liver dysfunction is taken into account. Turnbull et al126 found that storage iron,
determined by venesection, was less than 250mg in 3 patients; otherwise,
quantitative measurements of tissue iron have not been reported in EPP. However in
contrast to iron deficiency due to iron loss, sustainable iron is present in
erythroblasts.127 In homozygous FECHnlPas mice, total body iron is normal but iron
• i • 129is redistributed from peripheral tissues to an enlarged haematopoietic spleen.
Although these mice have liver disease, lower FECH activity and more severe
i 'jq # #
anaemia, it seems unlikely that FECH deficiency limits erythropoiesis and disturbs
iron metabolism by different mechanisms in the two species. The anomalous
197
observation in EPP of accumulation of iron in erythroblasts suggests that there
may also be redistribution of iron stores towards the site of erythropoiesis in EPP.
Thus in both species, FECH deficiency appears to provoke a response that leads to
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accumulation of PP but prevents accumulation of the other, more toxic substrate,
iron.
The analysis also showed that serum ferritin (sFe) and soluble transferrin receptor-1
(sTfR) concentrations were normal. The normal sTfR in our patients is consistent
with the degree of depletion of iron stores indicated by sFn and, together with the
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normal sFe, suggesting that erythropoiesis is not limited by iron supply. This
indicates that the reduction in iron stores has not led to iron deficient erythropoiesis.
Furthermore, the rate of erythropoiesis is not increased as this would also increase
sTfR levels. These findings suggest FECH deficiency in dEPP leads to the
establishment of a steady state in which iron absorption and supply is diminished but
matches the requirement for reduced erythropoiesis.
The mechanism of these changes in iron metabolism has not been established. Iron
metabolism is also altered in griseofulvin-induced protoporphyria.335 Because serum
transferrin is increased in FECH"lPas BALB/c mice and correlates with erythrocyte
protoporphyrin concentration, it has been suggested that PP may act as a signal to
increase hepatic transferrin synthesis when iron supply to erythroid cells is
insufficient and thus modulate iron metabolism.129 We found only a slight increase
in TIBC (Table 12) and no correlation with TEP. Alternatively, FECE1 deficiency
within enterocytes might affect duodenal iron transport by altering enterocyte
mitochondrial iron status.336 Finally, measurement of sTfR, in addition to sFn, may
help to distinguish those patients in whom the anaemia of EPP is exacerbated by iron
97T
loss and who might benefit from iron replacement.
4.5 Iron metabolism in EPP
We have shown anomalous haematopoiesis in EPP presenting as a microcytic
anaemia with apparent features of iron deficiency, a pattern which has previously
been reported.7 As discussed above, haematopoiesis does not appear to be limited by
iron supply.
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The role of iron supplementation in EPP is controversial and the literature limited,
consisting mainly of small series and case reports (Table 4). Oral iron and
transfusion of whole blood or haematin have been reported to normalise liver
function and erythrocyte protoporphyrin levels. " However others report
symptomatic and biochemical deterioration of EPP following oral iron
1 0*7"4 0*74 •
supplementation ' or whole blood transfusion, with improvement following the
discontinuation of treatment. Theories for the beneficial effects of iron
supplementation in EPP include reduced enterohepatic circulation due to chelation
with protoporphyrin in the intestine, increased non-enzymatic intracellular chelation
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with protoporphyrin, or facilitated chelation by residual active ferrochelatase.
Conversely deterioration following supplementation may result from stimulation of
haematopoiesis and increased production of protoporphyrin, or interaction with other
97T •
products such as the oral contraceptive, which predispose to cholestasis. Looking
at the entire EPP study population (not just the dEPP in whom the detailed
haematological analysis above was undertaken), ten subjects were taking oral iron
supplementation at the time of the study. Other than the expected lower Hb, MCV
and MCH, TIBC and sTfR were normal in all but 3, suggesting that supplementation
for the other 7 was unnecessary.
One study subject reported symptoms significantly improved whilst taking oral iron
(appendix VI (2)),333 which is only the second report of this phenomenon in EPP.
The first reported case was administered oral cholestyramine in addition to oral iron,
and the improved symptoms were associated with a reduction in erythrocyte and
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hepatic protoporphyrin. In contrast, protoporphyrin levels in our patient remained
constant throughout and following the course of iron therapy. Although a placebo
effect cannot be discounted in our case, a significant improvement did not occur with
a course of p-carotene. The demonstration of our patient's stable protoporphyrin
levels throughout the period of treatment with iron, suggests that there may be an
alternative, as yet unknown, mechanism for iron in improving the symptoms of EPP.
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4.6 Liver function in dominant EPP
Liver dysfunction in EPP patients was recognised shortly after the condition's initial
description in the 1960s.43"45 Despite advances in the understanding of the
condition's biochemistry, and genetic inheritance,5'247 there remains a lack of
prospective clinical data from studies containing large numbers of affected
individuals (table 3). Previous studies are retrospective analyses, often from tertiary
centres specialising in the treatment of liver disease, and report subjects in common,
many of whom are from large family pedigrees.2'6'7'9'115'137'161 Limitations of
ascertainment bias and small population size have restricted accurate investigation of
fundamental clinical issues around EPP such as risk factors for, and incidence of,
liver dysfunction.
While liver dysfunction in EPP is common and probably represents a range of
clinical involvement, liver failure is infrequent but usually rapidly fatal. The use of
transaminases to indicate the presence or otherwise of dysfunction can be regarded at
best as an accurate proxy. Although one study has suggested EPP individuals with
normal liver function had normal liver architecture, while those with liver
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dysfunction had protoporphyrin accumulation and liver damage, others have
reported the presence of fibrosis even in those with normal transaminases.161 Despite
this reservation, it was felt that liver biopsy would not be practicable for the large
geographically disparate cohort in this study, and therefore biochemical markers
were used. The incidence of 25% of subjects with liver dysfunction in this study sits
within the range reported from previous studies (table 3), suggesting the approach to
be reasonable.
The study demonstrated male sex, current age, age at symptom onset, time to onset
of symptoms after sunlight exposure, haemoglobin concentration, and elevated TEP
are significantly associated with LFTS, concording with some previously suggested
risk factors of sex,132 alcohol consumption,9'153 autosomal recessive inheritance147'149
and TEP.154 The demonstration of a link between the biologically active aetiological
chemical (TEP) in EPP and the resulting symptoms seems intuitive, yet has only
previously been recognised in fulminant hepatic failure.115'247 Despite this, and a
Erythropoietic Protoporphyria in the United Kingdom 131
demonstrated association between genotype and TEP, and TEP with LFTS, it is
perplexing that we did not identify a direct association between genotype and LFTS.
It seems reasonable to assume that the TEP level is a major factor in LFTS, and its
serum concentration is under a degree of genetic influence, but perhaps the TEP and
its effect of LFTS are both considerably influenced by multiple other factors, making
a direct genotype-LFTS association weak. The complex association between self-
reported alcohol consumption and liver dysfunction might be consequent to a degree
of under-reporting of intake by individuals. Common sense dictates that patients
with EPP should restrict alcohol consumption to modest levels and physicians caring
for patients with EPP should be alert to other causes of liver dysfunction. Overall
these findings provide a rationale for regular monitoring of haemoglobin, sFn, sTfR,
TEP and liver function to detect evidence of hepatic dysfunction in EPP, and to look
for trends that might suggest potential for hepatic failure.
Examination of the TEP results from those subjects who had a previous estimation
prior to the study, confirmed previous observations that the level of protoporphyrin
remains relatively constant for any one individual.115 One year following the end of
the study, one subject developed hepatic failure and had undergone orthotic liver
transplantation. At the time of the study, he had mild anaemia, elevated ALT and
yGT, and a TEP markedly higher than when measured 6 months previously. As with
the incidence of liver dysfunction, the prevalence of liver failure in EPP is not
known, and systematic long-term studies will be required both to answer this, and to
confirm that risk factors for dysfunction are also predictive for liver failure.
4.7 Vitamin D analyses
We identified a high prevalence of vitamin D deficiency (VDD) and vitamin D
insufficiency (VDI) in a large cohort of patients with EPP, whose main risk factors
were latitude of residence and their photodermatosis. In keeping with previous
findings, we demonstrated an increase in median 25-hydroxyvitamin D between
winter and summer.221,222'229'310 However, a sizable proportion were VDI even in
summer, implicating the photodermatosis and sun-avoidance measures as the most
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plausible explanation, and supporting the demonstrated association with sensitivity
and TEP.
Although previously recognised in cases reports, studies of photosensitive
populations with xeroderma pigmentosum (XP) and Smith-Lemli-Opitz syndrome
(SLOS), and normal populations using sunscreens have not shown similar levels of
vitamin D insufficiency.221'222'228'229,310 Explanations include low study sensitivities
due to smaller patient numbers, residency in sunnier environments, lack of skin
discomfort in XP (an efficient prompt for rigorous sunlight avoidance in EPP), or the
presence in SLOS of abnormally high concentrations of the vitamin D precursor, 7-
dehydrocholesterol.
Since completion of this study, controversy over the correct values of the 25-
hydroxyvitamin D normal range,216 has led to our laboratory now using 30ng/mL as
the lower end of the normal range, increasing the proportion of VDI in our cohort to
91%. Thus, a sizeable proportion of the EPP study cohort are VDI and at risk of
important clinical outcomes. Treatment with oral calcium and vitamin D increases
bone mass and reduces the risk of fractures, ' so clinicians advising patients with
EPP about sunlight avoidance should consider monitoring both serum 25-
hydroxyvitamin D and PTH, and giving supplementation throughout the year. As the
cutaneous synthesis of vitamin D is initiated by UVB-mediated photolysis of 7-
dehydrochloesterol, use of UVB phototherapy to reduce symptoms may have
additional therapeutic benefit.
4.8 Autosomal recessive EPP
The combination of palmar keratoderma, a relatively low TEP concentration and
autosomal recessive inheritance that we describe here in 9 patients from 6 families
constitutes a hitherto unrecognized subtype of EPP. Two of the 13 patients from 12
families with rEPP described previously4'65'116'147'175'186 are also included in this
report (P4, P8). Thus, of the 20 symptomatic patients from 16 families with rEPP
now reported, 9 from 6 families (45% of patients; 38% of families) have palmar
keratoderma. To date we have not seen a patient with keratoderma who has not had
Erythropoietic Protoporphyria in the United Kingdom 133
rEPP but more patients need to be studied before the reliability of palmar
keratoderma as a clinical indicator of rEPP can fully be assessed.
Keratoderma was not reported as a clinical feature of either dominant or recessive
Epp7 65.70,115,147,175,186 prjor t0 study; possibly because it is uncommon and, unless
large numbers of patients are investigated, the association of EPP with keratoderma
may be regarded as chance, as was initially the case for two of our families.
However, it seems unlikely that keratoderma has been overlooked in all previously
reported patients with rEPP. Where clinical descriptions have been
provided,11 ■147,186 it has not been noted and three other patients with recessive
disease that we have identified (this report and Whatley et al, 2004)4 did not have
keratoderma. There does not appear to be a clear association between keratoderma
and the knuckle skin thickening frequently reported in EPP - the finding of
thickening was present in four males and one female from the keratoderma cohort,
and absent in one male and three females.
Our findings are unlikely to be explained by an association of two separate disorders.
First, the keratoderma of EPP differs clinically from other syndromes that include
palmar keratoderma.311 The hyperkeratosis fluctuates, being worse in summer, tends
to be relatively mild on the soles, and may almost disappear with complete exclusion
of light; all of which suggest a role for UV exposure in its aetiology. This is
supported by the observation that those with mild involvement have signs only in the
first interdigital web. None of our patients described blistering, suggesting a non-
epidermolytic pattern; none had hyperhydrosis, the keratosis was not particularly at
sites of pressure, and was not punctuate in pattern. Second, we observed
hyperkeratosis only in rEPP and no family showed independent inheritance of the
two conditions. Third, the allelic heterogeneity of our patients makes close linkage
with a previously undescribed recessive form of keratoderma very unlikely.
Our patients with keratoderma also differed in other respects from other patients with
recessive or dominant EPP. TEP concentrations were lower and, in family I,
concentrations were increased by such a small amount (TEP: 2.0 and 2.3 pmol/L)
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that the diagnosis would not have been made without plasma and faecal porphyrin
measurements. In spite of the relatively low erythrocyte concentrations, plasma
porphyrin concentrations were the same as in EPP without keratoderma,
photosensitivity was severe and faecal PP concentrations were substantially
increased. These features suggest that the low TEP concentration is more likely due
to a redistribution of the equilibrium between erythrocytes and plasma than to less
formation of protoporphyrin by erythroid cells in the bone marrow than in EPP
without keratoderma.
There may also be clinical differences apart from keratoderma. Neurological
abnormalities were present in four of our patients but, apart from a reversible
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polyneuropathy after transplantation for protoporphyric liver failure, have not
previously been described as associated with any form of EPP. Developmental delay
has been reported in the recessive or 'homozygous' forms of the dominant acute
porphyrias, usually in association with other neurological and skeletal
abnormalities,339 which were not seen in our patients. Furthermore, 5 of the 12
(42%) reported patients with rEPP, in which keratoderma was apparently not present,
had liver disease.4'116'147,175 In contrast, none of our nine patients had liver
dysfunction. This raises the possibility that patients with keratoderma may be at
lower risk of liver disease than other patients with rEPP. Liver disease is
accompanied by markedly increased TEP although it is not clear whether these are
present before liver function deteriorates and their role as a risk factor for liver
disease is uncertain.130'132 The relatively low TEP and apparently effective biliary
elimination of PP shown by our patients may indicate the presence of a special
pattern of porphyrin metabolism that does not lead to excessive hepatic accumulation
of PP. However, only prolonged follow-up can determine whether a lower risk of
liver disease is another component of the syndrome that we describe.
The unusual phenotype that we describe here is inherited in a recessive pattern but it
is not clear why it is restricted to rEPP or present in only about 40% of such families.
Although FECHmutations on both alleles appear to be essential for its expression, it
seems unlikely that the phenotype is determined solely by the nature of the mutations
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at the FECH locus. There appear to be no features of the genotypes shown in table
16 that clearly distinguish them from those of other patients with rEPP.4'175 Most
mutations are missense; most are on FECH IVS3-48T alleles and the nine different
mutations are not clustered together in the FECH molecule.340 In four families, one
313 •of the mutations has been identified previously either in dEPP (IVS3+2T>G), or in
rEPP without keratoderma (P168S, D274N) with the D274N mutation being present
in two of our families and in two of those reported by Gouya et al, 2006.173 Another
mutation (P168S) was present in two of our patients; a homozygote without
keratoderma where it occurred on a hypomorphic allele and a compound
heterozygote with keratoderma (Table 17), the only one of our patients with a
hypomorphic allele, presumably again containing this mutation. The four other
mutations have only been reported in EPP with keratoderma. FECH genotype is the
main determinant of FECH activity in EPP.173 In general, FECH activities in rEPP
are lower than in dEPP though the presence on one or both alleles of a missense
mutation that has only a small effect on FECH activity may lead to-activities within
the range for dEPP.175 Prokaryotic expression of the missense mutations predicted
FECH activities for our patients with keratoderma of 1 - 25 % (mean 10%) normal
(Tables 16 and 17),4 close to the range of 4 - 29% reported for rEPP.175 Thus it
seems unlikely that the unusual phenotype shown by our patients is directly
determined either by FECH genotype or expression.
4.9 X-linked Dominant Protoporphyria
Prokaryotic expression studies showed that both deletions markedly increase ALAS2
activity. These findings of gain-of-function strongly suggest that PP accumulates in
XLPP because the rate ofALA formation is increased to such an extent that insertion
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of Fe into PP by FECH becomes rate limiting for haem synthesis. The resulting
accumulation of PP presents as an EPP clinical phenotype. The significantly higher
levels of TEP seen in XLPP compared to dEPP may explain the apparent increased
incidence of liver dysfunction in these individuals. Gain of function mutations have
not previously been identified in genes of the haem biosynthetic pathway341 but, as in
our families, characteristically cause dominant disorders.
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Urinary excretion of haem precursors is normal in XLPP indicating that most of the
ALA produced by erythroid cells is metabolised to PP. Some is used for
haemoglobin synthesis but the fate of the rest is uncertain. Since FECH activity in
31V
erythroid cells exceeds that required for haemoglobin synthesis, some may be
converted to free haem and exported from the cytoplasm. However the
accumulation of ZnPP in XLPP, indicating utilisation by FECH of its alternative
metal substrate, suggests that formation of excess haem is prevented by lack of
available iron. The phenotype of iron deficiency in XLPP (Table 19) closely
resembles that of the Ireb2~/~ mice in which deletion of iron-regulatory protein 2
(IRP2) leads to over-expression of ALAS2, erythroblast iron deficiency and
microcytic anaemia.343 In one patient (Table 19 BII,7), iron repletion decreased PP
accumulation and corrected the anaemia but, in contrast to iron deficiency without
XLPP, did not decrease ZnPP, possibly because its synthesis becomes limited by
intra-mitochondrial Zn2+ availability when PP synthesis is increased.343 Thus, our
findings suggest that the regulatory system that enables efficient utilisation of iron
for haem synthesis during erythroid differentiation344 allows matching of erythroblast
iron uptake to intra-mitochondrial haem synthesis to be maintained in the presence of
excess PP. The mechanism is unknown but may involve regulation of transferrin
receptor-1 expression in erythroblasts through haem-mediated degradation of
IRP2.345
The 26 C-terminal amino acids of ALAS2 are highly conserved and have diverged
from ALAS1 (figure 19 b) which suggests that this sequence may have an important,
but unknown, erythroid-specific function. During erythropoiesis, tight co-ordination
of substrate supply to FECH normally prevents accumulation of toxic amounts of PP.
Co-ordination is largely achieved through iron-dependant post-transcriptional
regulation of the synthesis of ALAS2.317 It seems probable that this system fails in
XLPP because the mutations that we have described stabilise the ALAS2 against
degradation, permitting excessive erythropoiesis in the absence of a matched supply
of iron. The marked increase in activity, the absence of C-terminus of the ALAS2
from ALASrc, (5-amino levulinate synthase from Rhodobacter capsulatus, the only
ALAS for which the crystal structure has been reported)346 and evidence that it is not
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directly involved in ALAS2 catalysis,346'347 favour this hypothesis over any intrinsic
increase in specific activity. The discovery of gain-of-function mutations of ALAS2
provides new information about the regulation of substrate supply for haem synthesis
during erythroid differentiation and identifies a potential tool for increasing erythroid
haem synthesis in experimental systems.
4.10 Conclusion
This work represents a study of the largest cohort of individuals with EPP reported to
date. It has clarified the presentation of the condition both in subjective and
objective clinical terms, and also in biochemical and haematological investigations.
Knowledge of the condition appears limited in general practice and among
paediatricians which can result in considerable delay in diagnosis, and suggests a
stratagem for focussed education of these groups. The previously unrecognised
significant impact of the condition in terms of quality of life has been documented.
Many previously described features of the condition, often only reported from case
reports or limited series, have been confirmed, while others have been refuted or not
supported. The apparent microcytic anaemia has been identified to be due to a
downward shift in haematopoiesis of the whole EPP population, and erythropoiesis
does not appear to be limited by iron supply. Abnormal liver function has been
linked to a number of factors, including for the first time the concentration of
erythrocyte protoporphyrin. The design of the study was such that risks for
developing liver failure were not directly sought and future longitudinal projects will
be required to investigate this. A clinically important deficiency of vitamin D was
identified for the first time to affect a considerable proportion of the population even
in summer, and presents an area in which supplementation should be considered.
Important differences in the clinical diagnosis and management of individual EPP
patients have been highlighted. The identification of haematological and
biochemical changes seen within the population, allows a stratagem for annual
review and monitoring of EPP patients. Two further novel findings have been the
identification of an apparent sub-type of recessive EPP associated with palmar
keratoderma, which may convey a lower risk of liver dysfunction, and a new entity,
X-linked dominant protoporphyria. This results from gain-of-function mutations to
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5-aminolevulinate synthase, the initial rate-limiting enzyme in the haem biosynthetic
pathway, which clinically presents as EPP, but has important haematological and
biochemical differences.
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Appendix 1. Abbreviations
AIP acute intermittant porphyria
ALA 5-amino levulinate
ALAD 5-amino levulinate dehydrogenase
ALADP 5-amino levulinate dehydrogenase porphyria
ALAS 5-amino levulinate synthase
5-amino levulinate synthase from Rhodobacter
ALASrc capsulatus
Alk
Phos serum alkaline phosphatase
bp base pairs
cDNA complementary DNA
CEP congenital eythropoietic porphyria
CP coproporphyria
dEPP dominant erythropoietic protoporphyria
EPP erythropoietic protoporphyria
FBC full blood count
FECH ferrochelatase






IRE iron responsive element
IRP2 iron-regulatory protein 2
ISCP isocoproporphyrin
LFT liver function tests
LFTSt liver function test status
MCH mean corpuscular haemoglobin
MCV mean cell volume
mRNA messenger ribonucleic acid
MSH melanocyte stimulating hormone
PAS periodic acid schiff
PBG porphobilinogen
PBGD porphobilinogen deaminase
PCT porphyria cutanea tarda
PP protoporphyrin
rEPP recessive erythropoietic protoporphyria
rs Spearman rank correlation
sFe serum iron
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sFn serum ferritin
SLOS Smith-Lemli-Opitz Syndrome
SPF sun protection factor
sTfR soluble transferrin receptor-1
TEP total erythrocyte protoporphyrin
TIBC total iron binding capacity
TS transferrin saturation
UK United Kingdom




VDD vitamin D deficient
VDI vitamin D insufficient
VP variagate porphyria
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Appendix III: Study Proforma
Date
Patient's initials D.O.B.
Sex M / F Age in years
1. How old were you when you first experience problems with the EPP?
2. What were these initial symptoms?
crying / screaming / burning / itching / tingling / other
3. How old were you when the diagnosis was made?
4. Who made diagnosis? GP / dermatologist / paediatrician / gastroenterologist /
other doctor / other person
5. What symptoms do you have now after sun exposure?
nil / crying / screaming / burning / itching / tingling / other
6. How long does it take for the symptoms to start after sunlight exposure?
7. How long does it take for the symptoms to settle?
8. Does your skin have any visible changes immediately after sunlight exposure?
nil / redness / swelling / eczema / bruising / blistering / crusting / other
9. Are there any visible changes later on?
nil / redness/ swelling/ eczema/ bruising/ blistering/ crusting/ other
10. Apart from the skin symptoms, do you feel unwell in any other way after sunlight exposure?
nil / fever / generally unwell / can't sleep / feel down / irritable / other
11. On the second day of sun exposure, are the symptoms the same, better or worse?
12. Is your skin sensitive to sunlight through window glass Y / N
13. Is your skin more sensitive on windy days? Y / N
14. Do your nails ever get affected by the sunlight? Y / N
15. Do you think your skin is more fragile / difficult to heal than others? Y / N
16. Do you think your skin sensitivity improves over the summer or stays about the samel
17. Do you think there has been any change in sensitivity as you've got older? Y / N
If yes, improved / deteriorated, and any thoughts why?
18. Is your skin ever sensitive over winter (November - February)? Y / N
If yes, how often / circumstances etc
19. Does your sunlight sensitivity interfere with your daily activities in summer? Y / N
20. Do you regularly try to avoid sunlight? Y / N
What kind of things do you do? stay inside / seek shade/ go out in evening / at night/
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21. Do you regularly wear special clothes to go out in sunlight? Y / N
hat / high collar / long sleeves / trousers / gloves / other
22. Do you use sunscreen? Y / N (if no go to
22)
23. What type and sun protection factor (SpF)?
24. How often? daily / at weekends / less often
all year / in any sunny weather / over summer only / abroad only / other
25. Are you aware what the star ratings for sunprotection mean? Y / N
26. Have you tried any of the following, and were they helpful?
antihistamines currently / previously / never helpful / not helpful
(3-carotene currently / previously / never helpful / not helpful
Dundee sunscreen currently / previously / never helpful / not helpful
cysteine currently / previously / never helpful /not helpful
hospital phototherapy currently / previously / never helpful / not helpful
sunbeds currently / previously / never helpful / not helpful
fake tan currently / previously / never helpful / not helpful
other treatments
27. Who is involved in the care of your skin problem?
No-one / GP / dermatologist / paediatrician / gastroenterologist / other
28. How often does each of these people see you?
Previous Medical History
29. Have you ever had any other medical conditions?
anaemia Y/N details:
iron deficiency Y/N details:
gallstones Y/N details:
hepatitis Y/N details:
other liver disease Y/N details:
liver treatment Y/N details:
arthritis Y/N details:
haematological cancer Y/N details:
30. Are you allergic to anything? Y / N
If yes, what
31. Are you currently taking medicines and tablets? Y / N
If yes, what
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Family and Social History
32. Are there any illnesses that run in your family? Y/N
If yes, what
33. Family tree: parents/siblings/marital status/children
Women only:
34. Does your sensitivity change with your menstrual cycle? Y/N
If yes, how?
35. If you had children, did you find any change in the EPP during your pregnancy? Y/N
significantly deteriorated / got worse / no change / improved / significantly better
36. Place of birth: UK / northern Europe / Mediterranean Europe / other
37. What would you describe your ethnic origin as?
Caucasian / indo-asian / far east asian / affo-caribbean / other:
38. Are you working? Y/N
And if so, what is your job?
Was your choice of profession influenced by your skin? Y/N
39. How much alcohol do you drink in an average week? Estimated units
beer / wine / spirits / other
40. Have you ever noticed your skin more sensitive after drinking alcohol
41. Do you smoke?
Y/N
Y/N
And if yes, how much per day? amount
42. Vegetarian / Non-vegetarian?
a ount
V/C
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Examination
Acute changes - erythema (RED), oedema (O), eczema (X), purpura (P), vesicobullous (B), crusted
erosions (E)
Chronic changes - excoriation (EXCOR) / thickened (TH) / hyperkeratosis (HK) / yellow (Y) /
excessively wrinkled (WR) / scarring (varrioliform/pitted/other) (SCAR V, P)
Evidence jaundice, hepatomegally, chronic liver dx - spider naevi, flap
Degree of involvement: + = mild, ++ = moderate, +++ = severe
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The aim of this questionnaire is to measure how much your skin problem has affected your life
OVER A SUNNY WEEK IN SUMMER. Please tick 0 one box for each question.
1. Over a sunny week, how itchy, sore,









Over a sunny week, how embarrassed
or self conscious would you have been









Over a sunny week, how much would your
skin interfere with you going shopping









4. Over a sunny week, how much would your









5. Over a sunny week, how much would your









Over a sunny week, how much would your
skin made it difficult for









7. Over a sunny week, how much would










8. Over a sunny week, how much would your
skin create problems with your partner









9. Over a sunny week, how much would









10. Over a sunny week, how much of a
problem would the treatment for your
skin been, for example by making
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The aim of the questionnaire is to measure how much your skin problem has
affected you OVER THE LAST WEEK. Please / one box for each question.
How itchy, 'scratchy', sore or
painful has your skin been?









How much has your skin
affected your friendships?
How much has your skin trouble


















How upset or embarrassed,
self conscious or sad have
you been because of your skin?
How much have you changed or
worn different or special clothes/
shoes because of your skin?
How much have you avoided
swimming or other sports
because of your skin trouble?
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Children's Dermatology Life Quality Index
OVER THE LAST WEEK
Either
If school time: How much did your









If holiday time: How has your skin
problem interfered with your
holiday plans?
How much trouble have you had
because of your skin with other
people calling you names, teasing,









CDLQI © M.S. Lewis-Jones, A.Y. Finlay. June 1993

















How much has your sleep been
affected by your skin problem ?
How much of a problem has the
treatment for your skin been ?
Please check that you have answered EVERY question. Thank you.
CLINICAL AND LABORATORY INVESTIGATIONS DO I 10.1111/j.l 3 65-2133.2006.07472.x
Erythropoietic protoporphyria in the U.K.: clinical features
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Background Erythropoietic protoporphyria (EPP) is a rare inherited photodermatosis
that causes lifelong painful photosensitivity. Neither its full clinical spectrmn nor
its impact on quality of life (QoL) has been investigated in a large cohort of
patients.
Objectives To document the clinical features of EPP and its impact on QoL in a high
proportion of all patients with EPP resident in the U.K.
Methods Patients with EPP were identified from U.K. clinical databases and assessed
by the same clinical investigator over a 7-month period using a standardized pro-
forma and validated adult (Dermatology Life Quality Index, DLQI) and children's
(Children's Dermatology Life Quality Index, CDLQI) QoL questionnaires.
Results Three hundred and eighty-nine living patients with EPP were identified, of
whom 223 [114 females, 109 males; median age 34 years (range: 5-87), from
193 families] were investigated. Total erythrocyte porphyrin (TEP) was higher in
males (median: 25'3 pmol L-1) than females (median: 19-3 pmol L~'). The
median ages at onset and diagnosis were 1 and 12 years, respectively. Median
times for onset of symptoms after sun exposure, onset of signs (oedema, ery¬
thema) and resolution of symptoms were 20 min, 6 h and 3 days, respectively.
Most patients reported absence of protection by glass (92%), priming (85%),
exacerbation by wind (68%), no family history of photosensitivity (56%), no
symptoms during winter (56%) and had chronic skin lesions (79%). Symptoms
changed little with age but improved during pregnancy in 47% of gravid
women. Most patients used protective clothing and a sunscreen; 28% were taking
(5-carotene and a further 56% had taken it; 29% were not under regular medical
care. Two patients (1%) had liver failure and 8% reported gallstone disease. QoL
was markedly impaired, with scores similar to those in severe dermatological dis¬
ease (mean DLQI score 14-0, n = 176; mean CDLQI score 12-8, n = 44), indica¬
ting a large effect on patients' lives. DLQI scores correlated weakly with TEP
(rs = 0-228; P = 0-002) and time to onset of symptoms (rs = -0-233; P =
0-002) but not with age at onset.
Conclusions EPP is a persistent, severely painful, socially disabling disease with a
marked impact on QoL. Its diagnosis is often overlooked. None of TEP, age at
onset nor time to onset of symptoms is a useful predictor of impaired QoL in
individual patients.
Erythropoietic protoporphyria (EPP, MIM 177000) is a rare
inherited photodermatosis with systemic complications that
has only been clearly recognized since 1961.1 Partial defici¬
ency of ferrochelatase (FECH), the terminal enzyme of haem
biosynthesis, causes excessive formation, mainly in the bone
marrow, of protoporphyrin DC which accumulates in erythro¬
cytes, plasma, liver and skin. Protoporphyrin in the skin,
through its photodynamic action, causes lifelong acute photo¬
sensitivity of sun-exposed areas,2'3 while its accumulation in
the liver leads to potentially fatal liver failure in 1-4% of
patients.2,+,s In most families, increased protoporphyrin for¬
mation sufficient to cause photosensitivity occurs only in indi¬
viduals who have inherited a low expression FECH gene
polymorphism, present in 13% of the U.K. population,6 trans
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to an FECH mutation that abolishes or markedly decreases
FECH activity.7
The clinical features of EPP, which are distinct from those
of other cutaneous porphyrias, have been described in various
case reports and small series, none containing >32
patients,2'8-10 while larger studies have focused on particular
aspects of the disease, such as genetics11 or liver disease.4
Information from such sources may be biased by selection
and may not reflect the full clinical spectrum. In addition, no
study has addressed the psychosocial consequences of EPP
despite the apparent severity of symptoms and substantial
changes to lifestyle necessary to avoid episodes of acute pho¬
tosensitivity. Here we report findings from a cross-sectional
study of a large cohort of patients with EPP which was
designed to record clinical features, methods of sun avoidance
and treatment, and impact on quality of life (QoL).
Patients and methods
Patients
The study was conducted in accord with the World Medical
Association Declaration of Helsinki ethical principles for med¬
ical research involving human subjects and its subsequent
amendments. Prior approval was obtained from the North
West Multicentre Research Ethics Committee and 84 local
research ethics committees. All patients or their parents gave
informed consent. Three hundred and eighty-nine living sub¬
jects, resident in all parts of the U.K., previously diagnosed as
having EPP, were identified from databases held in five refer¬
ral centres for either porphyrias or photodermatoses, located
in Cardiff, Dundee, Leeds, London and Manchester. The refer¬
ring physician for each subject was identified from the
records and sent details of the study asking for his/her
cooperation. Exclusion criteria were: children under the age
of 5 years, haematological malignancy or hepatic malignancy.
Permission was obtained to contact 352 patients of whom
258 (73%) replied to say they wished to take part. Of these,
223 (86%) subjects were seen in 30-min consultations at
their local National Health Service outpatient facility by a sin¬
gle clinician (S.A.H.) over a 7-month period. The remaining
individuals either found their appointment times inconvenient
or failed to attend. History and clinical features were recorded
using a standardized proforma that avoided ambiguous or
leading questions. The questions covered four main areas:
photosensitivity, photoprotective measures and treatments,
general medical history, and family, social and economic
background. Any additional comments about EPP made dur¬
ing the interview were recorded. All light-exposed skin was
examined, particularly that of the face, neck, arms, hands and
nails, and also any other affected skin volunteered by the sub¬
jects. Examination findings were grouped into acute (e.g. ery¬
thema, oedema, eczema, purpura, vesicobullous and crusted
erosions), chronic (e.g. excoriations, thickened skin, hyper¬
keratosis, yellowing, excessive wrinkling, scarring), and other
signs.
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Quality of life indices
QoL was assessed using dermatology-specific tools: the Der¬
matology Life Quality Index (DLQI)12 or, for patients aged
< 16 years, the cartoon version of the Children's Dermatology
Life Quality Index (CDLQI)13 (both of which may be viewed
at http://www.dermalology.org.uk). Both contain 10 ques¬
tions, each being scored up to 3 to give a maximum possible
score of 30, indicating the worst QoL. Both have been valid¬
ated in normal populations and those with dermatological
conditions for repeatability, internal consistency and sensitivity
to change.
Biochemical analyses
Erythrocyte and plasma porphyrins were determined using
standard methods.14
Statistical analyses
Data were analysed using SPSS software (SPSS, Chicago, IL,
U.S.A.). The Mann-Whitney lest was used to test the signifi¬
cance of differences between quantitative variables. Spearman
rank correlation (rs) was used to characterize and test the sig¬
nificance of the relationships between all possible pairs of the
four variables: total erythrocyte porphyrin (TEP), age at onset,
lime to symptoms and QoL. Confidence intervals (CIs) were




The study cohort contained 223 patients (median age:
34 years, range: 5-87) with a history of acute photosensitiv¬
ity. There were 114 females (median age: 33*5 years, range:
5-87) and 109 males (median age: 35 years, range: 7-77);
the age distribution was similar in both sexes. All were white
skinned apart from two Indo-Asians (originally from Pakistan
and Iraq, both skin phototype IV). The 223 patients came
from 193 families: 125 patients (56%) had no family history
of photosensitivity; 89 patients from 60 families had affected
relatives (only 29 of whom were seen in the study) and a fur¬
ther nine patients were uncertain. Only four patients were
excluded according to the exclusion criteria, all due to age
< 5 years.
Porphyrin analysis
TEP was increased in all the 211 patients from whom blood
was obtained (median: 25'3 pmol L-', range: 2-0-1 59-2; nor¬
mal subjects: < 1-7). Erythrocyte porphyrin was mainly free
protoporphyrin, and plasma fluorescent scanning indicated
that plasma protoporphyrin was increased in all subjects
(emission maxima: 626-634 nm). TEP was significantly
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higher in males (median: 25-3 pmol L_1, range: 2-0—159-2)
than females (median: 19-3 |Jmol L_1, range: 2*3—7 5-3; P =
0-003), and there was a slight increase with current age but
this did not reach statistical significance in either sex (rs =
0-115; P = 0-096).
Photosensitivity
Age at onset
The median age at onset of symptoms was 1 -0 years (range:
birth-12 years) (Fig. la), usually at the lime of first major
exposure to sunlight, and was inversely correlated with TEP
(rs = -0-241, 95% CI: -0-364 to -0-110; P = 0-001). How¬
ever, diagnosis was often delayed: the median age at diagnosis
was 12-0 years (range: 6 months-86 years), with the diagno¬
sis not being made in 75 patients (34%) until the age of
20 years or more (Fig. lb).
Symptoms
Patients often reported that the cutaneous sensation following
sunlight exposure was difficult to describe. The most fre¬
quently used terms included burning (85%), tingling (33%),
prickling (4%) and stinging (3%). The following descriptions
(a) Age of first symptoms
100-
80-
of the sensation convey the severity: Tike a burn on a candle
flame or bonfire', 'red hot needles under the skin', 'having
boiling water or oil poured on the skin', Tike blood boiling
and being burnt from the inside out'. The median lime for
onset of symptoms following exposure to sunlight was
20 min (lower quarlile: 10 min, upper quartile: 60 min,
range: immediately to 12 h or asymptomatic in the U.K.),
was significantly shorter in females (median: 1 5 min) than in
males (median: 30 min; P = 0-018) and showed a weak cor¬
relation with age at onset (rs — 0-214, 95% CI: 0-084—0-336;
P = 0-004) but not with TEP (rs = -0-134; P = 0-054). The
median time to resolution was 3 days (lower quarlile: I day,
upper quartile: 4 days, range: immediately to 4 weeks).
Two hundred and eleven (95%) patients said that onset of
symptoms was not associated with any immediate visible
change to the skin. Immediate changes reported were redden¬
ing (seven patients), swelling (three patients), purple discolor¬
ation and blanching (one patient each). Visible changes were
generally related to the duration of exposure: minimal expo¬
sure tended not to result in visible changes, while prolonged
exposure resulted in signs. Those most commonly reported
included swelling (179 patients, 80%), reddening (45
patients, 20%), blistering (37 patients, 17%), crusting/eczema
(32 patients, 14%), petechiae and/or bruising (20 patients,
9%) and Assuring (10 patients, 5%). Thirteen (13%) of 103
patients had noticed changes in their nails during acute epi¬
sodes. Sixty-one subjects estimated a median time for onset of
swelling postexposure of 6 h (lower quartile: 2 h, upper quar¬
tile: 12 h, range: 15 min to the next morning). Twenty-two
subjects (10%) reported no visible change at any time. Only
25 (13%) of 199 patients felt that their photosensitivity had
changed with age: 14 had improved and 11 had become more
sensitive. Other features of the photosensitivity of EPP are







O Is- t}- !-COlOC\JO>C0COOh-'3-
r-ww 't'fmtosNco
Age (years)
Fig 1. Ages at onset of symptoms (a) and at diagnosis (b) for 223
patients with erythropoietic protoporphyria.
Table 1 Photosensitivity in erythropoietic protoporphyria
No. of
patients No. of patients
responding with symptom
Symptom to question (%; 95% CI)
Priminga 219 186 (85; 80-89)
Photosensitive through glass 220 202 (92; 87-95)
Exacerbation by wind 202 137 (68; 61-74)
Improvement during summer 194 109 (56; 49-63)
('hardening of skin')
Skin fragile/slow to heal 115 75 (65; 56-73)
Photosensitive during winter 165 73 (44; 37-52)
(November-February)b
CI, confidence interval. Photosensitivity worse the day after sun
exposure.16 bContributory factors: sunny weather (95%), snow
(28%), wind (26%), water reflection (8%), seaside (5%),
increased exposure to artificial light (1%).
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Endocrine factors
Twenty-eight (47%) of 59 gravid female patients had noticed
an improvement in symptoms during pregnancy. Nine
patients spontaneously described this as very significant or that
they became asymptomatic. Several of the women who had
not noticed any change commented that they had been preg¬
nant mainly over winter or too scared to expose themselves to
sunlight; two others were seen early during their first preg¬
nancies and early in the year. Menses-related worsening of
photosensitivity was reported by eight (10%) of 81 menstru¬
ating females; six of these were gravid and five had noticed
improvement during pregnancy. Three women mentioned that
their symptoms had improved after their menopause. None
had noticed any worsening of photosensitivity during preg¬
nancy or postmenopause, or improvement during menses.
Other symptoms
Noncutaneous symptoms associated with photosensitive epi¬
sodes were reported by 189 patients and included problems
with sleeping (171 patients, 77%), irritability (66 patients,
30%), excessive temperature sensitivity (41 patients, 18%),
feeling down or depressed (26 patients, 12%), tired (24
patients, 11%), nauseated (13 patients, 6%) or generally
unwell (10 patients, 5%), and headache (seven patients, 3%).
Photoprotective measures and treatments
Sixty-seven subjects (29%) were not seen regularly by any
doctor for their EPP. The rest were under the care of a derma¬
tologist (58%), other hospital specialist (10%) or general
practitioner (3%) and reviewed at least once (59%) or twice
(29%) a year; all but six subjects in this group had blood tests
at least annually.
Photoprotection
Two hundred and four patients (92%) said that EPP interfered
with their daily activities on sunny days. The main sunlight
avoidance activities were staying inside (144 patients, 65%),
seeking shade (71 patients, 32%), and only going out in the
evening or early morning (26 patients, 12%). One hundred
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and ninety-four patients (87%) wore special clothes to protect
themselves from sunlight; long sleeves (174 patients, 90%),
trousers or long skirts (155 patients, 80%), hats (143 patients,
74%) and gloves (95 patients, 49%).
Sunscreen use
Seventy patients (31%) never used a sunscreen, citing reasons
such as poor efficacy, unacceptable cosmesis on skin and clo¬
thing, and expense. Among the 152 patients (68%) who used
a sunscreen, 40 patients used the Tayside Pharmaceuticals' Re-
fleclant Sunscreen (Appendix 1; usually the beige colour);
others used sun protection factor 60 (35 patients), 50 (20
patients), 30 (20 patients) or 25 (16 patients) sunscreens
from a variety of manufacturers. The frequency of application
ranged from occasional (9%) through once daily (77%) to
more than once a day (14%), with a maximum of eight limes
a day. Sunscreen was applied only in sunny weather (61%),
all summer (24%), all year (9%) or only when abroad (6%).
Only 30 of 221 patients (14%) were aware of the U.K. UVA
star rating of sunscreens.
Physician-suggested therapies
Table 2 shows the number of patients who had used or were
currently using physician-suggested therapies, and their opin¬
ions of efficacy. ((-Carotene was prescribed for 187 patients
but two-thirds of these had stopped it. Reasons given were
cosmetically unacceptable orange discoloration of skin and
body fluids (71%), retinal crystals associated with the with¬
drawn canthaxanthine preparation (15%), problems swallow¬
ing large capsules (7%), gastrointestinal side-effects (4%) and
media coverage of potential carcinogenic effects (2%).
Other treatments
Measures used to relieve the pain of acute photosensitivity
included immersion in cold water (52 patients, 23%), wet
cloths or flannels (47 patients, 21%), putting affected areas on
cold walls, metal cans from the refrigerator or under pillows
(16 patients, 7%), electric fans (12 patients, 5%), drinking
alcohol (10 patients, 5%) and, for 15 patients (7%), emol¬
lients, ice packs or immersion in hot water.
















































'Median dose 6 X 30 mg daily (range: 2-13 X 30 mg); bmedian dose 8 X 30 mg daily (range: 2-12 X 30 mg); c500 mg twice daily.
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Medical history
Two patients (1%) had protoporphyric liver failure: a
43-year-old man, who was under assessment for liver trans¬
plantation, and a 35-year-old man who had received a liver
transplant 1 year previously. Eighteen patients (8%; 15
women and three men) had gallstones, of whom 11 women
and three men (mean age: 51 years, range: 28-66) had had a
cholecystectomy. One hundred and fourteen patients (51 %)
reported an additional illness, none of which appeared to be
associated with EPP.
Family, social and economic background
One hundred and twenty-seven subjects (57%) were in
employment, and a further 60 (27%) were either school or
further education students. Sixty (47%) of the 1 27 patients in
employment felt their choice of profession had been signifi¬
cantly influenced by their skin condition. One hundred and
forty-three subjects (81% of those over the age of 16 years)
drank alcohol regularly. The median number of units con¬
sumed was seven units per week (range: 1-70). Twenty
patients (14%) noticed that their skin became more photosen¬
sitive for up to 2 days after drinking. Thirty-two patients
(14%) smoked tobacco (median: 10 cigarettes per day, range:
1-50).
Cutaneous examination
Only three patients, all children, had acute changes at the time
of examination: all had erythema, mainly over the nose,
cheeks, dorsa of hands and fingers, lower lips and upper helix
of the ears. Thirty-four (15%) patients had no changes evident
on any light-exposed skin (16 females, 18 males; median age:
37 years, range: 5-87). Scarring was the most commonly pre-
Table 3 Chronic changes on light-exposed skin of 223 subjects
Sign No. patients (%)
Scarring (total) 187 (84)
Facial scarring
Total 149 (67)





Thickened knuckle skin 78 (35)
Premature facial wrinkling 20 (9)
Rhagades and lip furrows 18 (8)
Palmar keratoderma 6 (3)
Pebbled facial skin 3 (1)
Pebbled hand skin 3 0)
Thickened waxy hand skin 3 (1)
Thickened waxy facial skin 2 (1)
Nail changes 1 (0-4)
sent chronic change, affecting mainly light-exposed skin of
the face (149 patients, 67%) and hands (138 patients, 62%;
Table 3). The observer-perceived severity for mild and moder¬
ate face and hand signs was in roughly equal proportions
(face, 31% and 29% of subjects, respectively; hands, 30% and
27%). Only a minority of subjects had scarring that was
assessed as severe (face, 6%; hands, 5%). Other chronic chan¬
ges such as thickening of knuckle skin were observed less fre¬
quently (Table 3).
Quality of life
Dermatology Life Quality Index scores
Two hundred and twenty patients completed QoL question¬
naires: 176 the adult DLQI and 44 the CDQLI. Their scores
are summarized in Table 4. Scores were not significantly influ¬
enced by age or sex. The median total DLQI score was 14
(range: 0-29, n = 176). It is possible to interpret the mean¬
ing of DLQI scores by applying simple validated descriptive
score bands.15 Six adults (3%) scored 0 or 1, indicating no
effect on their life over the preceding week and 15 (9%)
scored 2-5, indicating a small effect: in total only 21 subjects
(12%) scored 5 or less, indicating no or little effect on their
QoL. Thirty-two (18%) scored 6-10, indicating a moderate
effect, 92 (52%) scored 11-20, indicating a very large effect,
and 31 (18%) scored 21-30, indicating an extremely large
effect. Thus 123 of 176 adults (70%) scored over 10, indica¬
ting at least a very large effect on their QoL over the pre¬
ceding week. The highest-scoring DLQI questions were 4, 5
and 6, relating to clothing, social/leisure activities and sport.
All six adults (four women and two men; mean age:
Table 4 Total Dermatology Life Quality Index (DLQI) and Children's
Dermatology Life Quality Index (CDLQ1) scores in erythropoietic
protoporphyria
Age Mean Mean quality
range Number age of life score
(years) Sex of patients (years) (range)
6— 15a F 22 10-9 12-8 (5-20)
M 22 11-3 12-9 (6-21)
F and M 44 11-1 12-8 (5-21)
16-35b F 40 27-3 14 4 (0-29)
M 37 26-0 13-9 (4-25)
F and M 77 26-7 141 (0-29)
36-55b F 33 43-6 13-2 (0-25)
M 36 44-0 13 0 (1-29)
F and M 69 43-8 13-1 (0-29)
56-87b F 17 62-8 16-1 (4-27)
M 13 62-3 15-3 (0-27)
F and M 30 62-6 15-8 (0-27)
16-87b F 90 400 14-2 (0-29)
M 86 39-0 13-8 (0-29)
F and M 176 39-5 14-0 (0-29)
''CDQLI questionnaire; bDQLI questionnaire.
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Fig 2. Relationship between total erythrocyte porphyrin (TEP) and
quality of life (QoL) scores for 220 patients with erythropoietic
protoporphyria. QoL: Dermatology Life Quality Index scores for 176
adults (grey diamonds) and Children's Dermatology Life Quality Index
scores for 44 children (black triangles); r„ — Spearman rank
correlation.
47-5 years, range: 20-77) with a DLQI score of 0 or 1 had
minor symptoms which were not affecting iheir QoL; in three
of ihese EPP was not diagnosed until over 43 years after the
onset of symptoms.
The median total CDLQI score was 13 (range: 5-21, n =
44); no child scored < 5, and 35 (80%) scored > 10. The
highest-scoring CDLQI questions were 5, 1 and 9, relating to
social/leisure activities, skin symptoms and sleep.
Indices of severity of disease
The relationships between three potential indicators of severity
of disease and QoL were assessed. There was a positive corre¬
lation between TEP and adult DLQI scores (rs = 0-228; P =
0-002; n= 174) but not between TEP and CDLQI scores
(rs = 0-025; P = 0-888; n = 35; Fig. 2). In contrast, there
was a stronger inverse correlation with lime to onset of symp¬
toms for CDQLI scores (rs = —0-422; P = 0-004; n = 44)
than for adult DLQI scores (rs = —0-233; P = 0-002; n =
176). There was no significant relationship between age at
onset and either DLQI or CDQLI score.
Discussion
In addition to confirming previous descriptions of the clinical
features of EPP,2'8-"'16'17 our study provides quantitative data
about the frequency of these features (Tables 1 and 3) in a
much larger group than has been reported previously. It also
documents the measures taken to avoid acute photosensitivity.
Most patients depended mainly on physical protection from
direct sunlight, usually supplemented by the use of sunscreens.
Our study showed that patient choice of sunscreen was varied
and often uninformed, highlighting the need for both patient
information and expert advice. Subsequent to the completion
of this study a new patient information sheet for EPP was
prepared by us and is now available online (htlp://www.
bad.org.uk/public/leaflets/erythropoietic.asp). The Tayside
Pharmaceuticals' Reflectant Sunscreen is specially formulated to
protect the skin against visible light as well as ultraviolet
radiation, and details of this product are included in Appen¬
dix l.18 The clinical effectiveness of the most widely used drug
treatment for EPP, (3-carotene, is doubtful.2,10,19 Our study
confirms that two-thirds of those for whom P-carotene was
prescribed were no longer taking it, which suggests that its
benefits, if any, may be marginal (Table 2). Despite the high
rate of discontinuation for most forms of therapy, for those
remaining on treatments other than antihistamines there
appears to be a high rate of perceived efficacy. While a placebo
effect cannot be discounted, it is possible that these treatments
are indeed useful for selected patients, in which case affected
individuals could be offered a sequential trial of treatment
options to assess for potential benefits.
We identified 389 living individuals with EPP within the
U.K. and an additional 30 affected family members not inclu¬
ded in the databases that we searched. This gives a minimum
prevalence for EPP in the U.K. (population 59-8 million) of 1
in 143 000, close to the previously reported U.K. prevalence
of 1 : 130 OOO20 but lower than the 1 : 79 000 and
1 : 75 000 for Northern Ireland2 and the Netherlands10 where
there is some evidence for founder effects.2,11 The true U.K.
prevalence probably lies between these figures, given the diffi¬
culty in obtaining a diagnosis reported by many of our
patients and our identification since the study ended of new
patients who were symptomatic before the study period.
Differences, particularly in the frequencies of clinical fea¬
tures, between our data and those from previous descriptions
of Epp8"10-16-17 are probably explained mainly by the larger
number of patients and the inclusion of a higher proportion
of patients (32%) over the age of 40 years, but may also
reflect geographical differences. There may also be less obser¬
ver variation and participation bias in this study. All our
patients were seen by the same observer and we attempted to
minimize selection bias by recruiting as high a percentage of
known U.K. patients as possible. However, only 223 of an
identified 389 (57%) living U.K. patients with EPP were seen
in the study. There is therefore the possibility of bias either
through more mildly affected patients seeing little point in
participating, or perhaps more severely affected individuals
disillusioned with medical therapy declining to take part. Fur¬
thermore, identification of individuals using databases held by
specialist referral centres and the difficulty experienced in
obtaining a diagnosis might have led to fewer mildly affected
individuals being included.
The substantial impact of EPP on the lifestyle of most
patients is indicated by their QoL scores (Table 4) which were
unexpectedly high by comparison with those for other skin
diseases generally regarded as more severe, with levels of pain
comparable with severe eczema21 and epidermolysis bullosa22
(Table 52'-27). In contrast, relatively asymptomatic but visu¬
ally disfiguring conditions score lower overall.28 There are no
published studies of QoL in any other cutaneous porphyria,
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Table 5 Comparison of previous Dermatology Life Quality Index and
Children's Dermatology Life Quality Index study mean scores
Condition Adults Children
Erythropoietic protoporphyria 14-0 12-8
(current study)
Acne 57"
Atopic eczema 4-l-:2,~16'221 7'723-l 2:7
Dystrophic epidermolysis bullosa 7'522 ll'S22
Epidermolysis bullosa simplex 10*7 22 1522
Erythrokeratoderma variabilis 5'326 2-7S26




although the impact of acute, noncutaneous symptoms in the
acute porphyrias can be extensive,29 The high scores in EPP
are partly explained by high scoring in the social and leisure
categories, which may reflect the lifestyle restrictions imposed
by the need to avoid exposure to sunlight, whereas in most
other skin disorders symptom-related questions score high¬
est.30'31 Children, who may be less aware of the social impli¬
cations of their illness, tended to score higher on questions
about symptoms and sleeping, reflecting their reduced control
over sunlight exposure and the pain experienced when avoid¬
ance is not possible. Thus the main effect of EPP on QoL
comes from the morbidity produced by acute and prolonged
pain following sunlight exposure together with the social con¬
sequences of the measures needed to avoid this. The previ¬
ously reported trend for higher DLQI scores in younger
individuals and adults31 was not seen in EPP (Table 4). Like
others,9'10 we were unable to confirm that symptoms improve
with age.8
Photosensitivity increases with TEP concentration in EPP
patients with liver failure32 and it has been suggested that EPP
severity correlates directly with protoporphyrin concentra¬
tion.33 We found correlations between TEP and quantifiable
indicators of severity such as QoL score and age at onset of
symptoms but not time to onset of symptoms. However, these
correlations were weak and CIs loo wide for TEP to be a use¬
ful predictor of severity for individual patients (Fig. 2). It is
possible that plasma porphyrin concentrations, which were
not measured in this study, may provide a better correlation
with severity of disease than TEP.
In addition to confirming the improvement in symptoms
during pregnancy,8'11'17'34'35 we found that TEP was higher
in males than females, a difference that has not been noted
previously,2 and that some women experience more severe
symptoms around the time of their menses. These observa¬
tions add to the evidence that sex hormones influence EPP.
The mechanism for this effect remains unclear. There are
reports that TEP decreases17'34 or remains unchanged during
pregnancy.35 The human ABCG2 multidrug transporter protein
regulates intracellular protoporphyrin concentrations in erylh-
roid and hepatic cells.36 Its expression in human placental cells
is increased by progesterone and 17pS-estradiol,37 an effect that
might lead to removal of protoporphyrin from the maternal
circulation during pregnancy.
All 223 patients in this study developed symptoms before
they were 13 years old, although a few patients did not seek
medical advice until they were much older. This was an unex¬
pected finding, because other series have included patients
whose disease became manifest only during their teens or
later8'9 and there are several reports of adult onset of EPP,38
distinct from those caused by somatic mutation of the FECH
gene in haematopoietic cells.39 In contrast, the median age at
diagnosis was 12 years and the diagnosis was not made in a
third of our patients until they were 20 years of age or older.
Although laboratory methods for the diagnosis of EPP have
improved over the past three decades, analysis of our data
shows little change in the median time to diagnosis for each
decade from 1965. Such a finding highlights the need to
increase awareness of EPP, particularly among general practi¬
tioners, the primary point of medical contact, and paediatri¬
cians to whom the majority of patients will have been
referred following the onset of their symptoms. Increased
awareness in the wider community through the written and
broadcast media also has a role to play; 8% of our patients
were self-diagnosed or diagnosed by a family member after
seeing such information.
Acknowledgments
We thank all the physicians who helped with this study and
allowed access to their patients. We are most grateful to all
those who allowed us to use their patient databases: Dr Julian
Barth, Department of Clinical Biochemistry, Leeds General
Infirmary; Professor James Ferguson, Photobiology Unit, Der¬
matology Department, University of Dundee; Professor John
Hawk, Institute of Dermatology, St Thomas' Hospital, London;
Dr Lesley Rhodes and Dr Felicity Stewart, Departments of Der¬
matology and Clinical Biochemistry, Hope Hospital, Manches¬
ter; Dr Robert Sarkany, Department of Dermatology, St
George's Hospital, London; Dr David Todd, Department of
Dermatology, Essex County Hospital, Colchester. We thank
Professor Robert Newcombe, Department of Epidemiology,
Statistics and Public Health, Cardiff University for statistical
advice and analyses. We also thank Ms Jacqueline Woolf and
Ms Sonia van Lierop for expert laboratory and secretarial
assistance. The study was supported by grants from the Royal
College of Physicians (Lewis Thomas Gibbon Jenkins of Brit-
ton Ferry Memorial Trust), the Royal Gwent Hospital and the
Wales College of Medicine, Cardiff University.
References
1 Magnus IA, Jarrett A, Prankerd TA, Rimington C. Erydiropoietic
protoporphyria. A new porphyria syndrome with solar urticaria
due to protoporphyrinaemia. Lancet 1961; 278:448-51.
2 Todd DJ. Erythropoietic protoporphyria. Br J Dermatol 1994;
131:751-66.
© 2006 The Authors
Journal Compilation © 2006 British Association of Dermatologists • British Journal of Dermatology 2006 155, pp574-581
EPP, clinical features and quality of life, S.A. Holme et al. 581
3 Cox TM, Alexander GJM, Sarkany RPE. Protoporphyria. Semin Liver
Dis 1998; 18:85-93.
4 Doss M, Frank M. Hepatobiliary implications and complications in
protoporphyria, a 20-year study. Clin Biochem 1989; 22:223-9.
5 Meerman L. Erythropoietic protoporphyria: an overview with
emphasis on the liver. Scand J Gastroenterol 2000; 35 (Suppl.
232):79-85.
6 Whatley SD, Mason NG, Khan M et al. Autosomal recessive erythro¬
poietic protoporphyria in the United Kingdom: prevalence and
relationship to liver disease. J Med Genet 2004; 41:el05.
7 Gouya L, Martin-Schmitt C, Robreau A-M et al. Contribution of a
single-nucleotide polymorphism to the genetic predisposition for
erythropoietic protoporphyria. Am J Hum Genet 2006; 78:2-14.
8 Schmidt H, Snitker G, Thomsen K, Lintrup J. Erythropoietic proto¬
porphyria: a clinical study based on 29 cases in 14 families. Arch
Dermatol 1974; 110:58-64.
9 DeLeo VA, Poh-Fitzpatrick MB, Mathews-Roth MM, Harber LC.
Erythropoietic protoporphyria. 10 years experience. Am J Med 1976;
60:8-22.
10 Baart de la Faille H, Biljmer-Iest JC, van Hattum J et al. Erythropoi¬
etic protoporphyria: clinical aspects with emphasis on the skin. Curr
Probl Dermatol 1991; 20:123-34.
11 Went LN, Klasen EC. Genetic aspects of erythropoietic protopor¬
phyria. Ann Hum Genet 1984; 48:105-17.
12 Finlay AY, Khan G. Dermatology Life Quality Index (DLQI): a sim¬
ple practical measure for routine clinical use. Clin Exp Dermatol
1994; 19:210-16.
13 Holme SA, Man I, Sharpe JL et al. The Children's Dermatology Life
Quality Index (CDLQI): validation of the cartoon version. Br J Der¬
matol 2003; 148:285-90.
14 Deacon AC, Elder GH. Front line tests for the investigation of sus¬
pected porphyria. J Clin Pathol 2001; 54:500-7.
15 Hongbo Y, Thomas CL, Harrison MA et al. Translating the science
of quality of life into practice: what do dermatology life quality
index scores mean? J Invest Dermatol 2005; 125:659-64.
16 Poh-Fitzpatrick MB. The 'priming phenomenon' in the acute pho¬
totoxicity of erythropoietic protoporphyria. J Am Acad Dermatol
1989; 21:311.
17 Poh-Fitzpatrick MB. Human protoporphyria: reduced cutaneous
photosensitivity and lower erythrocyte porphyrin levels during
pregnancy. J Am Acad Dermatol 1997; 36:40-3.
18 Moseley H, Cameron H, MacLeod T et al. New sunscreens confer
improved protection for photosensitive patients in the blue light
region. Br J Dermatol 2001; 145:789-94.
19 Sarkany RP. Erythropoietic protoporphyria (EPP) at 40. Where are
we now? Photodermatol Photoimmunol Photomed 2002; 18:147-52.
20 Murphy GM, Hawk JLM, Corbett M. The UK erythropoietic proto¬
porphyria register: a progress report. Br J Dermatol 1985; 113
(Suppl. 29): 11 (Abstract).
21 Kurwa HA, Finlay AY. Dermatology in-patient management greatly
improves quality of life. Br J Dermatol 1995; 133:575-8.
22 Horn HM, Tidman MJ. Quality of life in epidermolysis bullosa. Clin
Exp Dermatol 2002; 27:707-10.
23 Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Qual¬
ity Index (CDLQI): initial validation and practical use. Br J Dermatol
1995; 132:942-9.
24 Badia X, Mascaro JM, Lozano R. Measuring health-related quality
of life in patients with mild to moderate eczema and psoriasis:
clinical validity, reliability and sensitivity to change of the DLQI. Br
J Dermatol 1999; 141:698-702.
25 Emerson RM, Lawton S, Williams HC. Do specialist eczema clinics
benefit children with atopic dermatitis? Br J Dermatol 1998; 139
(Suppl. 51):46 (Abstract).
26 Woo PN, White MI. A family study of erythrokeratoderma variabil¬
is. Br J Dermatol 2004; 151 (Suppl. 68):71 (Abstract).
27 Njoo MD, Bos JD, Westerhof W. Treatment of generalised vitiligo
in children with narrow-band (TL-01) UVB radiation therapy. J Am
Acad Dermatol 2000; 42:245-53.
28 Lewis VJ, Finlay AY. 10 years experience of the Dermatology Life
Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9:169-80.
29 Millward LM, Kelly P, Deacon A et al. Self-related psychosocial con¬
sequences and quality of life in the acute porphyrias. J Inherit Metal)
Dis 2001; 24:733-47.
30 Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on
quality of life. J Eur Acad Dermatol Venereol 2000; 15:137-9.
31 Moloney FJ, Keane S, O'Kelly P et al. The impact of skin disease
following renal transplantation on quality of life. Br J Dermatol
2005; 153:574-8.
32 Bloomer JR. The liver in protoporphyria. Hepatology 1988; 8:402-7.
33 Kauppinen R. Porphyrias. Lancet 2005; 365:241-52.
34 Bewley AP, Keefe M, White JE. Erythropoietic protoporphyria
improving during pregnancy. Br J Dermatol 1998; 139:145-7.
35 Jacquemyn Y. Erythropoietic protoporphyria in pregnancy. J Obstet
Gynaecol 2003; 23:196.
36 Krishnamurthy P, Schuetz JD. Role of abcg2/bcrp in biology and
medicine. Annu Rev Pharmacol Toxicol 2006; 46:381-410.
37 Wang H, Zhou L, Gupta A et al. regulation of BCRP/ABCG2 expres¬
sion by progesterone and 17beta-estradiol in human B0W0 placen¬
tal cells. Am J Physiol Endocrinol Metab 2006; 290:F.798~807.
38 Henderson CA, Jones S, Elder GH, Ilchyshyn A. Erythropoietic pro¬
toporphyria presenting in an adult. J R Soc Med 1995; 88:P476-7.
39 Goodwin RG, Kell WJ, Laidler P et al. Photosensitivity and acute
liver injury in myeloproliferative disorder secondary to late-onset
protoporphyria caused by deletion of a ferrochelatase gene in he¬
matopoietic cells. Blood 2006; 107:60-2.
Appendix 1. Formulation of Tayside
Pharmaceuticals' Reflectant Sunscreen
Tayside Pharmaceuticals' Reflectant Sunscreen Creams are
available in three colours: coral pink, beige and coffee. The
active ingredients in the sunscreen are titanium dioxide and
zinc oxide in a base containing colours and preservatives. The
creams do not contain lanolin and are fragrance free. They
contain the following ingredients:
Zinc oxide, titanium dioxide, distilled water, light liquid
paraffin BP, 1,3-butylene glycol, cetyl dimeticone copolyol-
EM90, glyceryl isostearate/sorbitan isostearate, silicon fluid
200/100 CS, sodium chloride BP, almond oil BP, bulylated
hydroxytoluene, methyl hydroxybenzoate BP, bronoprol BP.
The pigment in the 'coral pink' product is red iron oxide,
in the 'beige' product is yellow and black iron oxide, and in
the 'coffee' product is red, yellow and black iron oxide.
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Fig 2. A, Large pale-staining cells with vacuolated cyto¬
plasm and small basophilic nulei. (Hematoxylin-eosin
stain, original magnification: X400.) B, TdT-mediated
dUTP-biotin nick end labeling—positive balloon cells con¬
taining melanin in papillary dermis. Positive cells were
viewed under halogen and fluorescence lamp (inset).
Our data based on TdT-mediated dUTP-biotin
nick end labeling analysis suggest that apoptosis is
involved in the development of balloon cell nevus.
Interestingly, TdT labeling was not observed in nuclei
of ballooned cells without melanin. This finding
suggests either the limitation ofTdT-mediated dUTP-
biotin nick end labeling assay to detect different
phases of apoptosis, which was suggested by Zhao
et al7 in hepatocytes, or that cells exhibiting amela-
notic ballooning change may not have undergone a
pathway related to apoptosis. Melanogenesis may be
related to the apoptosis.8'9 Expression of apoptosis
regulatory molecules (ie, Bel down-regulation and
Bax up-regulation) are closely involved in melano¬
genesis.8 In addition, it was reported that mature
melanocytes may tend to undergo apoptosis after all-
trans retinoic acid treatment.9 Further study is needed
for more precise understanding of the ballooning
changes in association with apoptotic activity.
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Symptomatic response of erythropoietic
protoporphyria to iron supplementation
To the Editor: Erythropoietic protoporphyria (EPP) is
an inherited disorder of heme biosynthesis charac¬
terized by a relative deficiency of the mitochondrial
enzyme ferrochelatase, which catalyses the incorpo¬
ration of ferrous iron into protoporphyrin IX to form
heme. The defect causes increased free protopor¬
phyrin IX, producing acute cutaneous photosensi¬
tivity and scarring beginning in childhood and,
rarely, hepatic fibrosis and failure. The anomalous
hematopoiesis often presents as a microcytic anemia
with features of iron deficiency. Despite these find¬
ings, the role of iron supplementation in EPP remains
unclear. Following oral supplementation, both ex¬
acerbation and improvement of laboratory indices
and symptoms have been reported.1"3 We report a
case of apparentmild iron deficiency in EPP in which
the hematologic response to oral supplementation
was accompanied by an increased tolerance to
J Am Acad Dermatol
Volume 56, Number 6
Letters 1071
Table I. Laboratory values of patient 1 before












Mean corpuscular 83.5 85.1
volume (80-98 fl)
Mean corpuscular 27.6 28.0
hemoglobin
(27-34 pg)
Serum ferritin 13 42
(15-300 ftg/L)
Serum iron 16.6 40.2
(8.8-32.4 /tmol/L)
Total iron 83.2 63.1
binding capacity
(44.8-80.6 /umol/L)
Transferrin saturation 20.0 63.7
(16-50%)
sunlight, the second such report in the literature, and
uniquely without an apparent change in protopor¬
phyrin concentrations.
A white male had experienced burning paresthe¬
sia since his early childhood after about 3 hours of
sunlight exposure. The sensation generally took 3
days to completely resolve. He was diagnosed
biochemically and genotypically with EPP at 10
years of age. At a routine outpatient review at the
age of 17, his blood count revealed a mild anemia
associated with an apparent iron deficiency (Table I).
Tests for fecal occult blood were negative. He was
prescribed oral ferrous sulphate 200 mg twice daily
for 16 weeks, before reducing to 200 mg once daily.
After 6 months, the ferritin- and iron-binding capac¬
ities were within the normal range, although his
hemoglobin had not returned to normal (Table I).
The patient reported significant improvement in
sunlight tolerance (up to 8 hours symptom-free
exposure and resolution within 24 hours). Over
this period, there was no significant change in either
his protoporphyrin levels or biochemical tests of
liver function.
Hematologic investigations of EPP patients often
suggest an iron-deficient picture, although the
mechanism remains uncertain because no studies
have examined the etiology. It seems unlikely that
individuals are losing iron; the mechanism proba¬
bly involves either failure to absorb dietary iron
adequately or failure to utilize it. The role of iron
supplementation in EPP is controversial and the
literature limited (Table II). Oral iron and transfusion
of whole blood or hematin have been reported to
normalize liver function and erythrocyte protopor¬
phyrin levels.1 However, others report symptomatic
and biochemical deterioration of EPP following oral
supplementation2,3 or whole blood transfusion.'1
Theories for beneficial effects include reduced enter-
ohepatic circulation caused by gastrointestinal che¬
lation, nonenzymatic intracellular protoporphyrin
chelation, or facilitated chelation by residual active
ferrochelatase.1 Conversely, deterioration following
supplementation may result from stimulation of he-
matopoiesis and production of protoporphyrin or
interaction with other products predisposing to
cholestasis.2
Table II. Summary of previous EPP literature reporting effect of oral iron supplementation
Year of Number of Hematologic
paper subjects investigations Treatment Results of oral iron therapy Reference
2007 1 Low Hb, serum ferritin
raised TIBC
Oral iron Normalization of ferritin
and TIBC, improved Hb, no
change LFT or EPP-reduced
photosensitivity
Current report
1990 1 Low Hb, MCV, serum
ferritin
Oral iron Increased photosensivity raised LFT 2
1988 4 Case 1, iron deficiency
anemia; case 2, anemia;
case 3, iron deficiency
anemia; case 4, iron
deficiency anemia
Oral iron Case 1, increased photosensivity;
case 2, increased photosensivity;
case 3, increased photosensivity
raised EPP; case 4, increased
photosensivity raised EPP
3
1986 1 Low Hb, MCV, iron, serum
ferritin raised TIBC, LFT
Oral iron Reduced EPP improved LFT;
photosensitivity effect not reported
1





PP deposition on liver rebiopsy
5
EPP, Erythrocyte protoporphyrin; Hb, hemoglobin; LFT, liver function tests; MCV, mean corpuscular volume; TIBC, total iron binding capacity.
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Our patient's experience of significantly im¬
proved symptoms while taking oral iron supple¬
ments is the second report of this phenomenon in
EPP. The other reported patient was administered
oral cholestyramine and the improved symptoms
were associated with reduced erythrocyte and
hepatic protoporphyrin.5 In contrast, our patient's
protoporphyrin levels remained constant through¬
out and beyond iron supplementation. Although a
placebo effect cannot be discounted in the current
case, a similar improvement did not occur with beta
carotene. This demonstration of our patient's stable
protoporphyrin levels throughout the period of
treatment with iron suggests that there may be an
alternative, as yet unknown mechanism for iron in
improving the symptoms of EPP.
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Squamous cell carcinoma over tattoos
To the Editor: Tattooing has been associated with
a variety of complications, including inflammatory
Fig 2. Well-differentiated squamous cell carcinoma, with
pigment granules at periphery of tumor (case 2). (Hema-
toxylin-eosin stain; original magnification: X20.)
reactions, the transmission of infections, and neo¬
plasms. We report two cases of squamous cell
carcinoma (SCC) and a keratoacanthoma appearing
over tattoos.
Case 1 involved a 35-year-old man who presented
with an ulcerated nodular lesion. It had appeared 4
months earlier and was located over a tattoo on the
right arm that had been applied 10 years previously
with black ink (Fig 1). Complete removal of the
lesion was carried out. The histopathologic study
revealed islets of epithelial cells exhibiting marked
atypia and aberrant keratinization. Some zones
showed basal membrane rupture and spread of the
keratinized cells toward the dermis. Well-differenti¬
ated SCC was diagnosed.
Case 2 involved a 30-year-old woman who
presented with a recent ulcerated and indurated
nodular lesion over a tattoo that had been applied 10
months earlier, overlying a black pigment zone. The
lesion was completely removed, and the histologic
study revealed an epidermis with irregular acantho¬
sis and endophytic prolongations composed of cells
with an abundant and eosinophilic cytoplasm that
invaded the dermis. Nuclear atypia, individual ker¬
atinization, and keratin pearls were identified. The
lesion margins were of a pseudoepitheliomatous
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Gene Dosage Analysis Identifies Large Deletions
of the FECH Gene in 10% of Families with
Erythropoietic Protoporphyria
Sharon D. Whatley1, Nicola G. Mason1, S. Alexander Holme2, Alex V. Anstey3, George H. Elder1 and
Michael N. Badminton1
Erythropoietic protoporphyria (EPP) is an inherited cutaneous porphyria characterized by partial deficiency of
ferrochelatase (FECH), accumulation of protoporphyrin IX in erythrocytes, skin, and liver, and acute
photosensitivity. Genetic counseling in EPP requires identification of FECH mutations, but current sequen¬
cing-based procedures fail to detect mutations in about one in six families. We have used gene dosage analysis
by quantitative PCR to identify large deletions of the FECH gene in 19 (58%) of 33 unrelated UK patients with
EPP in whom mutations could not be detected by sequencing. Seven deletions were identified, six of which
were previously unreported. Breakpoints were identified for six deletions (c.1-7887-IVS1 +2425insTTCA;
C.1-9629-IVS1 +2437; IVS2-1987-IVS4+ 352del; c.768-IVS7 + 244del; IVS7 + 2784-IVS9 + 108del; IVS6 + 2350-
TGA + 95del). Five breakpoints were in intronic repeat sequences (AluSc, AluSq, AluSx, L1MC4). The remaining
deletion (Del Ex3M) is likely to be a large insertion-deletion. Combining quantitative PCR with routine
sequencing increased the sensitivity of mutation detection in 189 unrelated UK patients with EPP from 83% (95%
CI: 76-87%) to 93% (CI: 88-96%) (P= 0.003). Our findings show that large deletions of the FECH gene are an
important cause of EPP. Gene dosage analysis should be incorporated into routine procedures for mutation
detection in EPP.
Journal of Investigative Dermatology (2007) 127, 2790-2794; doi:10.1038/sj.jid.5700924; published online 28 June 2007
INTRODUCTION
Erythropoietic protoporphyria (EPP) (OMIM 177,000) is an
inherited cutaneous porphyria caused by partial deficiency
of ferrochelatase (FECH) (EC 4.99.1.1), the final enzyme
in the heme biosynthetic pathway, which catalyzes the
insertion of ferrous iron into protoporphyrin IX to form heme.
Deficiency of FECH leads to accumulation of protoporphyrin
IX in erythrocytes, plasma, skin, and liver. Accumulation
of protoporphyrin in the skin produces lifelong acute
photosensitivity while its deposition in the liver leads
to hepatobiliary disease in some patients (Todd, 1994;
Meerman, 2000).
The inheritance of EPP is complex. In most families,
clinical expression requires inheritance of a hypomorphic
FECH IVS3-48C trans to a disabling FECH mutation that is
inherited in an autosomal dominant fashion (Gouya et a!.,
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2006) but rare families with autosomal recessive EPP have
been reported (Lamoril etal., 1991; Sarkany etal., 1994; Poh-
Fitzpatrick et at., 2002; Whatley et at., 2004; Gouya et at.,
2006). The frequency of the hypomorphic FECH allele varies
between populations (Gouya et at., 2006), being present in
about 12% of white Europeans (Gouya et at., 2002, 2006;
Whatley et at., 2004) but in 68% of Japanese (Saruwatari
et at., 2006). Molecular analysis to identify the IVS3-48C
allele and disease-specific mutations in the FECH gene is
important for accurate genetic counseling of families with
EPP (Gouya et at., 2002).
Over 120 mutations in the FECH gene, which contains
11 exons spread over 45 kb, have been reported in EPP, most
of which are restricted to one or a few families (Gouya et at.,
2006; Saruwatari et at., 2006; Aurizi et at., 2007). Apart from
one complete gene deletion (Magness et at., 1994) and a
partial deletion (Wood et at., 2006), all have been detected
using methods that depend only on sequencing of exons and
their flanking regions, including up to 1.3 kb of 5' non-coding
sequence, to identify mutations. This approach fails to
identify an FECH mutation in about one in six families
(Rufenacht et at., 1998; Whatley et at., 2004; Gouya et at.,
2006). Here we show that gene dosage analysis by
quantitative PCR detects gross deletions of one or more
FECH exons in 19 of 33 (58%) of such "mutation-negative"
families and that deletions of this type are present in 10% of
UK families with EPP.
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RESULTS
Direct sequencing of all exons, 30-250 bp of intronic flanking
regions, and 1,000kb of 5' untranslated region (UTR)
identified an FECH mutation on one or both alleles in 156
(83%) of our 189 unrelated patients, 149 of whom had a
mutation on only one allele. Genotyping of the 33 mutation-
negative patients showed that 28 (85%) patients carried an
FECH IVS3-48C allele, a significantly lower frequency than in
the 149 patients who were heterozygous for an FECH
mutation, all but one of whom had at least one IVS3-48C
allele (X2 13.3; P<0.005).
Gene dosage analysis by quantitative PCR of genomic
DNA from the 33 mutation-negative patients identified
deletions encompassing one or more exons in 19 (58%)
patients, 18 of whom were either FECH IVS3-48CAT hetero-
zygotes or had the IVS3-48C allele trans to a deletion
(Table 1). Seven different deletions were detected, one of
which has been described previously (Wood et al., 2006)
(Table 1). Exon 1 was deleted in five patients; genotyping
with three highly informative microsatellite markers, two
flanking the FECH gene and one in intron 4, identified two
haplotypes that differed only at the 5' flanking site. Two
different deletions were identified: three patients had a
10,379 bp deletion with a small 4bp insertion and two
patients had a 12,133 bp deletion (Table 1). Two patients had
lost exons 3 and 4; one has previously been described (Wood
et al., 2006), the other had a deletion for which breakpoints
were not identified (Table 1). In two patients, a small deletion
involving part of exon 7 and 244 bp of 3' flanking sequence
removed the region in which one of the primers for
amplification of this exon is usually based. The presence of
a stop codon 68 codons 3' to this deletion suggests that any
mRNA produced from this allele will be truncated and
unstable. Exons 8 and 9 were deleted in eight patients;
genotyping with three microsateilite markers showed that this
mutation was present in at least two different FECH
haplotypes. The largest deletion removed exons 7, 8, 9, 10,
and 11 and was present in two patients.
Breakpoints for six deletions were defined by sequencing
(Table 2). The 10.4kb exon 1 deletion contained a four-base
insert with a sequence that was repeated in the 5' flanking
region (Table 2) and 30 bp 3' to the insertion. For four of the
five other deletions, the breakpoints shared the same 3, 4, or
5 bp sequences at the deletion junctions (Table 2). The 3'
breakpoints of both exon 1 deletion and the exon 7 deletion
and the 5' breakpoint of the exon 8-9 deletion were all sited
in Alu repeat regions while the 5' breakpoint of the exon 7-11
deletion was in an L1MC4 repeat sequence (Table 2). These
features have been reported for large deletions in other genes
and are believed to facilitate homologous recombination
(Woods-Samuels et al., 1991; Laccone et al., 2004).
We were unable to identify the breakpoint for one
deletion. This patient was heterozygous for a deletion that
included exons 3 and 4 and surrounding sequence from IVS2-
88 to IVS4 + 2046 and thus differed from the exon 3-4
deletion with defined breakpoints recently described in two
Italian families (Di Pierro et al., 2007). PCR amplification
using primers flanking the deleted region gave a 7kb band
consistent with the size of the deletion as identified by gene
dosage analysis. No smaller product was identified using
amplification conditions that are capable of detecting
fragments as small as 100bp. Restriction enzyme [NdeI)
digestion of the 7kb amplicon gave a normal pattern
consistent with the amplicon coming from the normal allele
alone. These findings exclude the presence of a 7 kb
insertion-deletion but not of an insertion-deletion too large
to amplify.
DISCUSSION
Most patients with EPP are heterozygous for disabling
mutations in the FECH gene (Gouya et al., 2006). Intragenic
deletions involving entire exons and their flanking regions,
including primer binding sites, are not identified in hetero-
zygotes by methods for mutation detection that rely on direct
sequencing of amplified genomic DNA because sequencing
does not distinguish between amplification of one or both
alleles. Quantitative analysis of amplified genomic DNA is
required for this purpose. Here, we have used gene dosage
analysis to show that large deletions of the FECH gene, likely
to abolish all FECH activity, were present in 19 (58%) of 33
patients with EPP in whom FECH mutations were not
identified by sequencing.
Such deletions are an important cause of human disease
and represent 5.6% of all mutations in the human gene
mutation database (www.hgmd.cf.ac.uk). There is evidence
that they result from various molecular interactions that are
Table 1. Deletions in the FECH gene in patients with EPP
Number of patients Deleted exons Deletion Size of deletion (bp) FECH IVS3-48 genotypes
3 Exon 1 c.1-7887 to IVS1 +2425insTTCA 10,379 CAT
2 Exon 1 c.1-9629 to IVS1+2437 12,133 err
11 Exons 3, 4 IVS2-1987 to IVS4+352 4,425 c/-
1 Exons 3, 4 See text > 7,000 c/-
2 Exon 7 (partial) C.768 to IVS7+244 280 crt, t/t
8 Exons 8, 9 IVS7+2784 to IVS9+108 2,196 c/t
2 Exons 7-11 IVS6+2350 to TGA+95 9,889 crt
1 Wood etal. (2006).
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Table 2. Deletion breakpoints in the FECH gene
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Wild-type (WT) sequences 5' and 3' to the breakpoints are shown. Junction points, except for the flush junction indicated by 11, and homologous sequences
present at both the 5' and 3' breakpoints are in capitals. The inserted sequence is indicated by italic capitals.
1 Previously reported (Wood et al., 2006).
dependent on the features of the surrounding DNA sequence
(Abeysinghe et al., 2006). Repetitive elements, which were
present in all but one of the deletions for which we defined
breakpoints, are known to facilitate the formation of
secondary structures such as hairpin loops and cruciforms
(non-B DNA conformations) that have been shown to
coincide with the breakpoints of gross deletions (Chuzhanova
et al., 2003; Bacolla et al., 2004).
The 33 patients came from a cohort of 189 apparently
unrelated patients identified by a cross-sectional study of EPP
in the UK (Holme et al., 2006). FECH mutations were
identified by sequencing in 156 (83%) of these 189 patients.
Here we show that a further 19 (10%) patients had large
intragenic deletions. Thus sequencing combined with gene
dosage analysis identifies mutations in 175 of UK patients
with EPP, increasing the sensitivity of mutation detection to
93% (95% confidence interval: 88-96%) (y2 8.7; P= 0.003),
which is higher than those reported previously (Rufenacht
et al., 1998; Whatley et al., 2004; Gouya et al., 2006).
Only one of the 19 patients with deletions was not hetero¬
zygous for the hypomorphic FECH IVS3-48C allele (Table 1).
This patient had the smallest deletion that we identified as
involving exon 7 and its 3' flanking region (Tables 1 and 2).
However, it is unlikely that the mutant allele gives rise to a
stable truncated protein (see Results) capable of exerting a
dominant-negative effect on FECH activity, as reported for an
exon 10 deletion in the mouse (Magness et al., 2002). At
present, it is not clear why rare patients with the dominant form
of EPP who have a mutation trans to a normal FECH IVS3-48T
allele develop photosensitivity (Wiman et al., 2003).
Sequencing combined with gene dosage analysis failed to
identify an FECH mutation in 14 (7%) of UK patients with
EPP. Ten of these patients were heterozygous for the
hypomorphic FECH IVS3-48C allele, a proportion that is
significantly higher than in the UK population (y2 26.0,
P<0.001). This suggests that most, if not all, of these 10
patients may be heterozygous for deleterious FECH mutations
that lie in regions of the gene that determine expression but
are outside the regions that we sequenced. The other four
patients all had the genotype FECH IVS3-48T/T, a proportion
that is much higher than that in other groups of EPP patients
(Risheq et al., 2003; Gouya et al., 2006) except for those
with mutations on both FECH alleles (Whatley et al., 2004;
Gouya et al., 2006). It seems unlikely that these patients are
homozygous or compound heterozygotes for FECH mutations
that were not detected by our methods since all patients with
recessive EPP yet reported have had at least one intra-exonic
mutation (Whatley et al., 2004; Gouya et al., 2006).
Alternatively, at least some of these patients may have
mutations in genes other than FECH. Deletion of the
Irp2 gene has recently been shown to produce proto¬
porphyria in mice (Cooperman et al., 2006), and the
possibility that EPP may also be caused by mutation of genes




Blood samples were obtained from 189 apparently unrelated
patients with EPP as part of a cross-sectional study of EPP in the
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UK (Holme et al., 2006). We investigated 33 of these patients (32
white British, one of Iraqi descent) in whom an FECH mutation could
not be identified by direct sequencing of all exons, 30-250bp of
intronic flanking regions, and 1,000 kb of 5' UTR. Total erythrocyte
porphyrin was increased in all 33 patients (mean 25.6/tmol/i, range
6.2-65.7 /tmol/l; reference range 0.4-1.7 /tmol/l) and was mainly free
protoporphyrin.
The study was conducted in accordance with the Declaration of
Helsinki Principles for medical research involving human subjects
and its subsequent amendments. Prior approval was obtained from
the North West Multicentre Research Ethics Committee and 84 local
research ethics committees. All patients or their parents gave
informed consent.
Preparation of DNA
Genomic DNA was extracted from whole blood using the QIAamp
DNA purification kit (Qiagen, Crawley, UK) for sequencing and the
Flexigene kit (Qiagen) for dosage studies.
Gene dosage analysis
A multiplex PCR was designed to simultaneously amplify exons 2-9
and 11 of the FECH gene, along with exon 9 of the HMBS gene and
exon 5 of the PPOX gene as internal controls. Exons 1 and 10 did not
amplify consistently within the multiplex, so they were analyzed
separately with exon 1 of the UROS gene and exon 4 of the HMBS
gene as internal controls. A fluorescent (5' FAM) label was
incorporated into one of each primer pair. Details of the primers
used for gene dosage analysis are available from the authors.
Amplification was carried out in 20/il volumes containing 5.39/il
DNA, 3.45 ^l primer mix (0.5-1.5 pmol (final concentration) of each
primer), and 10/il 2 x Qiagen multiplex PCR master mix (containing
HotStarTaq DNA polymerase, Qiagen multiplex PCR buffer (6uim
MgCI2, pH 8.7), dNTP mix). An initial denaturation of 15 minutes at
95°C was followed by 20 cycles of denaturation for 30seconds at
94°C, annealing for 1 minute 30seconds at 64°C, and extension for
I minute 30seconds at 72°C, with a final extension for 10 minutes at
72°C. The PCR products (2 /il) were added to a mixture containing
formamide (10/il) and GS500 standard (0.3/il) (PE Applied
Biosystems, Cheshire, UK) and denatured at 95°C for 3 minutes.
The samples were run on an ABI Prism 310 analyser at 60°C using
POP4 polymer (PE Applied Biosystems).
To determine the gene dosage for each exon, the peak areas were
compared with each other and against controls (Yau et al., 1996). A
locus with a double copy will give a theoretical value of 1.0 whereas
a locus with a deletion will give a value of 0.5 and 2.0 depending on
whether the deleted locus is the numerator or the denominator. To
exclude the presence of polymorphisms at the primer sites, all
deletions were confirmed using at least one other set of primers to
eliminate false positive results due to mis-priming. Primer sequences
are available from the authors.
Identification of breakpoints
To identify deletion breakpoints, pairs of primers were designed for
quantitative PCR-amplification of intronic regions around the
deleted exon; these primer sequences are available from the authors.
These amplicons were multiplexed with internal controls and
analyzed for dosage. The results indicated whether each amplicon
was within the deleted region or not. Pairs of primers were
redesigned at increasing or decreasing distance from the deletion,
depending on these results, partially localizing the deletion. Where
possible, the forward primer from a dial lei ic region 5' of the deletion
was used with the antisense primer from a dial lei ic region 3' of the
deletion to amplify a PCR product straddling the deletion. This
amplicon was sequenced and the breakpoints were identified.
Amplification across breakpoints was carried out using Elongase
enzyme mix (Invitrogen, Paisley, UK) according to the manufac¬
turer's instructions, using a final concentration of 1.8 mM magnesium
with an elongation time between 5 and 20minutes.
Haplotype analysis
Genotyping with two microsatellite markers flanking the FECH gene
(315.0kb 5' to the start codon, 267.6 kb 3' to the stop codon) and
with one microsatellite marker in intron 4 was carried out as
described by Parker (2006).
Sequencing of genomic DNA
PCR-amplified double-stranded DNA was purified from agarose gels
using the QIAquick gel extraction kit (Qiagen) before being cycle
sequenced using fluorescent ddNTPs (BigDye) and an ABI Prism
3100 Genetic Analyzer (PE Biosystems, Warrington, UK). Nucleo¬
tides are numbered from the cDNA sequence of human FECH
(GenBank accession number D00726) with the A of the ATG
initiation codon as "4-1".
Other methods
Erythrocyte porphyrins were analyzed as described (Deacon and
Elder, 2001).
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Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria
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Erythropoietic protoporphyria (EPP) re¬
sults from deficiency of ferrochelatase
(FECH). Accumulation of protoporphyrin
IX causes life-long acute photosensitivity.
Microcytic anemia occurs in 20% to 60%
of patients. We investigated 178 patients
with dominant EPP confirmed by molecu¬
lar analysis. Erythropoiesis was impaired
in all patients; all had a downward shift in
hemoglobin (Hb), and the mean decreased
Introduction
in males by 12 g/L (1.2 g/dL). By World
Health Organization criteria, 48% of
women and 33% of men were anemic.
Iron stores, assessed by serum ferritin
(sFn), were decreased by two-thirds, but
normal serum soluble transferrin
receptor-1 and iron concentrations sug¬
gested that erythropoiesis was not lim¬
ited by iron supply. FECH deficiency in
EPP appears to lead to a steady state in
which decreased erythropoiesis is
matched by reduced iron absorption and
supply. This response may in part be
mediated by protoporphyrin, but we found
no correlation between erythrocyte proto¬
porphyrin and Hb, sFn, total iron-binding
capacity, or transferrin saturation. (Blood.
2007;110:4108-4110)
© 2007 by The American Society of Hematology
Erythropoietic protoporphyria (EPP, MIM 177000) is an inherited
disorder caused by partial deficiency of ferrochelatase (FECH; EC
4.99.1.1) that catalyzes the chelation of ferrous iron by protoporphy¬
rin IX. FECH deficiency leads to accumulation of protoporphyrin
in normoblasts, erythrocytes, plasma, skin, and liver, causing
lifelong acute photosensitivity and, in approximately 2% of
patients, severe liver disease.1,2
Microcytic anemia occurs in 20% to 60% of patients.3"6 In
contrast to other inherited disorders of erythroid heme biosynthe¬
sis,7 the anemia is not dyserythropoietic, there is no iron overload,
and there is evidence for iron deficiency5,6,8,9 without iron loss.9
A mouse model of EPP, the homozygous Fech"'"'as mutant,
develops a similar microcytic anemia.10,11 Although it is probable
that the anemia of EPP reflects limitation of heme formation by
FECH deficiency, its incidence, nieehauiMii, and iclationship to
disoidered iron metabolism remain unclear.
Hematologic and biochemical measurements
All analyses were carried out in the same laboratory. Serum iron (sFe),14
total iron-binding capacity (TIBC),14 serum ferritin (sFn, Elecsys 2010;
Roche Diagnostics, Indianapolis, IN), soluble transferrin receptor-1 (sTfR;
R&D Systomc, Abingdon, United Kingdom), and erythrocyte protoporphy
rin15 were determined as doscribed. Other measurements were by standard
automated methods. Data obtained previously for 611 male first time blood
donors were used for comparisons.16
Statistical methods
Results were expressed as moan plus or minus a standard deviation (SD)
for normally distributed data and median and range for data (sFn,
protoporphyrin) with a log-normal distribution. Differences between
quantitative variables were assessed by the Mann-Whitney test. Spear¬
man rank correlation (rs) was used to test the significance of relation
ships between pairs of variables and the chi-square test for differences
between proportions.
Patients and methods
Patients and control subjects
Blood samples were obtained from 210 patients with EPP during a
cross-sectional study of EPP in the United Kingdom.12 One hundred
ninety-two patients had one FECH mutation with 1 or 2 FECH 1VS3^18C
alleles and were classified as dominant EPP (dEPP)13; 14 of these were
excluded because they had diseases likely to affect iron metabolism. Ethical
approval was obtained from the North West Multicentre Research Ethics
Committee and 84 local research ethics committees. Informed consent was




By World Health Organization criteria, 73 (41%; 95% confidence
interval: 34% 48%) of our patients with dEPP were anemic. All had
a mild microcytic, hypochromic anemia; 48% of females and 33%
of males were affected. The anemic patients did not form a separate
subgroup. In both sexes, hemoglobin (Hb; females: 119 ± 10 g/L
[11.9 ± 1.0 g/dL); males; 133 ± 10 g/L [13.3 ± 1.0 g/dL]), mean
cell volume (MCV), and mean corpuscular hemoglobin (MCH)
were normally distributed with a shift in thoir means toward
lower values (Table S 1, available on the Blood website; see the
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Figure 1. Hemoglobin, serum ferritin, and serum soluble transferrin receptor-1
concentrations in male patients with dominant EPP. (A). Hemoglobin concentra¬
tions in 66 male patients with dEPP aged 16 years or older (■) and in a sample of
5206 men aged 16 years or older from the English population17 (□). (B) Serum ferritin
concentrations in 66 male patients with dEPP aged 16 years or older (■) and in
612 male first-time blood donors from south Wales aged 17 to 62 years16 (□).
(C) Serum soluble transferrin receptor-1 concentrations in 61 male patients with
dEPP aged 16 years or older (18.6 ± 5.1 nM) (■) and in 225 hematological^ healthy
male and female subjects from the United States aged 17 to 97 years18 (□) assayed
using the same method.
Supplemental Materials link at the top of the online article); the
mean Hb for males was 12 g/L (1.2 g/L) lower than in the
general population (Figure 1 A). A similar shift has been noted in
Dutch EPP patients.19 This downward shift in Hb leads to some
patients falling within the definition of anemia; part of the wide
variation in reported incidences can be explained by use of
different definitions.2"6-9 Erythrocyte protoporphyrin concentra¬
tions (females: 21.9 fxM [range, 4.1-75.3 p.M]; males: 25.5 |xM
[range, 8.9-77.3 jjiM]) showed no correlation with Hb.
Table 1. Comparison of indicators of iron status in male patients
with dEPP and male first-time blood donors
Serum iron EPP patients, First-time blood donors,
indices n = 67 n = 611
sFe, |xM 15.1 ± 6.6* 16.7 ± 6.0
TIBC, jjlM 63.0 ± 6.9f 54.5 ± 10.0
TS, % 23.9 ± 10.3f 31.1 ± 10.9
sFn, n-g/L 37 (10-119)t 101 (35-220)
Values are means plus or minus SD, except for sFn, which are medians and 95%
ranges. EPP patients are males aged 16 to 77 years who have never been prescribed
iron supplements. Blood donors are male first-time donors aged 17 to 62 years from
South Wales15: samples for analysis were obtained prior to first donation. Only TIBC
showed any correlation with sFn (rs = -0.412, P < .001).
*P value is not significant.
tP < .001 compared with donors.
FECH activity in dEPP is approximately 35% of normal.13 Our
data show that this decrease is sufficient to produce in all patients a
mild defect of erythropoiesis that impairs hemoglobinization.
Defective erythropoiesis persists throughout life and our findings
(Table S1 legend) and previous reports8'20 suggest that it may not be
corrected by oral iron unless there is evidence of coexisting iron
loss.
Iron status
Both sexes showed evidence of iron depletion (Table S2). Differ¬
ences in sFn and transferrin saturation (TS) between women and
men suggested that more of the former had iron depletion due to
iron loss in addition to abnormalities caused by EPP. Therefore, we
restricted detailed analysis of iron indices to the 67 male patients
(Hb, 135 ± 9 g/L [13.5 ± 0.9 g/dL]) older than 15 years who had
never received iron supplements.
The main abnormality was a marked shift in sFn toward
lower values (Figure IB; Table 1); sFn correlated with Hb
(rs = 0.415; P < .001). Because protoporphyrin is hepatotoxic
and accumulates in the liver in EPP, and liver cell damage may
increase sFn, we assessed liver cell function by measuring liver
enzymes. One or more of these was increased in 17 (25%)
patients; sFn correlated with -/-glutamyl transpeptidase
(rs = 0.507; P < .001) and alanine aminotransferase (rs = 0.392;
P < .001) but not with aspartate aminotransferase. Since sFn
correlates with mobilizable iron stores,21 the downward shift in
sFn by approximately two-thirds (Figure IB; Table 1) suggests
that iron stores in dEPP are decreased to a similar extent or a
little more if the effect of liver dysfunction is taken into account.
Turnbull et al8 found that storage iron, determined by venesec¬
tion, was less than 250 mg in 3 patients; otherwise, quantitative
measurements of tissue iron have not been reported in EPP.
However, in contrast to iron deficiency due to iron loss,
stainable iron is present in erythroblasts.9
In homozygous Fecff",Pas mice, total body iron is normal but iron is
redistributed from peripheral tissues to an enlarged hematopoietic
spleen." Although these mice have liver disease, lower FECH activity
and more severe anemia," it seems unlikely that FECH deficiency limits
etythropoiesis and disturbs iron metabolism by different mechanisms in
the 2 species. The anomalous observation in EPP of accumulation of
iron in erythroblasts9 suggests that there may also be redistribution of
iron stores toward the site of erythropoiesis in EPP. Thus, in both
species, FECH deficiency appears to provoke a response that leads to
accumulation of protoporphyrin IX but prevents accumulation of the





From www.bloodjournal.org at Cardiff University on March 7, 2008. For personal use only.
4110 HOLME et al BLOOD, 1 DECEMBER 2007 • VOLUME 110, NUMBER 12
A second notable feature of iron depletion in dEPP is our finding
that sFe (Table 1) and sTfR (18.6 ± 5.1 nM; Figure 1C) concentra¬
tions are normal. The normal sTiR in our patients is consistent with
the degree of depletion of iron stores indicated by sFn and, together
with the normal sFe, suggests that erythropoiesis is not limited by
iron supply.22 This indicates that the reduction in iron stores has not
led to iron-deficient erythropoiesis. Furthermore, the rate of
erythropoiesis is not increased as this would also increase sTfR
levels. These findings suggest FECF1 deficiency in dEPP leads to
the establishment of a steady state in which iron absorption and
supply is diminished but matches the requirement for reduced
erythropoiesis.
The mechanism of these changes in iron metabolism has not
been established. Iron metabolism is also altered in griseofulvin-
induced protoporphyria.23 Because serum transferrin is in¬
creased in FechmlPas BALB/c mice and correlates with erythro¬
cyte protoporphyrin concentration, it has been suggested that
protoporphyrin may act as a signal to increase hepatic trans¬
ferrin synthesis when iron supply to erythroid cells is insuffi
cient and thus modulate iron metabolism." We found only a
slight increase in TIBC (Table 1) and no correlation with
erythrocyte protoporphyrin. Alternatively, FECH deficiency
within enterocytes might affect duodenal iron transport by
altering enterocyte mitochondrial iron status.24
Finally, measurement of sTfR, in addition to sFn, may help to
distinguish those patients in whom the anemia of EPP is exacer¬
bated by iron loss and who might benefit from iron replacement.25
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Background Vitamin D, produced by the action of sunlight on skin, is an important
hormone for calcium homeostasis and has been implicated as tumour-protective
agent. Some previous studies of photosensitive patients who actively avoid sun¬
light have failed to show convincing evidence of vitamin D insufficiency.
Objectives The aim of this study was to characterize the vitamin D status of a large
cohort of patients with erythropoietic protoporphyria (EPP).
Methods U.K. patients with EPP were recruited prospectively and seen locally by a
single study investigator. A blood sample was taken for vitamin D assay. All
blood analyses were performed in the same laboratory.
Results A cohort of 201 patients with known EPP was seen over a 7 month period
between January and July. Thirty-four patients (1 7%) were deficient in vitamin
D and 126 (63%) had insufficient vitamin D. Both insufficiency and deficiency
were significandy associated with the total erythrocyte protoporphyrin concentra
tion and inversely with the time in minutes to the onset of symptoms following
sunlight exposure.
Conclusions This is the first report of significant levels of vitamin D deficiency and
insufficiency in a large cohort of patients with a photodermatosis. Such individu¬
als are at risk of associated adverse events. In future, clinicians should consider
monitoring 25-hydroxyvitamin D levels and instigating oral supplementation or
dietary advice if appropriate.
Vitamin D is an essential fat-soluble hormone required for
bone integrity and calcium homeostasis.1 It may also protect
against the development of other conditions such as diabetes
mellituG, hypertension, tuberculosis and some malignancies.2"^
Approximately 90% of requisite vitamin D is formed within
the skin as a result of sunlight photolysis of 7-dehydrocholes-
terol by ultraviolet (UV) B radiation, before a temperature-
dependent isomerization to cholecalciferol.5 Previous studies
of photosensitive patients with xeroderma pigmentosum (XP)
and Smith-Lemli-Opitz syndrome (SLOS) who actively avoid
sunlight have failed to show convincing evidence of vitamin D
insufficiency.6,7
Erythropoietic protoporphyria (EPP, MIM 177000) is a rare
photodermatosis with systemic complications which results
from an inherited partial deficiency of ferrochclatasc, the ter
minal enzyme of haem biosynthesis. Excessive formation of its
substrate, protoporphyrin IX, results in protoporphyrinaemia
and accumulation in erythrocytes, plasma, skin and liver, prior
to excretion in the bile.8 Protoporphyrin can absorb light
energy, damaging surrounding tissues through the generation
of free radicals and clinically manifesting as painful photo¬
sensitivity within minutes of skin exposure to sunlight. The
discomfort ma)' last for several hours, cutaneous tolerance to
sunlight may be reduced for several days afterwards and come
individuals experience the symptoms even on cloud}' days and
in winter.9 Management of EPP is based mainly on mini¬
mizing the acute adverse effects of sunlight by use of broad-
spectrum sunscreens, occlusive clothing and behavioural
measures to avoid direct sunlight.
Patients and methods
During a prospective study of U.K. patients with EPP,9 we
sought to characterize their vitamin D status. A cohort of 210
outpatients was seen over a 7-month period between January
and July, representing a period with minimal and maximal
vitamin D levels in normal populations,10 at latitudes ranging
from 51°N to 57-.5°N. Each provided a blood sample for vita¬
min D assay and all analyses were performed in the same lab¬
oratory using a commercial radioimmunoassay (Diasorin Ltd,
© 2008 The Authors
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Wokingham, U.K.). Serum 25-hydroxyvitamin D concentra¬
tions of < 10 and < 20 ng mL-1 (25 and 50 nmol L_1) were
used to identify those who were vitamin D deficient (VDD) or
insufficient (VDI).11 Nine patients were withdrawn from the
analysis due to nonwhite skin coloration (n = 2: both VDI),
systemic malignancy (n = 2), renal failure (n = 1), hepatic
failure (n = 2), posl-orthotic liver transplant (n = 1) and a
patient taking ergocalciferol (n = 1). Statistical analysis was
performed using the Mann-Whitney test.
Eighty per cent of the cohort regularly avoided sunlight,
87% wore long-sleeved occlusive clothing daily, 9% used a
sunscreen at least once daily all year and 68% used sunscreen
once daily or more frequently in sunny weather. No patients
had ever had their vitamin D status checked by their phys¬
icians. Five patients reported coexistent osteoporosis, but other
than analgesics, were not taking any other treatments for this.
Three patients look fish liver oils daily as a health supplement,
one of whom also took a calcium supplement. One further
patient took calcium supplementation. Excepting a nonvegan
vegetarian, all patients were omnivores; a more detailed die¬
tary history was not taken.
Results
The mean serum hydroxyviiamin D was 18-32 ng mL-1
(range 4-9-51-4, quartiles 11-5, 23-5). One hundred and
twenty-six patients (63%; 58 males, 68 females) were VDI, of
whom 34 were VDD (17%; 15 males, 19 females). Of three
patients taking dietary fish oil supplements, one was VDI. Of
the twenty-one patients receiving UVB phototherapy to induce
'hardening' of their skin to sunlight sensitivity, only six
(29%) were VDI and none was VDD.
The mean monthly serum 25-hydroxyvitamin D rose over
the study period January to July from 15-5 to 21-3 ng mL"1
(Fig. 1). In the winter months of January and February 70%
of patients (19 of 27) were VDI and 44% (seven of 27) were
VDD: in the summer months of June and July 45% (34 of
75) were VDI and 37% (28 of 75) VDD. There appeared to
be a slightly smaller proportion of children aged 1 6 years or
under who were VDI or VDD compared with the overall
population [three of 34 (11%) vs. 18 of 92 (20%)]. One
hundred and eighty-one complete sample sets were available
for analysis of calcium, phosphate and parathyroid hormone
(PTH) biochemistry. Thirteen patients (7%) were deficient in
adjusted serum calcium (11 VDI, of whom three were VDD)
and 41 (23%) had an elevated serum phosphate (21 VDI, of
whom three were VDD). Hyperparathyroidism was seen in 12
patients, of whom nine were VDI (two VDD) and the remain¬
ing three had serum 25-hydroxyvitamin D at the lower end of
the normal range, al between 21 and 23 ng mL"1.
Statistical analysis suggested that being VDI was associated
with total erythrocyte protoporphyrin (TEP) (P = 0-009) and
inversely associated with the time in minutes to the onset of
symptoms following sunlight exposure (P = 0-008). Being
VDD was associated with the age at symptom onset








~i 1 1 r 1—~—r
Jan Feb Mar Apr May Jun Jul
Month
Fig 1. Boxplot of serum 25-hydroxyvitamin D by month of sampling
(deficiency < 10 ng ml/ , insufficiency < 20 ng mL"'). The boxes
contain results between the upper and lower quartiles and the dark
bars within the boxes represent the median value. The whiskers
represent smallest and largest values which are not outliers, while the
circles are oudiers (more than 1*5 box lengths above or below the
box) and the stars extreme outliers (more than 3 box lengths above
the box).
symptom onset (P = 0-03). There was no association with
calcium deficiency, raised phosphorus or elevated PTH,
although elevated PTII approached significance with VDI status
(P = 0-57).
Discussion
We have shown a high prevalence of VDD and VDI status
in a large cohort of patients with EPP, whose main risk
factors were latitude of residence and their photodermatosis.
In keeping with previous findings, we demonstrated an
increase in median 25-hydroxyvitamin D between winter
and summer.7'10'12,13 However, a sizable proportion was
VDI even in summer, implicating the photodermatosis and
sun-avoidance measures as the most plausible explanation,
and supporting the demonstrated association with sensitivity
and TEP.
Although previously recognized in cases reports, studies of
photosensitive populations with XP and SLOS, and normal
populations using sunscreens, have not shown similar levels of
vitamin D insufficiency. Explanations include low study
sensitivities due to smaller patient numbers, residency in sun¬
nier environments, lack of skin discomfort in XP (an efficient
prompt for rigorous sunlight avoidance in EPP), or the pres¬
ence in SLOS of abnormally high concentrations of the vitamin
D precursor, 7-dehydrocholesterol.
Since completion of this study, controversy over the correct
values of the 25-hydroxyvitamin D normal ranges has led to
© 2008 The Authors
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our laboratory now using 30 ng mL-1 as the lower end of the
normal range, increasing the proportion of VDI patients in
our cohort to 91 %. The findings of this study suggest that a
sizeable proportion of an EPP cohort is VDI and at risk of
important clinical outcomes. Treatment with oral calcium and
vitamin D increases bone mass and reduces the risk of frac¬
tures,14,15 so clinicians advising patients with EPP about
sunlight avoidance should consider monitoring both serum
25-hydroxyvitamin D and PTH, and giving supplementation
throughout the year. As the cutaneous synthesis of vitamin D
is initiated by UVB-mediated photolysis of 7-dehydrocholes-
terol, use of UVB phototherapy to reduce symptoms appears
to have additional therapeutic benefit.
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Skin Cancer, Sunlight and Vitamin D Deficiency
S. Alexander Holme, Consultant Dermatologist Dr Alexander V Anstey
Queen Margaret Hospital, Dunfermline. KY12 OSU
Sir,
The BMJ editorial by Professor Michael Holick on Vitamin D deficiency highlights a dilemma for clinicians and public health physicians when
advising patients and the public on sun exposure. [1] Too much sun is the main risk factor for skin cancer; on the other hand, too little sun
may lead to vitamin D deficiency. Hollick has reported previously that white populations may become vitamin D deficient in winter and that
only minimal exposure to ultraviolet (UV) radiation (5-10 minutes sun exposure three times a week of hands, arms and face) is required
during spring, summer and autumn to reverse this. [2] The message from the articles by Hollick (1] and Sievenpiper [3] highlighting the
consequences of vitamin D deficiency should not confuse the health promotion message emphasising the importance of UV protection to
prevent skin cancer. Non-melanoma skin cancer is now the UK's commonest malignancy with a steeply rising incidence, and malignant
melanoma is the commonest cancer in the 15-34 year group. [4]
In his editorial figure, Hollick suggests sunscreen use to be a cause of vitamin D deficiency. This is misleading as there is no convincing
evidence to support this claim in normal populations not actively avoiding sunlight; although sunscreen use does appear to cause a modest
reduction in 25-hydroxyvitamin D levels. [5,6] In cases where sunscreen use has been implicated in deficiency, other risk factors such as
ethnic skin pigmentation, institutional residency, age or occlusive clothing, have also been present. Two recent publications have reported an
additional risk factor for vitamin D deficiency to be the presence of severe photosensitivity such as occurs in erythropoietic protoporphyria or
cutaneous lupus erythematosus. [7,8] It is individuals with risk factors for vitamin D deficiency, such as the Asian women described by
Sievenpiper, who should be targeted for education or assessment, not the white population in whom the risk of skin cancer is higher.
Dr S. Alex Holme FRCP. Consultant Dermatologist, Queen Margaret Hospital, Whitefield Road, Dunfermline. KY12 OSU
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REPORT
C-Termina! Deletions in the ALAS2 Gene Lead
to Gain of Function and Cause X-linked Dominant
Protoporphyria without Anemia or Iron Overload
Sharon D. Whatley,1-9 Sarah Ducamp,2-3-9 Laurent Gouya,2>3 Bernard Grandchamp,3-4
Carole Beaumont,3 Michael N. Badminton,1 George H. Elder,1 S. Alexander Holme,5 Alexander
V. Anstey,5 Michelle Parker,6 Anne V. Corrigall,6 Peter N. Meissner,6 Richard J. Hift,6 Joanne
T. Marsden,7 Yun Ma,8 Giorgina Mieli-Vergani,8 Jean-Charles Deybach,2-3,* and Herve Puy2-3
All reportedmutations in AI,AS2, which encodes the rate-regulating enzyme oferythroid heme biosynthesis, cause X-linked sideroblastic
anemia. We describe eight families with ALAS2 deletions, either c.1706-1709 delAGTG (p.E569GfsX24) or c.1699-1700 delAT
(p.M567EfsX2), resulting in frameshifts that lead to replacement or deletion of the 19-20 C-terminal residues of the enzyme. Prokaryotic
expression studies show that both mutations markedly increase ALAS2 activity. These gain-of-function mutations cause a previously
unrecognized form of porphyria, X-linked dominant protoporphyria, characterized biochemically by a high proportion of zinc-proto-
porphyrin in erythrocytes, in which a mismatch between protoporphyrin production and the heme requirement of differentiating
erythroid cells leads to overproduction of protoporphyrin in amounts sufficient to cause photosensitivity and liver disease.
Each of the seven inherited porphyrias results from a partial
deficiency of an enzyme of heme biosynthesis. Mutations
that cause porphyria have been identified in all the genes
of the heme biosynthetic pathway except ALAS1 and
ALAS2, which encode the ubiquitously expressed
(ALAS1) and erythroid-specific (ALAS2) isoforms of mito¬
chondrial 5-aminolevulinate synthase (ALAS) (EC
2.3.1.37), the initial, rate-regulating enzyme of the path¬
way.1 ALAS2 is essential for hemoglobin formation by ery¬
throid cells, and ALAS1 cannot replace this function. No
mutations have been identified in ALAS1, but pathogenic
mutations in the 14.4 kb, 11 -exon-containing ALAS2 cause
X-linked hereditary sideroblastic anemia (XLSA [M1M
301300]) with iron overload.2
Erythropoietic protoporphyria (EPP [MIM 177000]) is an
inherited disorder caused by partial mitochondrial defi¬
ciency of ferrochelatase (FECH) (EC 4.99.1.1), the terminal
enzyme of heme biosynthesis. Accumulation of protopor¬
phyrin IX in erythrocytes and other tissues leads to lifelong
photosensitivity and, in about 2% of patients, severe liver
disease.3 Most patients have autosomal-dominant EPP
(dEPP), in which clinical expression normally requires co-
inheritance of an FECH mutation that abolishes or mark¬
edly reduces FECH activity trans to a hypomorphic FECH
IVS3-48C allele carried by about 11% of western Euro¬
peans.4 About 4% of families have autosomal-recessive
EPP.4 However, mutational analysis fails to detect FECH
mutations in about 7% of EPP families, of which about
3% are homozygous for the wild-type FECH TVS3-48T
allele,5 suggesting possible involvement of another locus.
Within this subgroup of families with mutation-nega¬
tive EPP, we studied eight families in which at least one in¬
dividual had acute photosensitivity clinically indistin¬
guishable from that of dEPP. These families were
identified through referral to specialist porphyria centers
or during surveys of EPP in the UK6 or South Africa7 and
were of western European (four families), Jewish, north
African, indo-Asian, or Sudanese (one family each) ances¬
try. Our study was conducted in accord with the World
Medical Association Declaration of Helsinki ethical princi¬
ples for medical research involving human subjects and its
subsequent amendments. All patients or their parents gave
informed consent to investigation. Prior ethical approval
was obtained for patient surveys.6,7
Genomic DNA was extracted from whole blood. For se¬
quencing of ALAS2, FECH, and SLC25A37 (MIM 610387)
(GenBank accession numbers: human ALAS2
[NM000032.3], FECH [NM000140], and SLC25A37
[NM0166112] cDNAs and ALAS2 [NT011630] and
SLC2SA37 [NT023666] genes), all exons and their flanking
sequences were amplified by polymerase chain reaction
(PCR) (primers and conditions are available from the au¬
thors). PCR-amplified double-stranded DNA was purified
from agarose gels with the QIAquick gel extraction kit
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Table 1. Erythrocyte Porphyrins, Hematological Measurements, and Serum Iron Indices in Patients with X-Linked Dominant
Protoporphyria and Their Unaffected Relatives
XLDPP Unaffected Relatives


































Measurements are medians and ranges. *p = 0.02 versus unaffected male relatives; **p = 0.04 versus unaffected relatives; differences between other
groups are not significant. Total porphyrin is expressed as n-fold increase (times upper limit of normal); for 17 patients with XLDPP in whom total eryth¬
rocyte porphyrin was measured by the same method,8 the median concentration was 51.2 pmol/liter, range 20.1-195.6 pmol/liter (reference range: less
than 1.7 pmol/liter). Values in italics include male and female subjects.
(QIAGEN, Cawley, UK) before being cycle sequenced with
fluorescent ddNTPs (BigDye) and an ABI Prism 3130XL Ge¬
netic Analyzer (PE Biosystems, Warrington, UK). We con¬
firmed the presence or absence ofmutations by sequencing
both strands. Genotyping with FECH intragenic single-
nucleotide polymorphisms (SNPs),4 and microsatellite
markers for FECH7 and ALA82 was performed on the ABI
PRISM 3100 automated sequencer. The ALAS2 microsatel¬
lite markers (16AG at position 54992283, 17GT at position
55066050, and 23AC at position 55535957) were identified
at the UCSC genome bioinformatics site (Santa Cruz, CA;
see Web Resources). Results were analyzed with the ABI
PRISM GeneMapper software version 3.0. Erythrocyte por¬
phyrins were measured as previously described 7,8 The per¬
centage of zinc protoporphyrin was calculated from floures-
cence emission spectra of ethanol8 or acetone9 extracts of
erythrocyte haemolystaes. FECH activity was measured as
described4 or indirectly from the amount of protoporphy¬
rin formed from 5-aminolevulinate in the presence and
absence of Fe2+.10 Differences between quantitative vari¬
ableswere assessedwith theMann-Whitney test, and those
between proportions were assessed with Fisher's exact test.
We differentiated patients in these eight families from
others with FECH mutation-negative EPP by showing
that the percentage of erythrocyte protoporphyrin present
as its zinc chelate (19%-65%, median 44%) was markedly
greater than in patients with dEPP (4%-13%, median
8%). Erythrocyte protoporphyrin concentrations were
also higher in our patients, in whom they were increased
24-fold (range: 6- to 103-fold) (Table 1) compared with
14-fold (range: 4- to 44-fold) in 171 patients with dEPP
(p < 0.001). In one patient with iron deficiency, erythro¬
cyte protoporphyrin increased markedly (101-fold) but
then decreased as iron stores were replenished (Figure 1).
Lymphocyte FECH activity, measured in ten patients,
ranged from 74%-106% (median 85%) of the mean nor¬
mal value, indicating that protoporphyrin accumulation
was not caused by FECH deficiency resulting from a muta¬
tion of the ubiquitously expressed FECH gene. We further
eliminated involvement of FECH by using intragenic
SNPs4 or microsatellite markers7 to show that protopor¬
phyrin accumulation did not segregate with FECH haplo-
types in two families; other families were uninformative
or not tested. Because abnormal expression of mRNA for
mitoferrin has been implicated in the pathogenesis of
a similar form of protoporphyria (Shaw et al., Blood 108,
ASH Annual Meeting Abstracts, 6a), we sequenced all
exons of SLC2SA37 and their flanking sequences in all
eight probands but were unable to identify any disease-
specific mutation.
Parent-child transmission of overt disease is uncommon
in EPP.11 Our families were unusual in showing an appar¬
ent dominant pattern of inheritance with an absence of
father-son transmission, which suggested X-linkage (Fig¬
ure 2). We therefore investigated two candidate genes
that are located on the X chromosome and are involved
in heme formation, GATA1 (MIM 305371) (data not
shown) and ALAS2. Protoporphyrin accumulation segre¬
gated with an X chromosome haplotype defined by micro-
satellite markers around ALAS2 in three families (data not
shown). Sequencing of genomic DNA identified two differ¬
ent deletions (c.1706-1709 delAGTG in six families;
c.1699-1700 delAT in two families) in ALAS2 exon 11, an
exon that is present in all ALAS2 transcripts.12 The frame-
shifts produced by these deletions lead to predicted alter¬
ations of the 19-20 C-terminal amino acids of ALAS2 (Fig¬
ures 3A and 3B); either deletion (delAT) or replacement by
a 23 residue sequence (delAGTG) that extends the enzyme
by 4 amino acids and alters the predicted secondary
structure (Supplemental Data; Figure 1). These mutations
segregated with photosensitivity (LOD score 7.8) and
were absent from 129 unrelated EPP patients (106
dEPP; 23 F£C7/-mutation-negative EPP) and 100 normal
chromosomes. The delAGTG mutation occurred on five





























different haplotypes, indicating that it has arisen on at
least five separate occasions, whereas the two delAT fami¬
lies, both from southwest England, had the same back¬
ground haplotype and may come from a single extended
family (data not shown). These findings show that these
deletions in ALAS2 cause a previously unrecognized X-
linked dominant protoporphyria (XLDPP) that, in contrast
to dEPP and other autosomal-dominant porphyrias,1 has
close to 100% penetrance (Figure 2).
All previously described mutations in ALAS2 have
caused XESA (Human Gene Mutation Database), including
a missense mutation (S568G) in the region lost or replaced
Figure 1. Treating Iron Deficiency
Decreases Erythrocyte Protoporphyrin
Concentrations
Iron deficiency caused by bleeding from




? null ALAS2 mutations causing XLSA
3 have been embryonically lethal in
2> males.2 In our families, both sexes
g were affected, and patients had nei¬
ther anemia nor iron overload (Table
1). Instead, there was some evidence
of diminished iron stores, particularly
in males (Table 1). Similar abnormali¬
ties have been observed in dEPP14 and
might result from accumulation of
protoporphyrin rather than FECH
deficiency.15 Five (17%) patients had
overt liver disease, suggesting that
XLPP, like autosomal recessive EPP3,4, carries a higher risk
of liver disease than dEPP. Liver disease was more common
in males (p = 0.008), and one obligate carrier was asymp¬
tomatic (Figure 2; family G, 114), but otherwise we found
no evidence that X inactivation led to milder disease in
females. Erythrocyte protoporphyrin concentrations in
photosensitive patients were not significantly different be¬
tween the sexes (Table 1). These data show that disruption
of the C-terminal region of ALAS2 leads to the production
of protoporphyrin in excess of the amount required for
hemoglobinization and in quantities sufficient to cause














in our patients. Previously reported frameshift or other FECH activity; this is a situation unique in human disease.
IV
Family E Family F Family G Family H
Family A Family B Family C Family D Figure 2. Pedigrees of Eight Families
with FFCW-Mutation-Negative Protopor¬
phyria
I "T* " | ZL J"T°' ^ Green circles and squares represent
II 'iptiVrB 3ia d 3ja©-y-0J patients with photosensitivity. Red circles
and squares represent patients with photo¬
sensitivity and clinically overt liver
disease. Protoporphyric liver disease was
confirmed at autopsy or by needle biopsy
in all these patients except patient II
(family H), for whom a diagnosis has not
been established. Patient 113 (family E)
I has been reported previously.23 Clinical
information was not obtainable for pa¬
tients C I, 3 and 4 or E I, 1 and 2.
Black dots within circles or squares
indicate individuals in whom either the
delAGTG (families A-E, H) ordelAT (families
F and G) ALAS2 mutations were identified.
Crosses within circles or squares indicate individuals in whom sequencing excluded the presence of an ALAS2 mutation. The absence of
a black dot or cross indicates an individual from whom a DNA sample was not available for analysis. The L0D score for linkage between
photosensitivity and the ALAS2 mutation was calculated for families A-E.
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TTTGAGCTCGAGTGAGTGGG TTTGAGCTCATGAGTGAGTGGG TT TGAGCTCATGAGTGGG
del AT VSVAACNFCRRPVHFELFX
del AGTG VSVAACNFCRRPVHFELMSGNVPTSGTWGPSMSPPMPEKPAAX







wt del AT del AGTG del AT del AGTG Del AT Del AGTG
Figure 3. C-Terminat Deletions in ALAS2 Cause X-Linked Dominant Protoporphyria
(A) Sequence analysis of genomic DNA from male patients showing deletions in the ALAS2 gene.
(B) Predicted effects of deletions on ALAS2 C-terminal sequences.
(C-E) Prokaryotic expression of wild-type and mutant ALAS2 enzymes: Rates of formation of ALA (C) and porphyrin (D) by bacterial
lysates; means and ranges for three experiments are shown. (E) Porphyrin fluorescence (UVA light) in bacterial pellets.
To investigate the effect of the mutants on ALAS2 ac¬
tivity, we expressed both mutant enzymes in Escherichia
coli. PCR-amplificd cDNAs for the dclAT and delAGTG
mutations were introduced into pMALc2-AE2 (ALAS2
WT)16 by site-directed mutagenesis with the Quick-
Change Site Directed Mutagenesis Kit (Stratagene, La
Jolla, GA) and the following oligonucleotides: delAT
sense 5'-ACACTTTGAGCTCGAGTGAGTGGGAACG-3' and
delAGTG sense 5'-CACTTTGAGCTCATGAGTGGG AACG
TfCCTACTTGC-3' and their complementary antisense
oligonucleotides. We confirmed the sequences of the re¬
sulting clones for the entire coding region, and we se¬
quenced each mutated ALAS2 cDNA to ensure that
only the desired mutation had been introduced and
that the remainder of the sequence was correct. Expres¬
sion constructs were transfected into Escherichia coli
BL21 (Invitrogen), and overnight cultures were grown
in LB (Lennox L Broth Base, Invitrogen) media with
100 mg/ml ampicillin (PANPHARMA).The next day,
20 ml cultures in LB/ampicillin media were initiated
with the overnight cultures and grown to 1.2 A600 units.
Induction with 0.1 mM isopropyl (i-D-thiogalactopyrano-
side was performed in LB/ampicillin media for 4 hr at
22°C. Cells were pelleted at 2500 rpm for 10 min. The
recombinant bacteria were grown, and ALAS2 activities
of controls and mutant enzymes were determined in bac¬
teria lysates as previously described but with minor
modifications.16 Enzyme activities were expressed in
pmol of 5-aminolevulinate (ALA) and porphyrin/hr/mg
protein at 37°C.
These expression studies showed that both deletions
markedly increase ALAS2 activity and that some of the
ALA that is produced is further metabolised to porphyrin
(Figures 3C-3E). E. coli BL21 transformed with mutant
plasmids accumulated porphyrin (mutant, 5000 nmol/g
protein; wild-type, less than 8 nmol/g) without the addi¬
tion of substrates for ALAS2. T hese findings of a gain of
function strongly suggest that protoporphyrin and its
zinc chelate accumulates in XLDPP because the rate of
ALA formation is increased to such an extent that insertion
of Fe2+ into PP by FECH becomes rate limiting for heme
synthesis. Gain-of-functionmutations have not previously
been identified in genes of the heme biosynthetic path¬
way1 but, as in our families, characteristically cause domi¬
nant disorders.
Excretion of ALA and other protoporphyrin precursors is
normal in XLDPP (data not shown), indicating that most of
the ALAproduced byerythroid cells ismetabolized to proto¬
porphyrin. Some is used for hemoglobin synthesis, but the
fate of the rest is uncertain. Because FECH activity in ery¬
throid cells exceeds that required for hemoglobin synthe¬
sis,2 some may be converted to free heme and exported
from the cytoplasm.17 However, the accumulation of zinc
protoporphyrin in XLDPP, indicating that FECH is using







































































Figure 4. Comparison of C-terminal Sequences of ALAS enzymes
(A) Alignment of ALAS C-terminal sequences.
(B) Phylogenetic tree showing relationships between ALAS genes constructed with ClustalW.
its alternative metal substrate, suggests that formation of
excess heme can be prevented by lack of available iron.
The phenotype of iron deficiency in XLDPP (Figure 1)
closely resembles that of lreb2~'~ mice, in which deletion
of iron-regulatory protein 2 (IRP2) leads to overexpression
of ALAS2, erythroblast iron deficiency, and microcytic ane¬
mia.18 In the patient whose clinical course is shown in
Figure 1, iron repletion decreased protoporphyrin accumu¬
lation and corrected the anemia. However, zinc protopor¬
phyrin did not decrease, as it does in uncomplicated iron
deficiency.19 This might indicate that the synthesis of zinc
protoporphyrin becomes limited by intra-mitochondrial
availability ofZn2+when the protoporphyrin pool is greatly
expanded.18 These findings are consistentwith the hypoth -
csis that the regulatory system that enables efficient
utilization of iron for heme synthesis duringcrythroid differ¬
entiation2" allows matching of erythroblast iron uptake to
intra mitochondria] heme synthesis to be maintained even
when excess protoporphyrin is present. The mechanism
bywhich this is achieved is unknown but might involve reg¬
ulation of transferrin receptor-1 expression in erythroblasts
through heme-mediated degradation of IRP2.21
The 26 C-terminal amino acids of ALAS2 are highly con¬
served and have diverged from ALAS1 (Figure 4), which
suggests that this sequence might have an important, but
unknown, erythroid-specific function. During erythropoi-
esis, tight coordination of substrate supply to FECH nor
mally prevents accumulation of toxic amounts of pro
toporphyrin. Coordination is largely achieved through
iron-dependent post-transcriptional regulation of synthe¬
sis of ALAS2.2 This system fails in XLDPP because the
mutations that we have described greatly increase ALAS2
activity. A possible mechanism might be stabilization
against degradation or an intrinsic increase in specific ac
tivity. This C-terminal sequence is not present in ALASRc,
the only ALAS for which the crystal structure has been
reported.22 Sequence similarities between ALASRt and
human ALAS222 suggest that it is not directly involved in
pyridoxal 5-phospate-dependent catalysis. Our findings
indicate that it modulates enzyme activity, but the mocha
nism of this effect remains to be determined. The discovery
of gain of function mutations in ALAS2 identifies a prcvi
ously undefined type of human porphyria, provides new
information about the regulation of substrate supply for
heme synthesis during erythroid differentiation, and iden
tifics a potential tool for increasing orythroid heme synthe
sis in experimental systems.
Supplemental Data
Supplemental Data include one figure, available online at http://
www.ajhg.org/.
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ORIGINAL ARTICLE
Seasonal Palmar Keratoderma in Erythropoietic
Protoporphyria Indicates Autosomal Recessive
Inheritance
S. Alexander Holme1, Sharon D. Whatley2, Andrew C. Roberts2, Alexander V. Anstey1, George H. Elder2,
Russell D. Ead3, M. Felicity Stewart4, Peter M. Farr5, Helen M. Lewis6, Nicholas Davies7, Marion I. White8,
R. Simon Ackroyd9 and Michael N. Badminton2
Erythropoietic protoporphyria (EPP) is an inherited disorder that results from partial deficiency of ferrochelatase
(FECH). It is characterized clinically by acute photosensitivity and, in 2% of patients, liver disease. Inheritance is
usually autosomal dominant with low penetrance but is recessive in about 4% of families. A cross-sectional
study of 223 patients with EPP in the United Kingdom identified six individuals with palmar keratoderma. We
now show that these and three additional patients, from six families, have an inherited subtype of EPP which is
characterized by seasonal palmar keratoderma, relatively low erythrocyte protoporphyrin concentrations, and
recessive inheritance. No patient had evidence of liver dysfunction; four patients had neurological
abnormalities. Patients were hetero- or homoallelic for nine different FECH mutations; four of which were
previously unreported. Prokaryotic expression predicted that FECH activities were 2.7-25% (mean 10.6%) of
normal. Neither mutation type nor FECH activity provided an explanation for the unusual phenotype. Our
findings show that palmar keratoderma is a clinical indicator of recessive EPP, identify a phenotype that occurs
in 38% of reported families with recessive FPP that to our knowledge is previously unreported, and suggest that
patients with this phenotype may carry a lower risk of liver disease than other patients with recessive EPP.
Journal of Investigative Dermatology (2009) 129, 599-605; doi:10.1038/jid.2008.272; published online 11 September 2008
INTRODUCTION
Erythropoietic protoporphyria (EPP) is an inherited disease
characterized by life-long acute photosensitivity with mini¬
mal cutaneous signs and occasional liver dysfunction (Todd,
1994; Cox, 2003). It results from partial deficiency of the
enzyme ferrochelatase (FECH) which leads to accumulation
of the photosensitizing pigment, protoporphyrin, in erythro¬
cytes, plasma, skin, and liver. Reduction of FECH activity to
below about 35% of normal is required for protoporphyrin to
1
Department of Dermatology, School ofMedicine, University Hospital of
Wales, Cardiff University, Cardiff, UK;2Department ofMedical Biochemistry
and Immunology, School ofMedicine, University Hospital of Wales, Cardiff
University, Cardiff, UK; 3Department of Dermatology, Hope Hospital,
Salford, UK; "Department of Clinical Biochemistry, Hope Hospital, Salford,
UK;5Department ofDermatology, Royal Victoria Infirmary, Newcastle-upon-
Tyne, UK; ''Department of Dermatology, Selly Oak Hospital, Birmingham,
UK; 7Department of Neurology, Birmingham Muscle and Nerve Centre,
University ofBirmingham NHS Foundation Trust, Birmingham, UK;
BDepartment of Dermatology, Aberdeen Royal Infirmary, Aberdeen, UK and
9Department of Paediatrics and Child Health, Cheltenham General Hospital,
Cheltenham, UK
Correspondence: Dr Michael N. Badminton, Department of Medical
Biochemistry and Immunology, School of Medicine, University Hospital of
Wales, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.
E-mail: badmintonmn@cardiff.ac.uk
Abbreviations: EPP, erythropoietic protoporphyria; FECH, fcrrochclatase
Received 20 March 2008; revised 9 July 2008; accepted 10 July 2008;
published online 11 September 2008
accumulate sufficiently to cause photosensitivity (Nordmann
and Deybach, 1990). In most families, this decrease is
brought about by coinheritance of a hypomorphic FECH
IV53-48C allele trans to a FECH mutation that markedly
decreases or abolishes FECH activity (Gouya et ai, 2002;
Couya et ai, 2006). The hypomorphic allele is present in
13% of the United Kingdom population (Whatley et ai,
2004). In these families, EPP is inherited as a dominant
disorder with low clinical penetrance (Couya et a/., 2002,
2006). More rarely, EPP may be transmitted as an autosomal
recessive trait with photosensitivity resulting from the
presence of FECH mutations on both alleles (Gouya et a I.,
2006). To date, only 12 families with autosomal recessive
EPP have been reported (Lamoril et al., 1991; Sarkany et ai.,
1994a; Poh-Fitzpatrick et ai., 2002; Whatley et al., 2004;
Gouya et al., 2006; Herrero et al., 2007). Recessive EPP
carries a higher risk of liver disease than the dominant form
(Sarkany et al., 1994a; Whatley et al., 2004; Gouya et al.,
2006; Herrero et al., 2007).
Chronic skin lesions in EPP are the result of repeated
episodes of acute photosensitivity. They are restricted to sun-
exposed areas and rarely amount to more than minor pitting
and scarring of the face with some waxy thickening of the
skin, particularly over the joints on the backs of the hands
(Schmidt eta!., 1974; DeLeo eta!., 1976; Todd, 1994; Holme
et al., 2006). In a cross-sectional study of 223 patients with
© 2009 The Society for Investigative Dermatology www.jidonline.org 599
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EPP (Holme et al., 2006), six patients were found to have
palmar keratoderma; a chronic skin condition that had not
previously been recognized as a feature of EPP. Here we show
that these and three additional patients have a previously
unreported inherited subtype of EPP characterized by palmar
keratoderma, relatively low erythrocyte protoporphyrin con¬
centrations and autosomal recessive inheritance.
RESULTS
Palmar keratoderma is an uncommon feature of EPP
We identified nine patients with EPP and palmar
keratoderma; five males and four females, aged 8-63 years,
from six families (Table 1). Six of these, from five families,
were identified during a cross-sectional study of the
clinical features of 223 patients with EPP in the UK, of
whom 193 were unrelated, (Holme et al., 2006), giving
prevalences for palmar keratoderma in EPP of 2.7% for all
patients and 2.6% (95% confidence interval: 1.0-5.1%) for
families.
In all patients, hyperkeratosis had been present since early
childhood and in seven patients had developed before the
diagnosis of EPP was made. In three patients the development
of mild palmar keratoderma was preceded during infancy by
a scaly rash, mainly on the dorsum of the hands, initially
thought to be eczema; a third patient has areas of
hyperpigmentation and lichenified skin over her knees, neck,
and elbows which were present before the onset of
photosensitivity and have persisted. Hyperkeratosis was
worse in summer and often resolved in winter. In one
patient, occlusion of the skin with a plaster cast for 6 weeks
following a wrist fracture led to almost complete resolution of
the keratoderma.
The hyperkeratosis ranged in severity from waxy kerato¬
derma over the whole palm to mild hyperkeratosis of the first
interdigital web (Figure 1; Table 1). Palmar keratoderma was
sharply demarcated at the wrist with, in most cases, minimal
transgredience onto the extensor surface, and without an
erythematous border (Figure 1). Two patients had mild
onycholysis but otherwise nails were not affected. Sweating
appeared unimpaired. All patients had thickened skin over their
knuckle joints, a sign which is present in 35% of 223 UK
patients with EPP (Holme et al., 2006). This thickening was mild
or moderate in severity. No patient with dominant EPP and
thickened knuckle skin, even those with severe thickening and
scarring, showed any evidence of changes on the palmar
surface. Two unrelated patients also had mild plantar hyper¬
keratosis (Table 1). Hyperkeratosis was not particularly marked
at sites of pressure or punctuate in pattern. No patient reported
blistering or hyperhydrosis. Only a very small punch biopsy
from the hand of one patient (patient 2) was examined
histopathologically. The limited amount of epidermis present
was slightly thickened and spongiotic and there were some
prominent upper dermal vessels with a hint of periodic acid
Schiff (PAS)-positive hyaline change. There was not enough
epidermis to determine whether the keratin layer was thickened.
The severity of photosensitivity varied within families but
was similar to that in patients with EPP without keratoderma
(Holme et al., 2006). All became photosensitive between the
ages of 3 and 17 months. Symptoms started within
1-30minutes after exposure to sunlight and quality of life,
assessed by childhood dermatology quality of life index or
dermatology quality of life index scores (Holme et al., 2006),
was severely impaired in the six patients in which it was
measured (mean scores 12, range 5-18).










I Pi F y 1.4 sib1 2.3 Cunflueiil waxy palmar hyperkeratosis with fine peeling;
sharp cutoff at wrists.
P2 M 10 1.0 Sib1 2.0 Hyperkeratosis and peeling of first interdigital web and patchy keratosis
and peeling over palmar surface of digit joints and pulps.
II2 P3 F 58 0.5 sib 7.4 Palmar hyperkeratosis with sharp cutoff at wrist; transgredience to involve
first interdigital web; focal plantar hyperkeratosis with fissuring over
heels and MCT joints
P4 M 52 0.4 sib 6.2 Mild hyperkeratosis of first interdigital web.
III P5 M 27 0.3 15.5 Conflnent palmar hyperkeratosis with peeling; lateral aspects dry, white,
and cracked; slight onycholysis; hyperkeratosis on medial aspect of forefoot
and great toes.
IV P6 M 63 <1 — 7,9 Marked keratosis of first interdigital web and radial border of index fingers
with fissuring at index finger joints.
V P7 F 17 0.25 — 6.8 Waxy keratoderma over the whole palm; mild fine peeling; more obvious
in cummer, regresses in winter; sharp i.ulnff al wrist Nail dystrophy.
VI PR M 13 0.25 sib 10.5 Mild hypeikeratosis of first interdigital web-
P9 F 12 2.0 sib 11.2 MilJ hypeikeratosis of first imerdigiral weh
RBC, red blood cell
'Great grandmother has UPP without keratoderma (see text).
2Consanguineous parontc.
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and biochemical tests of liver function were normal in all
patients, except for one female patient who had a hemo¬
globin concentration of 11.9g(100ml)~1.
Erythrocyte protoporphyrin concentrations are lower in EPP
with keratoderma than in EPP without keratoderma
Erythrocyte porphyrin concentrations in the 9 patients with
keratoderma (median 7.4pmoll~', range 2.0-15.5 pmol I-1;
normal subjects, 0.4-1.7 pmol I-1) were significantly lower
than in 203 patients without keratoderma (median
22.8pmoll_1, range 4.1-159.2 pmol I"1) (P<0.001). When
two members of the same family were affected, erythrocyte
porphyrin concentrations were similar. The percentage of free
erythrocyte protoporphyrin (41-91%) was increased in all
patients but in those with the lowest total erythrocyte
porphyrin was only approximately equal in amount to
zinc-protoporphyrin. In contrast, the plasma protoporphyrin
concentrations in the patients with keratoderma (median
55.0 nmol I-1, range 13.4-115.1 nmoll-1; normal subjects,
less than 10.5 nmol 1~1) did not differ significantly from those
in 11 randomly selected patients with EPP without kerato¬
derma (median 68.4, range 18.8-396.0) whose erythrocyte
porphyrin concentrations ranged from 12.4 to 159.2 pmol I""1
(median 30.1 pmoll-1). Fecal total porphyrin excretion was
substantially increased (median 1,198 nmol g~1 dry weight;
range 523-1,940 nmol g"1; normal subjects, less than
200 nmol g~1) in the seven patients in whom it was
measured, with protoporphyrin accounting for greater than
80% of the total.
Figure 1. Palmar keratoderma in EPP. For clinical details see Table 1; (a)
patient 7, (b) patient 6, (c) patient 2.
Four patients from three families had neurological
abnormalities. Three patients (P7, P8, P9) had slight or
moderately severe cognitive and motor developmental delay,
without regression since early childhood, and one of these
suffered from fits until the age of 2 years. Older siblings in
both families had neither EPP nor developmental delay. One
patient (P4) presented in his early 30s with a spastic
paraparesis that has progressed; extensive investigations to
identify a cause were negative. Hemoglobin concentrations
EPP with palmar keratoderma is inherited in an autosomal
recessive pattern
Three patients had no family history of overt EPP or palmar
keratoderma. In families II and VI, two siblings had EPP with
keratoderma but no other relative had either condition. In
family I, two of three siblings had EPP with keratoderma; the
third had neither condition but their maternal great grand¬
mother had a lifelong history of photosensitivity without
keratoderma. Photosensitivity and keratoderma always oc¬
curred together when more than one member of the same
generation had EPP and overall keratoderma was not reported
in any family member who did not have EPP.
Mutational analysis showed that all patients with EPP and
palmar keratoderma were either compound heterozygous or
homozygous for FECH mutations and that only one patient
(family III) had inherited the hypomorphic FECH IVS3-48C
allele (Table 2). All but one of the mutations were missense;
four of these (c.0302T>C; c.0854A>G; c.0898G>T;
c.0502C>T) are previously unreported. Mutational analyses
of families II and VI have been reported (Whatley et al.,
2004). Both patients in family I were compound hetero-
zygotes for a missense mutation and a mutation
(IVS3 + 2T>G) that is known to impair splicing of exon 3
(Sarkany et al., 1994b). In their maternal grandmother, this
mutation was trans to an FECH IVS3-48C allele; a genotype
that has been identified in other patients with the typical
dominant form of EPP (Whatley SD, unpublished informa¬
tion). Mutational analysis of 184 unrelated patients without
www.jidonline.org 601
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Table 2. EPP with palmar keratoderma: FECH genotypes with predicted FECH activities.
Predicted FECH
Family Allele Mutation Effect FECH IVS3-48 activity (%)
I1 1 C.0302T > C L101P T 2.73
2 IVS3+2T > C Splice defect T
II1 1 c.0416A>T Q139L T 18
2 c.0416A>T Q139L T
111 1 c.0503C>T P168S TorC 5.63
2 C.0854A> C Q28SR C or T
IV 1 C.0820G > A D274N T 5.9
2 c.0898C>T V300L T
V 1 C.0707G > A C236Y T 6.4
2 C.0820G > A D274N T
VI' 1 c.1137C>G K379N T 25
2 C.0707G > A C236Y T
FECH, ferrochelatase.
Previously unreported mutations are shown in bold.
'Both affected siblings had the same genotype.
2
Assuming no activity from the IVS3+2T>G allele.
3
Assuming IVS3-48C cis to P168S (see text). Predicted FECH activity was calculated from data in Table 3 and Whatley et al. (2004).
Table 3. Prokaryotic expression of mutant and wild
type FECH alleles
FECH activity Percent wild-type
FECH allele (nmol h"1 mg-1)1 activity









keratoderma identified 2 additional patients with recessive
EPP; one of whom has been reported previously (Whatley
et al., 2004). The other was homozygous for both a
previously unreported mutation (c.0502C>T; P168L) and
the hypomorphic 1VS3-48C allele.
Five of the eight missense mutations that we identified
were expressed in a prokaryotic expression system and their
effect on FECH activity determined (Table 3). These activities,
together with those previously reported for the three other
missense mutations (Whatley et al., 2004), were used to
calculate the FECH activities in our patients (Table 2) on the
assumption that they were similar to those expressed by these
alleles in human tissues.
DISCUSSION
The combination of palmar keratoderma, a relatively low
erythrocyte protoporphyrin concentration and autosomal
recessive inheritance that we describe here in nine patients
from six families constitutes a hitherto unrecognized subtype
of EPP. Of the 13, 2 patients from 12 families with recessive
EPP described previously (Lamoril et al., 1991; Sarkany et al.,
1994a; Poh-Fitzpatrick et al., 2002; Whatley et al., 2004;
Gouya et al., 2006; Herrero et al., 2007) are also included in
this report (P4, P8). Thus, of the 20 symptomatic patients from
16 families with recessive EPP now reported, 9 from 6
families (45% of patients; 38% of families) have palmar
keratoderma. To date we have not seen a patient with
keratoderma who has not had recessive EPP but more patients
need to be studied before the reliability of palmar kerato¬
derma as a clinical indicator of recessive EPP can fully be
assessed.
Keratoderma was not reported as a clinical feature of
either dominant or recessive EPP (Schmidt et al., 1974;
DeLeo etal., 1976; Lamoril et al., 1991; Todd, 1994; Sarkany
etai, 1994a; Poh-Fitzpatrick etal., 2002; Gouya etal., 2006)
before our study of 223 UK patients with this disorder (Holme
et al., 2006); possibly because it is uncommon and, unless
large numbers of patients are investigated, the association of
EPP with keratoderma may be regarded as chance, as was
initially the case for two of our families. However, it seems
unlikely that keratoderma has been overlooked in all
previously reported patients with recessive EPP. Where
clinical descriptions have been provided (Lamoril et al.,
1991; Sarkany et al., 1994a; Herrero etal., 2007), it has not
been noted and three of the patients with recessive disease
that we have identified (this report; Whatley et al., 2004) did
not have keratoderma.
Our findings are unlikely to be explained by an association
of two separate disorders. First, the keratoderma of EPP differs
clinically from other syndromes that include palmar kerato¬
derma (Itin and Fistarol, 2005). The hyperkeratosis fluctuates,
being worse in summer, tends to be relatively mild on the
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soles, and may almost disappear with complete exclusion of
light; all of which suggest a role for UV exposure in its
etiology. This is supported by the observation that those
with mild involvement have signs only in the first interdigital
web. None of our patients described blistering, suggesting a
nonepidermolytic pattern; none had hyperhydrosis, the
keratosis was not particularly at sites of pressure, and was
not punctuate in pattern. Second, we observed hyperkeratosis
only in recessive EPP and no family showed independent
inheritance of the two conditions. Third, the allelic
heterogeneity of our patients makes close linkage with a
previously undescribed recessive form of keratoderma
very unlikely and fourthly the incidence of inherited
keratoderma in normal populations has been estimated at
between 0.05 (Gulati et al., 1997) and 0.55% (Gamborg
Nielsen et al., 1994) whereas it was present in 2.7% of our
EPP population.
Our patients with keratoderma also differed in other
respects from other patients with autosomal recessive or
dominant EPP. Erythrocyte protoporphyrin concentrations
were lower and, in family I, concentrations were increased by
such a small amount (total erythrocyte porphyrin: 2.0 and
2.3pmoll~1) that the diagnosis would not have been made
without plasma and fecal porphyrin measurements. In spite of
the relatively low erythrocyte concentrations, plasma por¬
phyrin concentrations were the same as in EPP without
keratoderma, photosensitivity was severe and fecal proto¬
porphyrin concentrations were substantially increased. These
features suggest that our patients may be producing proto¬
porphyrin in amounts that are similar to those in EPP without
keratoderma but the explanation for their low erythrocyte
protoporphyrin concentrations is unknown.
There may also be clinical differences apart from
keratoderma. Neurological abnormalities were present in
four of our patients but, apart from a reversible polyneuro¬
pathy after transplantation for protoporphyric liver failure
(McGuire etal., 2005), have not previously been described as
associated with any form of EPP. Developmental delay has
been reported in the recessive or "homozygous" forms of the
dominant acute porphyrias, usually in association with other
neurological and skeletal abnormalities (Elder, 1997), which
were not seen in our patients. Also, 5 of the 12 (42%)
reported patients with autosomal recessive EPP, in which
keratoderma was apparently not present, had liver disease
(Sarkany et al., 1994a; Whatley et al., 2004; Gouya et al.,
2006; Herrero et al., 2007). In contrast, none of our nine
patients had liver dysfunction. This raises the possibility that
patients with keratoderma may be at lower risk of liver
disease than other patients with recessive EPP. Liver disease is
accompanied by markedly increased erythrocyte protopor¬
phyrin concentrations though it is not clear whether these are
present before liver function deteriorates and their role as a
risk factor for liver disease is uncertain (Bloomer, 1988;
Meerman, 2000). The relatively low erythrocyte porphyrin
concentrations and apparently effective biliary elimination of
protoporphyrin shown by our patients may indicate the
presence of a special pattern of porphyrin metabolism
that does not lead to excessive hepatic accumulation of
protoporphyrin. However, only prolonged follow-up can
determine whether a lower risk of liver disease is another
component of the syndrome that we describe.
The unusual phenotype that we describe here is inherited
in a recessive pattern but it is not clear why it is restricted to
this type of EPP or present in only about 40% of such families.
Although FECH mutations on both alleles appear to be
essential for its expression, it seems unlikely that the
phenotype is determined solely by the nature of the mutations
at the FECH locus. There appear to be no features of the
genotypes shown in Table 2 that clearly distinguish them
from those of other patients with recessive EPP (Whatley
et al., 2004; Gouya et al., 2006). Most mutations are
missense; most are on FECH IVS3-48T alleles and the nine
different mutations are not clustered together in the FECH
molecule (Wu et al., 2001). In four families, one of the
mutations has been identified previously either in dominant
EPP (IVS3+2T>G) (Sarkany et al., 1994b) or in recessive
EPP without keratoderma (P168S, D274N) with the D274N
mutation being present in two of our families and in two of
those reported by Gouya et al. (2006). Another mutation
(P168S) was present in two of our patients; a homozygote
without keratoderma where it occurred on a hypomorphic
allele and a compound heterozygote with keratoderma
(Table 2), the only one of our patients with a hypomorphic
allele, presumably again containing this mutation. The four
other mutations have only been reported in EPP with
keratoderma. FECH genotype is the main determinant of
FECH activity in EPP (Gouya et al., 2006). In general, FECH
activities in recessive EPP are lower than in dominant EPP
though the presence on one or both alleles of a missense
mutation that has only a small effect on FECH activity may
lead to activities within the range for dominant EPP (Gouya
et al., 2006). Prokaryotic expression of the missense
mutations predicted FECH activities for our patients with
keratoderma of 1-25% (mean 10%) normal (Table 2 and
Table 3; Whatley et al., 2004), close to the range of 4-29%
reported for autosomal recessive EPP (Gouya et al., 2006).
Thus it seems unlikely that the unusual phenotype shown by




The study was conducted in accordance with the Declaration of
Helsinki ethical principles for medical research involving human
subjects and its subsequent amendments. Prior approval was
obtained from the North West Multicentre Research Ethics Commit¬
tee and 84 local research ethics committees. All patients or their
parents gave informed consent, including consent for publication of
photographs. Six of the patients with palmar keratoderma were
identified during a cross-sectional study of EPP in the United
Kingdom during which the clinical features of 223 patients from 193
families were noted by the same investigator (SAH) (Holme et al.,
2006). Two additional patients were referred to SAH; one other was
a sibling of a patient included in the cross-sectional study. Blood
samples were obtained from all patients with keratoderma and from
203 EPP patients who did not have keratoderma (Holme et al.,
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2006). Quality of life was assessed using dermatology-specific
questionnaires (Holme et al., 2006).
DNA analysis
Genomic DNA was extracted from whole blood using the QIAamp
DNA purification kit (Qiagen, Crawley, UK). For identification of
FECH mutations and SNPs, all exons with 20-300 bp flanking
sequence and 1,300 bp of the promoter region of the FECH gene
were PCR amplified (primers and conditions are available from the
authors) and sequenced. For sequencing, PCR-amplified double-
stranded DNA was purified from agarose gels using the QIAquick gel
extraction kit (Qiagen) before being cycle sequenced using
fluorescent ddNTPs (BigDye) and an ABI Prism 3100 Genetic
Analyzer (PE Biosystcms, Warrington, UK). The presence or absence
of mutations was confirmed by sequencing both strands. Partial or
complete FECH gene deletions were excluded in apparent homo-
zygotes by quantitative gene dosage analysis (Wood et al., 2006).
Nucleotides are numbered from the cDNA sequence of human
FECH (GenBank accession number D00726) with the A of the ATG
initiation codon as " + 1".
Prokaryotic expression of missense mutations
The effect of mutations on FECH activity was determined using the
bacterial expression vector pHisTF20E (Burden et al., 1999).
Mutations were created using the Quickchange mutagenesis
protocol (Stratagene, Stockport, Cheshire, UK) with 50 ng of vector
and 12 cycles of 30seconds denaturation at 95°C, 30seconds
annealing at 55 aC and 8 minutes extension at 68 °C. Primer
sequences are available from the authors. After digestion with Dpnl
to eliminate the template vector DNA, the PCR products were used
to transform chemically competent E. coli JM109. Colonies were
screened by automated fluorescent DNA sequencing.
For each mutation, a single bacterial colony was grown in 5 ml of
Luria-Bertani broth containing 100pgml_l carbenicillin for 6hours.
A 25 pi aliquot was then used to inoculate 25 ml Luria-Bertani
(lOOpgmU1 carbenicillin) and the culture grown at 37 °C for
18hours. Cells were harvested by centrifugation at 6,000 g for
15 minutes and resuspended in 1.5 ml of 50mM Tris/HCI (pH 7.6)
containing 20% glycerol and 1 mM phenylmethylsulphonyl fluoride.
Cells were disrupted by sonication on ice (3 x 30seconds) and
centrifuged at 13,500g for 2 minutes. The supernatant, which
contains the recombinant FECH, was stored at —70 °C. FECH
activity was determined as described by Gouya etal. (2006). A blank
without cell lysate was included and endogenous bacterial FECH
activity was assayed using an empty vector control. Protein
concentrations were determined using the BCA protein assay (Pierce,
Cramlington, Northumberland, UK).
Other methods
Porphyrins in erythrocyte, plasma, and feces were determined by
standard methods (Deacon and Elder, 2001). Percentages of
protoporphyrin and its zinc chelate were determined by fluores¬
cence emission spectroscopy of ethanol extracts of whole blood,
using protoporphyrin and zinc-protoporphyrin as standards.
Statistical methods
Data were analyzed using Microsoft Excel and Minitab v 13.
Measurements were expressed as medians and ranges. The
significance of differences between quantitative variables was
assessed by the Mann-Whitney test.
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both a clinical indicator of recessive EPP, and appears to be as¬
sociated with a decreased risk of liver disease. This is in
marked contrast to the recently described X linked dominant
protoporphyria which has the clinical phenotype of severe
EPP, yet is caused by a mutation in a different haem
biosynlhctic gene and is associated with an increased risk of
liver disease.10
The report by Mendez et al. is a useful addition to the EPP
literature. However, their case should be interpreted in the
context of what is already known (and published) about this
interesting clinical phenotype of EPP. This vignette illustrates
the continuing importance of phenotype,■'genotype studies in
addressing clinically relevant issues.
A homozygous mutation in the ferrochelatase
gene underlies erythropoietic protoporphyria
associated with palmar keratoderma - reply
DOI: 10.111 l/j.1365-2133.2009.09407.x
Sir, We were interested to read the recent report by Mendez
et al.,1 which describes a single patient with the unusual com¬
bination of erythropoietic protoporphyria (EPP) and palmar
keratoderma. They reported homozygous inheritance of a fer-
rochelalase (FECH) gene mutation and stated erroneously that
this is 'the first incidence of homozygous inheritance of a
novel missense mutation in the FECH gene underlying the
uncommon phenotype of EPP associated with palmar keralo-
derma'.
Our group undertook a cross-sectional study of 223 U.K.
individuals with EPP in 2004, and from this cohort we identi¬
fied six individuals with similar coincident seasonal palmar
keratoderma.2 In a subsequent publication we reported these,
and three additional British patients identified with the same
phenoiype.1 In addition to palmar keratoderma, all nine Indi¬
viduals from six families exhibited autosomal recessive inheri¬
tance, being hetero- or homo-allelic for nine different FECH
mutations, four of which were novel. Prokaryotic expression
predicted that FECH activities were 2-7-25% (mean 10-6%) of
normal. Neither mutation type nor FECH activity provided an
explanation for the unusual phenotype. In addition, we dem¬
onstrated that these patients had low erythrocyte protoporphy¬
rin concentrations when compared with the larger EPP cohort,
in combination with plasma porphyrin concentrations at levels
usually seen in dominant EPP. Furthermore, none of these
nine patients had evidence of liver dysfunction while four had
neurological abnormalities. Prior to our publication only 12
families with autosomal recessive EPP had been reported;4^9
based on these individuals it had been suggested that recessive
EPP carried a higher risk of liver disease than the dominant
form. Our findings challenged this dogma by confirming that
this recessively inherited clinical variant of EPP appears to
carry a decreased risk of liver disease compared with recessive
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Successful treatment of Hailey-Hailey disease
with topical 5-fluorouracil
DOI: 10.111 l/j.1365-2133.2009.09408.x
Sir, Hailey-Hailey disease (HHD) is a rare, autosomal domi-
nantly inherited genodermatosis, also known as familial
benign chronic pemphigus, first discovered by the Hailey
brothers in 1939.1 Current therapeutic alternatives are based
on topical steroids or surgical excision without high efficacity.
We report an alternative therapeutic approach with topical
5-fluorouracil (5-FU), used until now for pre-epitheliomatous
keratosis, with encouraging results.
A 43-year-old white man, with a sedentary profession, pre¬
sented with typical lesions of HHD that had evolved over a
period of 23 years. The patient complained of chronic pruritic
erythematous and fissured plaques complicated by four or five
acute painful exacerbations per year. He was significantly
bothered by the discomfort, which interfered with his daily
physical and professional activities and his sex life, especially
during the relapses. There was no family history of HHD.
Examination revealed moist erythematous papulovesicular
patches bilaterally measuring 3-4 cm in diameter, scaling, and
crusting in the axillae as well as in the deep folds of the groin
(Fig. la). Skin biopsy showed broad, nearly full-thickness
areas of numerous acantholytic cells overlying suprabasilar
clefts and underlying chronic inflammation. Direct and indir¬
ect immunofluorescence was negative. Topical corticosteroid
application was unsuccessful, as were other treatments includ¬
ing topical and oral antibiotics.
We administered 5-FU cream at a concentration of 5%
three times weekly for 3 months followed by once weekly for
3 months with monthly clinical follow-up and 3-monlhly full
blood count. An almost complete remission was obtained after
3 months (Fig. lb), and this clinical improvement was main¬
tained during treatment. No local or systemic side-effects have
been observed to date. He has been followed up for 1 year.
No relapses occurred during the first 6 months after the end
of treatment. A minor relapse with pruritic lesions was treated
with the same cream and remission was obtained in few days.
Quality of life was significally improved.
HHD is a rare intraepidermal blistering disorder, which
manifests as recurrent erosions on the axillae and groin. It is
caused by mutations in the ATP2C1 gene encoding the secre¬
tory pathway calcium ATPase 1 (SPCA1).2-4 This protein
resides in the Golgi apparatus, and functions as an intracellular
Fig 1. (a) Inflammatory moist erythematous papular patches in the
deep folds of the groin, (b) Clinical improvement after 3 months of
treatment with topical 5-fluorouracil.
Ca2+/Mn2+pump.5 These findings suggest that intracellular
Ca2+ stores play an important role in regulation of epidermal
cell-cell adhesion and differentiation.4
Topical 5-FU is an analogue of nucleic acid uracil resulting
in inhibition of DNA synthesis. It has been extensively used to
treat actinic keratoses in photodamaged skin using twice-daily
applications for 3-6 weeks.6 To the best of our knowledge
this is the first therapeutic trial of topical 5-FU in HHD.
The efficiency of topical low-dose 5-FU was demonstrated
in Darier disease (DD) which shares a similar pathogenesis
with HHD.7"9 DD was shown to be caused by mutations in
the ATP2A2 gene on 12q24.1, which encodes the sarco/endo-
plasmic reticulum Ca2+ ATPase isoform 2 (SERCA2).5
It has been hypothesized that 5-FU restores normal intracy-
toplasmic calcium concentrations.9 Given the similar patho¬
genesis of HHD and DD and the improvement of our patient
by 5-FU, we consider that this hypothesis is likely. Another
hypothesis was based on the inhibition of hyperproliferation
and abnormal cytokeratin production in DD,7 but there is no
dyskeratosis or keratinocyte proliferation in HHD.
© 2009 The Authors
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Molecular epidemiology of erythropoietic protoporphyria
in the U.K.
S.D. Whatley, N.G. Mason, S.A. Holme,* A.V. Anstey,* G.H. Elder and M.N. Badminton
Department of Medical Biochemistry and Immunology and *Department of Dermatology, University Hospital of Wales and School of Medicine, Cardiff University,
Cardiff CF14 4XN, U.K.
Summary
Background Erythropoietic protoporphyria (EPP) is a cutaneous porphyria caused by
mutations in the ferrochelatase (FECH) or, less frequently, the delta-aminolaevuli-
nate synthase 2 (ALAS2) gene. Predictive genetic counselling requires accurate
molecular diagnosis and knowledge of patterns of inheritance.
Objectives To investigate the molecular epidemiology of EPP in the U.K.
Methods DNA samples from 191 unrelated patients resident in the U.K. were anal¬
ysed for mutations in the FECH and ALAS2 genes and for the FECH IVS3-48
dimorphism.
Results Mutations were identified in 179 (94%) patients. Most (169; 94%) had a
FECH mutation on one allele and were classified as having pseudodominant EPP
(psdEPP); seven (4%) patients had FECH mutations on both alleles (autosomal
recessive EPP) and three (2%) patients had ALAS2 mutations (X-linked dominant
protoporphyria). The FECH IVS3-48C allele was strongly associated with psdEPP
and with the absence of mutations at the FECH or ALAS2 loci. Fifty-six FECH mu¬
tations were identified, 19 being previously unreported. Missense mutations were
predominant in autosomal recessive EPP (82%) but not in psdEPP (32%). One
mutation (c.314 4 2T>G) was present in 41 (24%) of EPP families, most of
whom appeared to be descended from a common ancestor resident in the north
of England.
Conclusions These data define the prevalence and molecular epidemiology of each
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Erythropoietic protoporphyria (EPP) is a cutaneous porphyria
that affects at least one in 140 000 of the population of the
U.K.1-3 Increased concentrations of protoporphyrin IX in
blood and other tissues lead to life-long acute photosensitivity
and, in about 2% of patients, severe liver disease. Three pat¬
terns of inheritance have been identified. In most families, ac¬
cumulation of protoporphyrin results from partial deficiency
of ferrochelatase (FECH) (OMIM 177000).1-2 In the majority
of these, photosensitivity is inherited in a pseudodominant
fashion (psdEPP) and is normally manifest only in individuals
in whom a deleterious FECH mutation, that markedly decreases
or abolishes FECH activity, is inherited trans to a hypomorphic
allele (FECH IVS3-48C, C.31S-48C)4 that is present in 13% of
the U.K. population.5 About 4% of families have autosomal
recessive EPP (arEPP) in which a FECH mutation is present on
both alleles.5-6 In a few families, overproduction of protopor¬
phyrin is caused by gain-in-function mutations in the ALAS2
gene that encodes the initial enzyme of erythroid haem bio¬
synthesis, S-aminolaevulinate synthase.7 This variant form of
EPP has been named X-linked dominant protoporphyria
(XLDPP; OMIM 300752).7
Although 110 FECH mutations have now been reported in
EPP families," there are only a few descriptions of the molecu¬
lar epidemiology of EPP in defined populations.6-9,10 Here we
describe the molecular characterization of 191 apparently




Samples for DNA analysis were obtained from 223 patients
during a cross-sectional study of EPP in the U.K.;3 191 of
these samples were from patients who were unrelated. Clin¬
ical details of these patients have been reported.3-11 Prior
approval was obtained from the North West Multicentre
Research Ethics Committee and 84 local research ethics
642
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committees. All patients or their parents gave informed
consent.
Molecular analyses
Genomic DNA was extracted from whole blood using the
QIAamp DNA purification kit (Qiagen, Crawley, U.K.) or, for
gene dosage analysis, the Flexigene kit (Qiagen). The FECH
gene was screened for mutations and genotyped for the IVS3-
48C/T dimorphism by heteroduplex analysis using a WAVE™
denaturing high-performance liquid chromatography (dHPLC)
instrument (Transgenomic, Omaha, NE, U.S.A.) with absor-
bance detection at 260 nm. Following polymerase chain reac¬
tion (PCR) amplification of individual exons and their
flanking regions (30-300 bp) reaction mixtures were cooled
by 1 °C s"1 to 4 °C. PCR products (5 pi.) were injected on to
a reverse-phase HPLC column at a temperature determined
theoretically using the Navigator software (Transgenomic) and
optimized empirically using DNA containing known mutations
whenever possible. Primer sequences and temperatures are
available from the authors on request. The dimorphism at
IVS3-48C/T separated into two homoduplex peaks in addition
to heteroduplex peaks enabling identification of the genotype.
Exons and flanking regions showing shifts in the dHPLC trace
that indicated possible mutations were further analysed by
sequencing. Exon 1 was sequenced in all patients. When no
shift was detected all exons including 30-250 bp of flanking
intronic sequence and 250 bp of the promoter region were
sequenced.12 When no FECH mutation was detected by
sequencing, gene dosage analysis to identify large
deletions and characterization of deletion breakpoints was car¬
ried out.12 FECH haplotypes were determined by genotyping
with two microsatellite markers (chrl 8:531013 75—S31014-21,
chr 18:53 719877-53 719917) flanking the FECH gene and with
one intragenic marker (chrl8:53388333-53388377) as desc¬
ribed.2 The 4 IAS2 gene was sequenced as previously
described.7
Nucleotides are numbered from the cDNA sequence of
human FECH (NCBI reference sequence NM_000140.3) and
human ALAS2 (NM_000032.4) with the A of the ATG initia¬
tion codon as '+1'. Functional effects of missense mutations
were predicted using AGVGD (http://agvgd.iarc.fr), SIFT
(http://blocks.fhcrc.org) and Polyphen (http://genetics.bwh.
harvard.edu/pph/) programs.
In addition, erythrocyte porphyrins were analysed as
described.13
Statistical methods
Data were analysed using Microsoft Excel and Minitab v 13.
Measurements were expressed as medians and ranges. The sig¬
nificance of differences between quantitative variables was
assessed by the Mann-Whitney test.
Results
Mutations were identified in 1 79 (94%; 95% confidence inter¬
val, CI 89—96%) of 191 unrelated patients. Of these, 169
patients had a FECH mutation on one allele and were classified
as having psdEPP (Table I). Seven patients had FECH muta¬
tions on both alleles (arEPP) and three patients had ALAS2 mu¬
tations (XLDPP) (Table 1). The arEPP and XLDPP families have
been reported previously. ' '
The hypomorphic FECH IVS3-48C allele was strongly associ¬
ated with psdEPP, being absent from only two patients
(Table 1) (P < 0-001), but its frequency was not increased in
the patients with arEPP or XLDPP in comparison with the gen¬
eral U.K. population (Table 1). There was also a strong associ¬
ation with this allele in the group of 12 patients in whom no
mutations were detected (P < 0-001), only two of whom had
the genotype IVS3-48T/T (Table 1). One of these patients had
the biochemical features of XLDPP (erythrocyte protoporphy¬
rin 45-6 pmol L~ ; 33% zinc protoporphyrin) but no family
history of photosensitivity. Erythrocyte protoporphyrin con¬
centrations (median 18-2 pmol L ', range 11-2—32-5) in the
other 11 patients in whom no mutation was detected did not
differ from those in psdEPP (Table 2) (P = 0-15) and no dis¬
tinctive clinical features were observed. The proportions of the
TVS3-48C/C or IVS3-48T/T genotypes in this group of
patients did not differ significantly from those in psdEPP
(P = 0-27 and 0-17, respectively).
Among patients in whom FECH mutations were identified,
erythrocyte porphyrin concentrations were lower in the
patients with missense mutations than in other patients
Table 1 Frequency of different types of protoporphyria in the U.K.
Type of protoporphyria
No. of unrelated patients
(% of total; 95% CI)
FECH IVS3-48 genotype (no. of patients)
C/C C/T T/T
FECH mutation on one allele (psdEPP) 169 (88-5; 83-2-92-3) 3 164 2
FECH mutation on two alleles (arEPP) 7 (3-7; l-8-7-4)a 1 1 5
ALAS2 mutation (XLDPP) 3 (1-6; 0-5-4-5)a 0 0 3
No FECH or ALAS2 mutation 12 (6-3; 3-6-10-7) 1 9 2
"arEPP vs. XLDPP P = 0-17. The difference between the prevalences of arEPP and XLDPP is not statistically significant.
CI, confidence interval; psdEPP, pseudodominant erythropoietic protoporphyria; arEPP, autosomal recessive erythropoietic protoporphyria;
XLDPP, X-linked dominant protoporphyria.
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psdEPP 169 23-7 (4 1-77-3)
Pro334Leu 10 11-1 (4-1-47-2)
Missense mutations6 26 13-9 (4-1-47-2)
Splicing mutations 73 22-6 (7-9-99-5)
Frameshift, nonsense, 70 24-8 (6-2-94-5)
gross deletions
includes zinc protoporphyrin, ' includes Pro334Leu.
psdEPP, pseudodominant erythropoietic protoporphyria.
(P = 0-0002). This difference was largely due to the presence
of 10 patients (24%) with the mutation Pro334Leu among
those with missense mutations. This mutation may be associ¬
ated with a mild form of EPP.14 Erythrocyte porphyrin con¬
centrations in patients witli mutations predicting defective
RNA splicing did not differ from those in patients with null
mutations (frameshift, nonsense or gross deletion) (P = 0-30).
Fifty-six different mutations were identified in the FECPi
gene, of which 19 have not previously been reported (Fig. 1).
In psdEPP, 25% of mutations were small deletions or inser¬
tions, 16% were splice site mutations, 32% were missense
mutations, 14% were nonsense mutations and 13% were large
deletions that were detected only by gene dosage analysis.12
In contrast, nine (82%) of the 11 different mutations in arEPP
were missense, none of which was found in psdEPP (Fig. 1).
Eight mutations were found in five or more families and
together accounted for the mutations in 58% (98/169) of
psdEPP families (Fig. I). One mutation (c.314 + 2T>G) was
particularly common, being present in 41 (24%) families,
including one family with arEPP. Genotyping with micro-
satellite markers within and flanking the FECH gene in one
family identified a haplotype that segregated with this muta¬
tion. The microsatellite polymorphisms comprising this haplo¬
type were present in 37 of the apparently unrelated patients
with this mutation, suggesting that they were descended from
a common ancestor. Mapping the places of residence of these
3 7 patients suggested that their common ancestor may have
lived in south Yorkshire or Lancashire (Fig. 2).
Discussion
Our 191 apparently unrelated patients were recruited to a
cross-sectional study of EPP in the U.K. using a procedure that
minimized selection bias.3 Thus the prevalence for each type
of EPP shown in Table 1 is likely to reflect that among all
U.K. patients. A similar prevalence for arEPP has been reported
for France.6 Although we identified fewer families with XLDPP
than arEPP, their prevalences were not significantly different.
Our data show that, as in other countries,6,9'13-20 several
different FECH mutations are found in EPP in the U.K. How¬
ever, allelic heterogeneity is less than for the autosomal domi¬
nant acute porphyrias,21 largely due to the presence of a
single large extended family with the mutation
c.314 + 2T>G. Similarly high frequencies of a single mutation
c. 1-9828 67+2437 (2)







c.286C>T p Arg 96X (3)
C.302T>C p Le-u 101 Pro (1)
C.314»2T>G <41)
C 705+2350 TGA+95«Sel9889 (2)
c 707G>A. p Cys236Tyr (2)
C479A>G. pTyf160Cys(1) c 734T>C. p Leu245Pro(1)
C.490C>T, p Arg164Trp (4)
C 502C"*T. p ero16BS<X (2)
C557T>C p lte186Thr (1)
c 599 2A>G (2)
i i I
I I I
c 68-1987 463+352<JeW42S (1)




c416A>T. p Gln139Leu (1)
t 461C>A a thr154Lys (1)
c.463*1G>C (12)
c 74Ck1»IAn> c 945detA (9)
c.757_761de»AGAAG<2> c 903delG < 11
c 7fiflJ104+244(1fl!28G 12) C 1QQ1C»T. P Pro334lmi (10)
c 778T>C. p P»Te260Leu (1) c 10S9J060deUC (11
c 804+2785_ 1077♦ 106del2197 (8) c. 1077G>A (splice) (7) C.1231T>G. p.Cys41 iGly (4)
) t yf200X (1}
n rrp221X<2>
C 820G>A p Asp274Asn (1) c.1135A>T. p Lys379X (5)
c 854A>G p Gln285Arg (1) c. 1137G>C. p Lys379Asn (1
c 898G>T. p Vat300teu (1) C.1137+2T>G (4)
C.1137+3A>G (3)
Fig 1. FECH mutations in U.K. patients. Previously unreported mutations are shown in green and mutations found only in autosomal recessive
families in red. Numbers in parentheses indicate the number of unrelated patients with that mutation.
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Fig 2. Geographical distribution of families with FECH c.314 + 2T>G
mutation.
among apparently unrelated families have been reported for
EPP in Northern Ireland,22 in South Africans of European des¬
cent9 and in Switzerland.10
The percentages of different types of mutation showed a
marked difference between arEPP and psdEPP, with missense
mutations predominating in arEPP. No missense mutation was
found in both arEPP and psdEPP. This difference probably
reflects the need for at least one allele in arEPP to carry a
mutation that preserves sufficient residual FECH activity to
maintain normal development; such 'mild' missense mutations
may be less likely to produce psdEPP when trans to a hypo-
morphic allele. Reports of mutation patterns from other coun¬
tries have not distinguished between the two forms of EPP or
included patients with large deletions but otherwise show no
marked differences from the overall pattern in U.K. patients.6
Nineteen (34%) of the mutations that we identified have
not been reported previously. Most were small deletions or
insertions leading to frameshifts, splice site mutations pre¬
dicted to cause aberrant RNA splicing or nonsense mutations
introducing premature stop codons (Fig. I) and therefore pre¬
dicted to have a marked effect on FECH activity. Three were
missense mutations. Of these, p.Cys403Tyr altered one of the
four ligating cysteine residues in the iron-sulphur cluster that
is essential for human FECH activity23 while the other two
(p.Thrl 54Lys, p.Glyl62Gln) were highly conserved, indicat¬
ing likely interference with protein function.
All but two of our patients in whom a single FECH muta¬
tion was identified had the genotypes IVS3-48C/T or IVS3-
48C/C (Table 1). This strong association is consistent with the
notion that clinical expression of psdEPP requires the hypo-
morphic IVS3-48C allele to be trans to a deleterious mutation,6
although we were unable to demonstrate this directly because
we did not determine phase. The two patients without these
genotypes both had mutations (c.314+2T>G; c.768_804+
244del280) that are known to cause psdEPP in conjunction
with a hypomorphic allele. They had lower erythrocyte proto¬
porphyrin concentrations (8-9, 6-2 pmol IT1) than most
patients with psdEPP (4-7% had < 9 pmol L"1) and milder
disease with one patient (c.314+2T>G) not presenting until
the age of 10 years and neither being recognized to have EPP
until their fourth decades. Others have also reported rare
patients with psdEPP and the genotype IVS3-48T/T.6'16 In one
such patient, delayed appearance of symptoms was apparently
provoked by partial hepatectomy for multiple adenomas.6 It is
not clear why these rare patients with a single FECH mutation
trans to an IVS3-48T allele develop photosensitivity; an uniden¬
tified hypomorphic allele or acquired factors, separately or
together, may be required. However, the finding that 1-2%
(95% CI 0-3—4-2%) of patients with psdEPP have not inherited
an IVS3-48C allele does have consequences for predictive
counselling as it shows that a small risk of having an affected
child remains even when the unaffected partner has the geno¬
type TVS3-48T/T.
No FECH or ALAS2 mutation was identified in 12 patients
(Table 1). One patient with the TVS3-48T/T genotype had the
biochemical features of XLDPP and may have an unidentified
mutation in ALAS2 or a gene that regulates ALAS2. In the other
patients, the distribution of FECH FVS3-48 genotypes was not
significantly different from psdEPP (Table 1). FECH activity
was not measured in these patients because nucleated cells
were not available for analysis but the strong association with
the hypomorphic allele suggests that it may be decreased.
Thus, FECH mutations in regions of the gene not analysed by
our procedures (approximately 40 kb of noncoding sequence)
seem the most likely explanation for EPP in the majority of
these patients. One of our mutation-negative patients had the
genotype IVS3-48C/C diat decreases FECH activity by 30—
40%.4,8 However, our patient, unlike a recently reported
patient with this genotype who had mild photosensitivity, a
small increase in protoporphyrin concentration and normal
plasma porphyrin,8 had typical EPP (erythrocyte porphyrin
18-2 pmol IT1).
Finally, what is the role of molecular analysis in the man¬
agement of EPP? Predictive genetic counselling requires prior
identification of the pattern of inheritance in individual fami¬
lies. Our findings identify the extent of genetic heterogeneity
of EPP in the U.K. and add to the evidence that mutation
identification, in addition to FECH IVS3-48C/T genotyping, is
required to support accurate genetic counselling. However,
the usefulness of mutation identification as part of the initial
diagnostic protocol in all patients with EPP requires further
evaluation.
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What's already known about this topic?
• Erythropoietic protoporphyria (EPP) is a cutaneous por¬
phyria that affects at least one in 140 000 of the popula
tion of the U.K.
• Patients have life-long acute photosensitivity with about
2% developing severe liver disease.
• EPP is caused by mutations in the ferrochelatase (FECH)
or, less frequently, the delta aminolaevulinate synthase 2
(4LAS2) gene.
What does this study add?
• This study of EPP is the largest to date and defines the
prevalence and molecular epidemiology of EPP in the U.K.
• Most patients were found to have a FECH gene mutation
associated with a low expression allele and were classified
as having pseudodominant EPP. The autosomal recessive
form of EPP was identified in 4% of patients while 2%
were found to have the recently identified X-linked domi¬
nant protoporphyria.
• One mutation was found to be present in 24% of fami
lies with pseudodominant EPP.
Acknowledgments
We thank all those physicians who helped with this study and
allowed access to their patients; Ms Jacqueline Woolf for
expert laboratory assistance; and Ms Sonia van Lierop for sec¬
retarial assistance. The study was supported in part by grants
from the Royal College of Physicians (Lewis Thomas Gibbon
Jenkins of Britton Ferry Memorial Trust), the British Skin
Foundation, the Royal Gwent FLospital and the School of Med¬
icine, Cardiff University.
References
1 Todd DJ. Erythropoietic protoporphyria. Br J Dermatol 1994;
131:751-66.
2 Cox TM. Protoporphyria. In: The Porphyrin Handbook (Kadish KM,
Smith KM, Guilard R, eds). Amsterdam: Academic Press, 2003;
121-50.
3 Holme SA, Anstey AV, Finlay AY et al. Erythropoietic protoporphy¬
ria in the U.K.: clinical features and effect on quality of life. Br J
Dermatol 2006; 155:574-81.
4 Gouya L, Puy H, Robreau AM et al. The penetrance of dominant
erythropoietic protoporphyria is modulated by expression of wild-
type FECH. Nat Genet 2002; 30:27-8.
5 Whatley SD, Mason NG, Khan M ct al. Autosomal recessive erythro¬
poietic protoporphyria in the United Kingdom: prevalence and
relationship to liver disease. J Med Genet 2004; 41:el05.
6 Gouya L, Martin-Schmitt C, Robreau A-M et al. Contribution of a
single-nucleotide polymorphism to the genetic predisposition for
erythropoietic protoporphyria. Am J Hum Genet 2006; 78:2—14.
7 Whatley SD, Ducamp S, Gouya L et al. C-terminal deletions in the
AIAS2 gene lead to gain of function and cause X-linked dominant
protoporphyria without anemia or iron overload. Am J Hum Genet
2008; 83:408-14.
8 Schneider-Yin X, Mamet R, Minder EI, Schoenfeld N. Biochemical
and molecular diagnosis of erythropoietic protoporphyria in an
Ashkenazi Jewish family. J Inherit Metab Dis 2008 Aug 31 [Epub].
9 Parker M, Corrigall AV, Hift RJ, Meissner PN. Molecular character¬
ization of erythropoietic protoporphyria in South Africa. Br J Derma¬
tol 2008; 159:182-91.
10 Schneider-Yin X, Harms J, Minder EI. Porphyria in Switzerland,
15 years experience. Swiss Med Wkly 2009; 139:198-206.
11 Holme SA, Whadey SD, Roberts AG et al. Seasonal palmar kerato-
derma in erythropoietic protoporphyria indicates autosomal reces¬
sive inheritance. J Invest Dermatol 2009; 129:599—605.
12 Whatley SD, Mason NG, Holme SA et al. Gene dosage analysis
identifies large deletions of the FECH gene in 10% of families
widi erythropoietic protoporphyria. J Invest Dermatol 2007;
127:2790-4.
13 Deacon AC, Elder GH. Front line tests for the investigation of sus¬
pected porphyria. J Clin Pathol 2001; 54:500—7.
14 Berroeta L, Man I, Goudie DR et al. Late presentation of erydiropoi-
etic protoporphyria: case report and genetic analysis of family
members. Br J Dermatol 2007; 157:1030-1.
15 Riifenaclit UB, Gouya L, Schneider-Yin X et al. Systematic anal¬
ysis of molecular defects in the ferrochelatase gene from patients
with erythropoietic protoporphyria. Am J Hum Genet 1998; 62:
1341-52.
16 Wiman A, Floderus Y, Harper P. Novel mutations and phenotypic
effect of the splice site modulator IVS3-48C in nine Swedish fami¬
lies with erythropoietic protoporphyria. J Hum Genet 2003; 48:70—
6.
17 Risheg H, Chen FP, Bloomer JR. Genotypic determinants of pheno-
type in North American patients with erythropoietic protoporphy¬
ria. Mol Genet Metab 2003; 80:196-206.
18 Saruwatari H, Ueki Y, Yotsumoto S et al. Genetic analysis of the
ferrochelatase gene in eight Japanese patients from seven families
with erythropoietic protoporphyria. J Dermatol 2006; 33:603-8.
19 Aurizi C, Schneider-Yin X, Sorge F et al. Heterogeneity of muta¬
tions in die ferrochelatase gene in Italian patients with erythropoi¬
etic protoporphyria. Mol Genet Metab 2007; 90:402—7.
20 Herrero C, To-Figueras J, Badenas C et al. Clinical, biochemical,
and genetic study of 11 patients with erythropoietic protoporphy¬
ria including one with homozygous disease. Arch Dermatol 2007;
143:1 125-9.
21 Whadey SD, Mason NG, Woolf JR et al. Diagnostic strategies for
autosomal dominant acute porphyrias: retrospective analysis of 467
unrelated patients referred for mutational analysis of die HMBS,
CPOX, or PPOX gene. Clin Chem 2009; 55:1406-14.
22 Todd DJ, Hughes AE, Ennis KT et al. Identification of a single base
pair deletion (40 del G) in exon 1 of the ferrochelatase gene in
patients with erythropoietic protoporphyria. Hum Mol Genet 1993;
2:1495-6.
23 Schneider-Yin X, Gouya L, Dorsey M et al. Mutations in the iron-
sulfur cluster ligands of the human ferrochelatase lead to erythro¬
poietic protoporphyria. Blood 2000; 96:1545—9.
© 2010 The Authors
Journal Compilation © 2010 British Association of Dermatologists • British Journal of Dermatology 2010 162, pp642-646
ERYTHROPOIETIC PROTOPORPHYRIA
What are the aims of this leaflet?
This leaflet has been written to help you understand more about
erythropoietic protoporphyria (EPP). It tells you what it is, what causes it,
what can be done about it and where you can find out more about it.
What is erythropoietic protoporphyria?
The word 'erythropoietic' means associated with red blood cells ('erythro-')
and their formation ('-poietic'). The porphyrias are a group of uncommon
diseases caused by something going wrong with the production of chemicals
known as porphyrins. These chemicals are the building blocks of haem,
which, when combined with a protein (globin), forms haemoglobin, the
material in red blood cells that carries oxygen round the body. In the case of
EPP, there is a build up of one of these porphyrins (protoporphyrin) in the
blood, especially in the red blood cells. This leads to a sensitivity to sunlight.
What causes EPP?
An enzyme is a protein that helps to convert one chemical substance into
another. In EPP, there is a shortage of one particular enzyme
(ferrochelatase), which normally helps to convert protoporphyrin into haem by
adding iron to it. As a result of this enzyme deficiency, protoporphyrin levels
build up in the blood. As blood passes through the skin, the protoporphyrin
absorbs the energy from sunlight and this sets off a chemical reaction that
can damage surrounding tissues. The nerve endings in the skin interpret this
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as itching or burning pain, and if the blood vessels are affected, they can leak
fluid, causing swelling.
The light that protoporphyrin absorbs is different from that which causes
ordinary sunburn. Usually sunburn is caused by the shorter wavelengths of
ultraviolet light (UVB), but in EPP the skin is more sensitive to visible light
and to longer ultraviolet wavelengths (UVA).
Is EPP hereditary?
Yes, but there is not always a family history of the condition. Everyone has
two genes for ferrochelatase in each cell in their body (one coming from their
mother and one from their father). In most families, EPP occurs when an
affected individual inherits a gene for a severely underactive ferrochelatase
enzyme from one parent, and a less severely affected gene from the other
parent. The less severely affected gene is quite common, being present in
about 10% of the general population, but it never causes EPP by itself. The
genetics is quite complex and advice from your local genetics service may be
useful.
What are the symptoms of EPP?
Typically EPP starts with abnormal sensitivity to sunlight. Exposure to
sunlight causes tingling, itching or burning, which may be associated with
redness and swelling. These symptoms usually occur within a few minutes
of skin exposure to sunlight, and often they take hours or days to resolve.
During this time the skin may feel more sensitive than usual to sunlight and
extremes of temperature. The light producing these changes need not be
direct - light reflected off water and sand, or passing through window glass,
including car windscreens, can also cause the symptoms.
EPP usually starts in childhood, and affects males and females equally.
Infants may cry or scream after being taken out into the sunlight and older
children may complain of burning, try to wave their hands in the air, or put
them into cold water to try to relieve the pain. A very small number of people
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who have had with EPP for many years may develop liver damage.
Fortunately this is rare.
What does EPP look like?
Despite severe discomfort, there may be nothing abnormal to see on the
skin. Sometimes there can be swelling of the skin, initially like a nettle rash.
With time, some people develop thickening of the skin over their knuckles,
and small scars on sun-exposed skin such as that on the cheeks, nose, and
backs of the hands. However these skin changes show wide variation
between different individuals.
How is EPP diagnosed?
The diagnosis is usually suspected from the story, and can be confirmed by a
blood test. This measures the amount of protoporphyrin in the blood (serum
protoporphyrin) and in the red blood cells (erythrocyte free protoporphyrin).
Some doctors will also ask for a stool sample to measure the level of
protoporphyrin in the faeces. No urine tests are relevant to this condition
except to exclude other types of porphyria.
Although it is unlikely that you will develop liver problems as a complication of
EPP, your doctor may monitor the way your liver is working by yearly blood
tests. If there is any evidence of a deterioration in liver function, there are
certain interventions that may help to halt or reverse this.
As EPP affects the production of haemoglobin, it is not uncommon for people
with EPP to be slightly anaemic. Your doctor will probably also measure your
blood count to make sure that you are not becoming too anaemic.
Can EPP be cured?
At present there is no cure for EPP.
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How can EPP be treated?
The aim of most treatments is to give your skin extra protection from sunlight,
so that you tolerate sunlight better. Advice about clothing and sunscreens is
given later in this leaflet.
Medical treatments for EPP include the use of:
• Beta-carotene. This is derived from the chemical that makes carrots
orange. Some people with EPP find that taking beta-carotene
capsules is helpful. The capsules are available on prescription
(supplier details are given at the end of the sheet), are taken by
mouth, and usually give the skin a slightly orange colour. This
medicine is considered to be safe, but may occasionally cause a slight
tummy upset. Large studies showed some health gains e.g. fewer
strokes, but there may also be an increased risk of lung cancer in
smokers.
• Antihistamines. These tablets or syrups may help the few people for
whom the nettle rash response of the skin is a major problem.
• Phototherapy. Narrow-band UVB therapy is a type of ultraviolet light
treatment used in dermatology departments. It involves careful
exposure to artificial ultraviolet light, usually three times a week for
about five weeks in the spring, to allow the skin to thicken slightly and
develop a tan. This acts as a natural sun block and may improve
tolerance to sun exposure over the summer.
• Treatments still being developed include the possible use of L-acetyl
cysteine, MSH (Melanotan), and dihydroxyacetone paint.
What can I do?
It is sensible to avoid unnecessary exposure to sunlight. Other helpful
measures include the wearing of protective clothing and the use of
sunscreens:
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• Clothing - simple measures include the wearing of clothes made from
tightly woven dark-coloured cloth, long sleeves, a hat (ideally brimmed
or Foreign Legion-style); shoes rather than sandals, and gloves,
particularly for driving. Some manufacturers provide information about
the degree of protection provided by clothing using the UV protection
factor (UPF) rating which measures protection from clothing against
UVB and UVA. While it does not automatically follow that this equates
to visible-light protection, in practice this is likely to be the case.
• Sunscreens - as EPP is characterised by sensitivity mainly to visible
light, conventional sunscreens that are formulated to protect against
ultraviolet (particularly UVB) are usually not effective. Reflectant
sunscreens that are based on titanium dioxide or zinc oxide will be
more effective as they cover both UVA, UVB, and visible light to a
degree. In the UK, the SPF (sun protection factor) number tells you
how effective the sunscreen is for UVB, and the star rating (usually
found on the back of the bottle, with a maximum 4 stars) gives a
measure of the UVA protection.
A tinted reflectant sunscreen is available on prescription from Dundee
Pharmaceuticals in three colours: coral pink, beige, and coffee. These
can be mixed to obtain a good colour match with your skin (Dundee
Pharmaceuticals, Ninewells Hospital, Dundee. DD1 9SY, telephone:
01382 632052).
• Reactions to other medications. Unlike other types of porphyria,
EPP does not cause porphyria 'crises' as an effect of certain
medicines and anaesthetics. Some doctors and pharmacists confuse
EPP with these other porphyrias and may tell you to avoid certain
medicines. In general you can take whatever medicines your health
requires.
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Where can I get more information about EPP?
As EPP is so uncommon, many general practitioners will have had little
experience of dealing with it. However, dermatologists see most people with
EPP, but if they too have little personal experience of the problem, they may
refer you to a colleague with particular expertise, for investigations and
discussion. If you are concerned about the likelihood of passing the
condition onto your children, you may be referred to a geneticist for
information about this complex area. There are a number of other sources of
information, most of which are on the Internet. Most give details about all
forms of porphyria, although a few specialise just in EPP.
1. Organisations specialising in EPP.




National Centre for Biotechnology Information - OMIM
www. ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=177000
Pubmed - search for medical journal articles
www.ncbi.nlm.nih.gov/entrez/query.fcgi
EPP information, links and results from recent research
http://Alzuko.tripod.com/epp.htm
2. Organisations dealing with all forms of porphyria
British Porphyria Association




Canadian Porphyria Foundation CPF
Box 1206, CA-Neepawa, ROJ 1H0 Phone/Fax: Country code, then 204 476
2800
www.cpf-inc.ca
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American Porphyria Foundation
P.O.Box 22712 US-Houston, TX 77227 USA
University of Cape Town Porphyria Service, South Africa
http://web.uct.ac.za/depts/porphyria/
University of Queensland, Australia
www.uq.edu.au/porphyria/
CLIMB - children living with inherited metabolic diseases
176, Nantwich Road, Crewe. CW2 6BG Telephone: 0870 7700 326
www.climb.org.uk
3. Other information:
Beta-Carotene - sources and dosage:
Beta-carotene is available on prescription, and the dosage required may be
up to 200mg per day. In the UK, the only licensed preparation is a 3mg
capsule. Higher strength preparations are available via a company called
IDIS, which imports them from abroad. As these preparations do not have a
product licence in the UK, IDIS requires written confirmation from your
consultant of the reason why these higher strength capsules are required.
This is to satisfy the Medicines Control Agency that there is a need to import
the product even though a licensed product is available in the UK. The
contact details for IDIS can be found on their website: www.idisonline.com.
Window film to cut out UV/to cover operating theatre lights:
Bonwyke Window Films Ltd., 41-43 Redlands Lane, Fareham, Hampshire.
POM 1HL Telephone: 01329 289621
Madico (Madico CLS200XR) 45 Industrial Parkway, Woburn, MA 01888,
USA. Telephone: 001 800 225 1926. Email: info@madico.com
(Whilst every effort has been made to ensure that the information given
in this leaflet is accurate, not every treatment will be suitable or




4 Fitzroy Square, London WIT 5HQ
Tel: 020 7383 0266 Fax: 020 7388 5263 e-mail: admin@bad.org.uk
Registered Charity No. 258474
